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ABSTRACT 
Chronic joint injury, characteristic of patients with 
rheumatoid arthritis (RA), possibly involves T-cell 
mediated immune responses triggered by a limited number of 
self antigens or epitopes expressed in the target tissue, 
that is, the synovium. There is evidence that in MHC-
restricted autoimmune reactions, at least in some animal 
models of autoimmune diseases, certain T-cell receptors 
(TcRs) are involved in the recognition of a particular 
autoantigen and that the response mediated by pathogenic 
T-cells can be inhibited by agents directed against the 
specific variable (V) gene products. Current data regarding 
. . 
restricted TcR heterogeneity in rheumatoid joints are 
conflicting and have led to a controversy over the 
feasibility of TcR-based immune intervention in the 
treatment of RA and other human autoimmune diseases. 
This thesis describes the molecular characterisation of the 
TcRs expressed by T-cells in the inflamed synovium and 
peripheral blood of RA patients. V gene family-specific 
polymerase chain reaction (PCR) amplification of rearranged 
TcR rnRNA transcripts was used to determine Va/~ and V 1/8 
gene expression profiles in paired samples of RA synovial 
membrane (SMC) and peripheral blood mononuclear cells 
(PBMC). Using a panel of primers specific for 19 TcR Va 
gene families and 18 TcR V~ gene families, there was no 
V 
evidence for preferential usage of particular Va or Vfi 
genes since TcR transcripts expressing most of these V gene 
families were detected in both RA SMC and PBMC, although 
there were quantitative differences in TcR Vfi gene 
expression. For v1 gene usage, there were no marked 
differences between the TcR 1-chain repertoires expressed 
in the synovial and peripheral blood compartments of any of 
the patients examined. In contrast, most patients expressed 
a highly restricted SMC TcR a-chain repertoire biased 
towards Vol and to a lesser extent Vo2. The TcR a-chain 
repertoires of PBMC from healthy individuals were also 
characterised. There was variation in the TcR a-chain 
repertoires of PBMC from patients when compared with 
controls, particularly with respect to expression of Vo4. 
Vo4 mRNA transcripts were expressed significantly less 
often in RA PBMC compared with control PBMC. Thus, in 
patients with RA of long duration, the a/fi TcR repertoire 
in the rheumatoid synovium is diverse and therefore the 
synovial T-cell response is likely to be polyclonal. 
Conversely, the findings of restricted usage of Vo but not 
v1 genes in RA synovium indicate a potential contribution 
of a Vo region-specific antigen to the pathogenesis of RA. 
The clonality among Vol, Vo2 and V19 T-cell populations in 
RA SMC was investigated by DNA sequencing the V-joining (J) 
junctions of TcR transcripts expressing these V-region 
genes. Sequences were compared with those found in PBMC of 
' Vl 
the same patients and control PBMC. In control PBMC, TcR 
transcripts showed extensive junctional region diversity 
with a unique sequence observed in each TcR cDNA clone 
examined. In contrast, Vol and Vo2 transcripts in RA PBMC 
showed a strong bias towards usage of the same V-J 
combination and junctional region sequences. Furthermore, a 
high degree of V19 oligoclonality was detected in RA PBMC 
which correlated with either Vol or Vo2 oligoclonality. TcR 
oligoclonality was generally less marked in RA SMC, 
although a few dominant transcripts, different to those 
found in the PBMC, were prevalent in the SMC rather than 
the PBMC. Moreover, in SMC of all patients V19 transcripts 
expressed predominantly J12 as opposed to preferential 
usage of J1P in control PBMC. The specific sequences of · the 
dominant transcripts detected mainly in RA PBMC were unique 
in each patient, and, in some cases, the same transcript 
was found in the corresponding SMC but with a lower degree 
of oligoclonality. 
This study also demonstrated the persistence of such 
clonally-expanded 1/0 T-cells in the periphery, by 
screening TcR cDNA clones, derived from RA PBMC prepared 
from the same patients up to three years later, with 
oligonucleotides specific for the relevant oligoclonal 
junctional regions. The dominant transcripts were expressed 
in the new PBMC samples and in most cases at a lower 
frequency than was originally detected, although in one 
patient there was almost 100% oligoclonality of V19 
' ' Vll 
transcripts, progressing from 55% oligoclonality in 15 
months. 
These results indicate that Vol-, Vo2- and v19-expressing 
1/0 T-cells in the peripheral blood of RA patients are 
largely derived from in vivo clonal expansion whereas the 
synovial T-cell infiltrate is mainly polyclonal, but shows 
clonal dominance in some patients. The data strongly 
support a role for these 1/0 T-cells in the development or 
regulation of RA, and, although the nature of the 
antigen(s) recognised by these cells remains elusive, this 
report suggests the potential involvement of antigen (s) 
specific for the V-region and V-J junction. 
In view of the potential for immunointervention in the 
treatment of human autoimmune disorders, the findings 
presented in this thesis may have important therapeutic 
implications for RA. The results are discussed in terms of 
a putative pathogenic model for autoimmunity and RA and the 
prospects of immunotherapy. 
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CHAPTER 1 
GENERAL INTRODUCTION 
1 
1.1 INTRODUCTION 
Rheumatoid arthritis (RA) is an autoimmune disease 
characterised primarily by chronic inflammation of the 
tissue (synovium) lining the joint cavity which leads to 
joint destruction. The disease is diagnosed according to 
certain criteria related to clinical manifestations (Table 
1.1) and can be subdivided into several classifications 
(Mitchell and Fries, 1982) and pathological stages (Table 
1.2) (Harris, 1990). Rheumatoid factors are present in the 
sera of most patients with RA (Mitchell and Fries, 1982) 
and serve to distinguish between seropositive RA, which is 
discussed in this thesis, and the less severe seronegative 
RA, largely considered a separate disease entity (Alarcon 
et al . , 19 8 2) . 
The etiology of RA is unknown, although multiple factors, 
including genetic and environmental factors, contribute to 
the pathogenesis of the disease. Massive infiltration of 
the rheumatoid synovium predominantly by activated T-cells 
(Burmester et al., 1981; Burmester et al., · 1984), and 
linkage of the disease with certain HLA-DR4 haplotypes, in 
particular the DR~l-encoded Dw4 and Dw14 determinants 
(Nepom et al., 1986; Nepom et al., 1989; Wordsworth et al; 
1989), has led to the proposal that antigen-specific 
(autoreactive) T-cells probably play a crucial role in 
mediating chronic joint inflammation (reviewed by Panayi et 
al., 1992). However, the T-cell receptors (TcRs) expressed 
by arthritogenic T-cells and the nature of the target 
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Table 1.1 Arthritis Rheumatism Association criteria for the 
diagnosis of rheumatoid arthritis and incidence in a series 
of rheumatoid arthritis patients (reprinted by permission 
of Arthritis Rheum. 25: No. 5, p. 482, 1982). 
Criteriaa) Incidence 
( % ) 
1. Morning stiffness 66 
2. Joint pain on motion or tenderness 91 
3~ Swelling of a joint 82 
4. Second joint swelling 75 
5. Symmetric joint swelling 68 
6. Subcutaneous nodules 19 
7. Positive rheumatoid factor test 74 
8. X-ray erosions 47 
9. Poor ~ynovial fluid mucin precipitate 
10. Positive synovial biopsy 
11. Positive nodule biopsy 
a) Patients are classified as having "equivocal" (1-2), 
"probable" (3-4), "definite" (5-6), or "classic" (7-10) 
rheumatoid arthritis, depending on the number of clinical 
manifestations, as shown in brackets. 
Table 1 . 2 Pathological stages of rheumatoid arthritis (reprinted by permission of the N. Engl. J. Med. 322 : No. 18, 
p. 1278, 1990). 
Stage Pathological process 
1 
2 
3 
4 
5 
Presentation of antigen 
to T-cells 
T- and B-cell proliferation 
Angiogenesis in SM 
Accumulation of neutrophils 
in SF 
Synovial-cell proliferation 
Polarization of synovitis 
into an invasive pannus 
Activation of chondrocytes 
Initiation of enzyme 
degradation of cartilage 
Erosion of subchondral bone 
Invasion of cartilage by 
pannus 
Chondrocyte proliferation 
Stretched ligaments around 
joints 
Symptoms 
None 
Malaise, mild joint 
stiffness and swelling 
Physical signs 
Swelling of small joints 
of hands or wrist 
Radiographic changes 
None 
Joint pain and swelling, Warm, swollen joints, Soft-tissue 
swelling morning stiffness, 
malaise and weakness 
Sarne as stage III 
Sarne as stage III, 
plus loss of function 
and early deformity 
excess SF, soft-tissue 
proliferation, pain and 
limitation of motion, 
rheumatoid nodules 
Sarne as stage III, but 
more pronounced swelling 
Sarne as stage III, plus 
instability of joints, 
flexion contractures, 
limited motion, 
extraarticular complications 
MRI reveals 
proliferative pannus; 
radiographic evidence 
of periarticular 
osteopenia 
Early erosions and 
narrowing of joint 
spaces 
MRI: Magnetic resonance imaging; SF: Synovial fluid; SM: Synovial membrane. 
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autoantigen(s) which trigger T-cell activation in RA, 
remain to be defined. 
1.2 RHEUMATOID ARTHRITIS: A MULTIFACTORIAL DISEASE 
1.2.1 Epidemiology of RA 
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The incidence of RA has been reported to be about 1% in the 
worldwide population (Harris, 1990), compatible with that 
found in Americans (0.3%-1.5%) (Pisetsky et al., 1991) and 
other populations (Linos et al., 1980). Depending on 
geographical locations and ethnic backgrounds, the 
incidence and prevalence of RA varies between different 
populations (Linos et al., 1980). There is a female 
predominance of RA with two- to three-fold more females 
affected than males (Linos et al., 1980). Furthermore, RA 
incidence rates have been shown to increase with age (Linos 
et al., 1980; Dugowson et al., 1991) and, although the age 
of onset is . variable, occurring in both young and elderly 
individuals, disease is prevalent among 60-64 year-old 
women (Dugowson et al., 1991). 
1.2.2 Immunogenetics of RA 
The HLA-DR4 family of class II MHC molecules comprises a 
series of related alleles, encoded by the HLA-DRBl locus, 
which differ in residues 57, 86 and codons 67-74, of the 
third hypervariable region (HVR) of the DR~l molecule 
( Figure 1. 1) (Gregerson et al. , 19 86) . 
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Figure 1.1 HLA-DR~l third hypervariable region amino acid 
sequences (residues 67-77) of RA-associated (A) and some 
HLA-DR4-positive alleles that are not associated with risk 
for RA (B). Compiled from Gregerson et al. (1986) and 
Wordsworth et al. (1989). 
{A) 
HLA-DRBl 
Allele 57 . . . . . . . . . 67 68 69 70 71 72 73 74 75 76 77 . . . . . . . . 86 
0101 DRl (Dwl) Asp . ........ Leu Leu Glu Gln Arg Arg Ala Ala Val Asp Thr ........ Gly 
0404 DR4(Dw14) Asp . ........ - - - - - - - - - - - . . . . . . . . Val 
0405 DR4 (Dw15) Ser . ........ - - - - - - - - - - - . . . . . . . . G 1 y 
0401 DR4(Dw4) Asp . ........ - - - - Lys - - - - - - . . . . . . . . Gl y 
1001 DRlO(-) Asp . ........ - - - Arg - - - - - - - . . . . . . . . Gl y 
1402 DR14 (Dw16) Asp . ......... - - - - - - - - - - - . . . . . . . . Gly 
{B) 
0402 DR4 (DwlO) Asp . ........ Ile - - Asp Glu - - - - - - . . . . . . . Val 
0403 DR4 (Dw13) Asp . ...... · .. - - - - - - - Glu - - - . . . . . . . Val 
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As mentioned previously, Dw4 (DRB1* 04 01 ) and Dw14 
(DRB1*0404 ) are the major susceptibility alleles each 
conferring risk for the development of seropositive RA in 
Caucasoids (Nepom et al., 1986; Nepom et al., 1989; 
Wordsworth et al., 1989). Moreover, a recent study (Weyand 
et al., 1992a) indicated that genotypes homozygous for t h e 
DRB1*0401 allele may predispose individuals to a more 
severe form of RA. These two RA-linked subtypes share a 
sequence motif, QRRAA or QKRAA, at residues 70-74, 
differing by a single arginine (Dw14) to lysine (Dw4 ) amino 
acid substitution at residue 71 (Wordsworth et al., 1989 ) . 
Figure 1.1 shows the DR~l third HVR amino acid sequences 
(residues 67-77) of RA-associated and some HLA-DR4-positive 
alleles that are not associated with risk for RA. 
In the study by Nepom et al. (1989), although Dw4 and Dw14 
accounted for most of the HLA genetic contribution to 
predisposition to RA, the majority of HLA-DR4-negative 
individuals carried the HLA-DRl(Dwl ) allele. This allele, 
as with DwlS, shares an identical Dw14-related sequence in 
the third HVR of the first domain of the DR~l molecule, 
unlike DwlO and Dw13, which have amino acid substitutions 
in this region of the domain (see Figure 1.1 ) . Both Dwl 
(Schiff et al., 1982; Gao et al., 1990b ) and DwlS (Ohta et 
al., 1982 ) have been associated with susceptibility to RA. 
In addition, DRlO and DR14 (Dw16 ) each has a Dw14-related 
sequence (Seyfried et al., 1988 ) ; both of these alleles 
have been reported to be increased in frequency in RA 
(Goronzy et al., 1986; Willkens et al., 1991 ) . 
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This Dw14-related sequence is part of a recognition si t e 
for T-cells (Goronzy et al., 1986; Sefried et al., 1988; 
Morel et al., 1990), and may be critical for the 
presentation of "arthritogenic" peptides to T-cells in the 
rheumatoid synovium (Todd et al., 1988). These findings of 
a shared Dwl4-related T-cell recognition epitope support 
the "shared epitope hypothesis" to explain disease 
susceptibility associated with diverse HLA haplotypes and 
may account for the apparent genetic heterogeneity among RA 
patients (Gregerson et al., 1987). 
The HLA-DR region, however, is probably not responsible for 
the entire genetic contribution to predisposition to RA. 
Therefore, in an attempt to identify additional genes 
conferring risk for RA, other loci have been examined. Most 
studies of immunoglobulin (Ig) heavy (Gm) and light chain 
(Km) genes revealed no association with particular Gm, or 
Km allotypes and susceptibility to RA, although some found 
an increase in the Glm(x) allotype in DR4-positive patients 
(reviewed by Sanders and Grennan, 1989). Furthermore, a DNA 
polymorphism of the Ig kappa light chain was shown to 
confer risk for RA among HLA-DR4-negative individuals 
(Moxley, 1989). In a study of HLA-DP gene polymorphisms and 
RA, an apparent increase in DPw4 was found, implicating a 
new class II association (Stephens et al., 1989). Gao et 
al. (1988) reported an association between RA and a TcR 
V~8-associated polymorphism. Lastly, although there was no 
linkage with DQa and DXa polymorphisms and RA (Bate et al., 
1990), several reports have shown an increase in 
DQB1*0301(DQ7) among DR4, DQ3 haplotypes (Singal et al., 
1987; Sansom et al., 1987; Gao et al., 1988), indicating 
that DQ~ genes may influence HLA-linked susceptibility to 
RA. 
In conclusion, although it is likely that HLA-DR is the 
major susceptibility locus in RA, there is some evidence 
that other genes may contribute to predisposition to the 
disease. 
1.2.3 Environmental factors and RA 
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Numerous infectious agents have been proposed as the 
initial trigger of RA in genetically susceptible 
individuals and in other arthritides of humans, such as 
Lyme arthritis, a microbial causative agent has been 
identified (for review see Espinoza et al., 1988). 
Proliferative responses of T-cells from patients with Lyme 
arthritis have been shown against antigens of the 
spirochete Borrelia burgdorferi (Yoshinari et al., 1991), 
including a 60-kDa protein, most likely a member of the 
60- to 65-kDa heat-shock protein (hsp) family (HSP60) 
(Shanafelt et al., 1991). In addition, chronic Lyme 
arthritis appears to have an irnrnunogenetic basis, since 
most patients are usually HLA-DR4 or HLA-DR2 (Steere et 
al., 1990), indicating that an MrfC-restricted immune 
response to B. burgdorferi triggers chronic arthritis. 
Pathogens potentially associated with RA include 
Mycobacteria (Strober and Holoshitz, 1990; Lydyard et al., 
1991; Res et al., 1991; Van Eden, 1991 ) , parvoviruses 
(Simpson et al., 1984), Epstein-Barr virus (Depper and 
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Zvaifler, 1981), rubella virus (Martenis et al., 1968) and 
mycoplasma (Cole and Cassell, 1979). The association is 
usually based on serum antibody titres, or a recent history 
of infection, concurrent with the initial presentation of 
the disease. However, because of the inability to isolate 
infectious organisms from affected joints, there is no 
substantial evidence to implicate these agents in the 
pathogenesis of RA. In the case of Epstein-Barr virus 
infection, linkage with RA is supported because of homology 
between the viral glycoprotein gpllO and the RA 
susceptibility determinant, Dw4 (Roudier et al., 1988; 
Roudier et al., 1989). Disease could be triggered by 
molecular mimicry between the foreign environmental antigen 
and the host self antigen (Oldstone, 1987), resulting in 
cross-reactivity of T-cells specific for viral gpllO with 
the HLA-Dw4 molecule. Possible shared epitopes between 
. 
other microbial agents and self antigens (see Table 1.3), 
such as hepatitis B virus DNA polymerase and the myelin 
basic protein (MBP)-encephalitogenic determinant (Fujinami 
and Oldstone, 1985), further support the concept of 
molecular mimicry and infectious agents as the etiological 
agents of autoimmune diseases. 
Table 1.3 Possible antigenic molecular mimicry. 
Relevant autoimmune 
disease 
Self antigen/microbial antigen* Infectious agent Reference 
Rheumatoid arthritis Cartilage component/heat-shock protein 65 Mycobacterium tuberculosis a 
lactoferrin, transferrin and HLA-DR~/heat Mycobacterium tuberculosis b 
-shock protein 65 
Multiple sclerosis 
Myasthenia gravis 
Coeliac disease 
Myelin basic protein/DNA polymerase Hepatitis B virus 
Acetylcholine receptor/capsid protein VP2 Poliovirus 
A-gliadin of wheat gluten/Elb protein Adenovirus type 12 
Ankylosing spondilytis, HLA-B27/nitrogenase 
Reiter's syndrome 
Insulin - dependent 
diabetes mellitus 
Glutamic acid decarboxylase/P2-C protein 
HLA-DQB/El envelope protein 
*Based on sequence homology and/or immunological cross-reac tivity. 
Klebsiella pneumoniae 
Coxsackie virus 
Rubella, Epstein - Barr virus 
C 
d 
e 
f 
g 
h 
References: avan Eden et al., 1985; Holoshitz et al., 1986; Van Eden et al., 1988, bAguas et al., 199 0, 
cFujinami and Oldstone, 1985, doldstone, 1987, eKagnoff et al., 1984, fschwimmbeck et al., 1987, 
9Kaufman et al., 1992, hHorn et al., 1988. f--' 
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1.2.3.1 Association of Mycobacteria with RA 
There is strong evidence implicating a role for 
Mycobacteria, especially hsp, in the pathogenesis of RA 
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(for review see Strober and Holoshitz, 1990; Lydyard et 
al., 1991; Res et al., 1991; Van Eden, 1991). Firstly, the 
skin-test response to tuberculin has been shown to be 
increased in DR4-positive RA patients, indicating enhanced 
T-cell mediated responsiveness to Mycobacteria (Bahr et 
al., 1988). In addition, serum IgG antibody levels to 
mycobacterial hsp65 are significantly higher in RA patients 
compared to controls (Tsoulfa et al., 1989). There is an 
altered N-glycosylation pattern of serum IgG in patients 
with RA, resulting in an increase of IgG glycoforms that 
lack terminal galactose and have a higher content of 
agalactosyl oligosaccharides (Parekh et al., 1985; 
Rademacher et al., 1988). Elevated levels of agalactosyl 
IgG occurs in tuberculosis and some types of leprosy, which 
are known mycobacterial diseases, and in Crohn's disease, 
thought to be associated with Mycobacteria (Rademacher et 
al., 1988; Lydyard et al., 1991). 
Adjuvant arthritis (AA), an animal model of human RA, can 
be induced in irradiated rats by transfer of T-cell clones 
or lines specific for mycobacterial antigens, in particular 
hsp65 (Holoshitz et al., 1983; Van Eden et al., 1985), 
implicating a primary role for hsp-reactive T-cells in the 
pathogenesis of AA. Proliferative responses of synovial 
fluid (SF) T-cells from rheumatoid joints have been 
demonstrated against mycobacterial antigens (Holoshitz et 
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al., 1986; Holoshitz et al., 1989; Pope et al., 1991; Sioud 
et al., 1991b), including hsp65 (Res et al., 1988; Gaston 
et al., 1989; Holoshitz et al., 1989; Soderstrom et al., 
1990; Pope et al., 1992), implicating the involvement of 
hsp-reactive T-cells in the development of RA. The enhanced 
SF T-cell reactivity to Mycobacteria may reflect 
. . in vivo 
expansion within the joint of those T-cells that have 
cross-reacted with self antigen(s), such as cartilage 
components (Holoshitz et al., 1986), self hsp (Karlsson-
Parra et al., 1990; Li et al., 1992), or DRfi molecules 
(Aguas et al., 1990). Furthermore, there is evidence that 
T-cells bearing 1/8 TcRs preferentially recognise 
mycobacterial antigens, as reviewed later in this Chapter. 
1.2.4 Hormonal regulation in RA 
Although the MHC is clearly important in determining 
susceptibility to RA, its role in regulation of the immune 
response does not readily explain other aspects of the 
disease, such as female predominance, which indicates that 
sex hormones may also play a role (Wilder, 1990). There is 
some evidence for a protective effect of pregnancy (Spector 
et al., 1990; Silman et al., 1992) and oral contraceptive 
use (Wingrave, 1978; Vandenbroucke et al., 1982) on the 
development of RA. Similarly, in animal models of arthritis 
such as collagen-induced arthritis (CIA) (Holmdahl et al., 
1990), female rats are more susceptible to disease than 
males (Larsson et al., 1990) although pregnancy protects 
mice against developing CIA (Waites and Whyte, 1987). 
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Furthermore, oestrogen is an important irnrnunomodulator in 
the development of experimentally-induced arthritis and has 
been shown to suppress CIA in rats (Larsson and Holmdahl, 
1987). Together, these findings indicate that sex hormones 
are at least partly responsible for the differences in 
gender observed in human RA and animal arthritis. 
In streptococcal cell wall-induced arthritis in rats 
susceptibility is related to defective hypothalamic-
pituitary-adrenal (HPA) axis responsiveness to inflammatory 
mediators (Sternberg et al., 1989a) and is caused partly by 
an inability to synthesise corticotropin-releasing hormone 
(Sternber et al., 1989b). Consequently, regulation or 
suppression of autoimmune responses via enhanced production 
of corticosteroids and other HPA axis hormones, is 
prevented. Abnormalities of the hypothalamus have not been 
demonstrated in RA patients despite the disease-suppressive 
effects of corticosteroids (Wilder, 1990). Recent reports, 
though, have suggested dysfunction of the HPA axis in RA 
patients, because of decreased numbers of receptors for 
immunosuppressive glucocorticoids (Schlaghecke et al., 
1992) and impaired HPA axis responsiveness to inflammatory 
stimuli (Chikanza et al., 1992). Finally, neuropeptides, 
such as substance P, shown to contribute to the severity of 
experimental arthritis (Levine et al., 1984), may also 
influence the development of RA. 
1.2.5 Immunological factors and RA: Mediators of joint 
inflammation 
Migration of T-cells through the endothelium and i n to the 
synovial microenvironment is mediated by a wide array of 
cell surface adhesion molecules (reviewed by Stoolman, 
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1989; Osborn, 1990; Springer, 1990), that are induced in 
response to various inflammatory mediators such as 
interferon-gamma (INF-1), interleukin (IL) -1 and tumour 
necrosis factor (TNF) (Pisetsky et al., 1991). T-cells 
isolated from RA synovial membrane (SM) and synovial fluid 
showed enhanced binding to endothelial molecules, 
endothelial-leukocyte adhesion molecule (ELAM) -1 and 
vascular cell adhesion molecule (VCAM)-1, which, together 
with very late activation (VLA)-4 mediated proliferation in 
response to interaction with VCAM-1 and fibronectin, may 
allow continual entry of T-cells into the inflamed synovium 
(Postigo et al., 1992). The expression of adhesion 
receptors by activated T-cells may facilitate the homing of 
specific T-cells to the sites of inflammation. 
The rheumatoid synovium is characterised by an intense 
lymphocytic infiltration (Van Boxel and Paget, 1975 ) 
containing predominantly activated T-cells (Burmester et 
al., 1981; Burmester et al., 1984), as defined by the 
expression of various molecules including class II MHC and 
IL-2 receptor (IL-2R). Most T-cells infiltrating the 
rheumatoid joint are of the CD4+ a/fi phenotype (Duke et 
al., 1982; Poulter et al., 1985; Reme et al., 199 0) 
although 1/0 T-cells are also prominent (Reme et al., 1990) 
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as well as B-cells and macrophages (Abrahamsen et al., 
1975; Janossy et al., 1981 ) . After encountering a limite d 
number of joint-specific self antigenic determinants, 
infiltrating T-cells are thought to initiate an autoimmune 
response which leads to chronic inflammation and joint 
damage (Panayi et al., 1992 ) . 
Several cytokines and growth factors have been detected in 
rheumatoid joints and are likely to play an important role 
in the inflammatory process (for review see Harris, 1990; 
Panayi et al., 1992; Brennan and Feldmann, 1992 ) . For 
example, IL-1 (Nouri et al., 1984), TNF-a (Saxne et al., 
1988), IL-6 (Bhardwaj et al., 1989) and granulocyte-
macrophage colony-stimulating factor (Xu et al., 1989 ) , 
derived mainly from macrophages and fibroblasts, are found 
in abundance. In addition, platelet-derived growth factor 
(Kumkumian et al., 1989) and transforming growth factor-fi 
(Layfyatis et al., 1989) are present in rheumatoid joints. 
Despite the presence of activated T-cells in affected 
joints, low levels of T-cell activation products such as 
IL-2 (Firestein et al., 1988) and IFN-1 (Firestein and 
Zvaifler, 1987) have been reported even though rnRNAs for 
IL-2, IL-2R and IFN-1 are readily detected (Buchan et al., 
1988; Warren et al., 1991; Waalen et al., 1992 ) . IL-2 and 
IL-4 appear to be important mediators of SF T-cell 
activation induced by Mycobacteria (Burford-Foggs et al., 
1991 ) . A detailed discussion of cytokines in inflammat o ry 
responses is not the issue of this thesis, but it i s 
important to emphasise their involvement in RA. 
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1.3 BIOLOGY OF THE HUMAN T-CELL RECEPTORS 
1.3.1 Structure of the TcR complex: TcR subunits 
The TcR complex expressed by human T-cells (see Figure 
1.2), comprises, as in the mouse, two variable TcR chains 
and at least five invariant CD3 chains (reviewed by Allison 
and Lanier, 1987; Klausner et al., 1990; Ashwell and 
Klausner, 1990; Altman et al., 1990). The TcR is a 
polymorphic, disulphide-linked heterodimeric glycoprotein, 
composed of a/~ or 1/8 subunits. The primary structure of 
each TcR polypeptide (Figure 1.3) is predominantly 
extracellular and comprises a hydrophobic leader sequence, 
a variable (V) region including joining (J) and diversity 
(D) (~- and 8-chains) segments and a constant (C) region 
with hinge or connecting peptide (Allison and Lanier, 1987; 
Davis and Bjorkman, 1988). The transmembrane region 
precedes a short cytoplasmic tail (Allison and Lanier, 
1987). There are conserved cysteine residues in the v- and 
C-regions, at positions consistent with the presence of 
internal disulphide bonds, and a cysteine residue proximal 
to the transmembrane region that is probably involved in 
interchain disulphide bonding (Allison and Lanier, 1987; 
Davis and Bjorkman, 1988). In addition, each clonotypic 
chain has at least one positively charged lysine residue in 
the transmembrane region (Allison and Lanier, 1987; Altman 
et al., 1990). 
Each TcR chain is a member of the Ig gene superfamily, 
which contains, amongst others, the light (~ and A) - and 
17 
Figure 1.2 Schematic representation of the subunit 
structure of the most common a/fi-containing T-cell receptor 
complex (adapted from Klausner et al., 1990). The majority 
of receptor complexes contain ss-homodimers whereas a small 
proportion have rn-heterodimers. Charged amino acid 
residues in the transmernbrane regions of both T-cell 
receptor (TcR) and CD3 components are indicated, as well as 
the presence of disulphide bonds (S-S). 
Extracellular 
Intracellular 
ss 
- -
a 
ss 
+ + 
+ 
CD3 zeta TcR 
chains chains 
8 
- -
CD3 
chains 
y 
-
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Figure 1.3 Primary structure of T-cell receptor 
polypeptides. The contributions of the various T-cell 
receptor gene segments to the immunoglobulin-related 
variable and constant domains are illustrated. Cysteine 
residues are indicated as 11 8 11 and lysine as "K". C: 
constant; CY: cytoplasmic; D: diversity (~- and 8-chains); 
H: hinge; J: joining; L: leader; TM: transmembrane; V: 
variable. 
L V D J C H 1M CY 
s s s s s 
Variable domain Constant domain 
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heavy-chain Ig gene families and the class I and class II 
genes of the MHC (Hunkapillar and Hood, 1986; Williams, 
1987; reviewed by Hunkapillar and Hood, 1989). Single-gene 
members include the T-cell accessory molecules, CD4 and 
CD8, and the CD3 1, 8 and E genes (Williams, 1987; 
Hunkapillar and Hood, 1989). Members of the Ig gene 
superfamily share a protein structure that contains at 
least one Ig homology unit, representing a sequence of 
about 110 amino acids with a central intrachain disulphide 
bond (Hunkapillar and Hood, 1986). The TcR chains are 
composed of extracellular lg-related V and C domains each 
comprising a series of~ strands, that form two~ sheets 
stabilised by a disulphide bridge (Hunkapillar and Hood, 
1986; Hunkapillar and Hood, 1989). 
1.3.1.1 a/8 TcR 
The a/~ heterodimer (reviewed by Kappler et al., 1983; 
Haskins et al., 1983; Meuer et al., 1984) has a molecular 
weight of 90-kDa and consists of an acidic a-chain (49-kDa) 
and a more basic ~-chain (43-kDa) (Meuer et al., 1983). 
This receptor is expressed on the majority of mature 
peripheral blood CD3+ T-cells and is MHC-restricted in 
activity (Haskins et al., 1983; Meuer et al., 1984). On 
helper CD4+ T-cells, the receptor recognises antigen in 
association with class II MHC molecules whereas cytotoxic 
CDs+ T-cells recognise antigen in the context of class I 
molecules (Meuer et al., 1984). Evidence suggests that CD4 
and CDS enhance the T-cell response, by binding to non-
polymorphic regions of the MHC class II and class I 
molecules, respectively, thereby stabilising the 
interaction between the TcR and antigen-presenting cell 
(Meure et al. 1984; Parnes, 1989). 
1.3.1.2 1/8 TcR 
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The 1/8 heterodimer (reviewed by Brenner et al., 1988; 
Porcelli et al., 1991) consists of a 1-chain (55-kDa) and a 
8-chain (40-kDa) and is associated with the CD3 protein 
complex (Brenner et al., 1986). The majority of this 
receptor type is expressed on the CD4-CD8- subset of 
peripheral blood cn3+ T-cells, accounting for about 0.5-16% 
of the T-cell population (Borst et al., 1987; Lanier et 
al., 1987; Groh et al., 1989). Unlike T-cells expressing 
a/~ TcR, 1/8 T-cells display cytotoxic activity which is 
usually non-MHC-restricted (Borst et al., 1987; Brenner et 
al., 1987), although there is evidence that 1/8 T-cells 
also recognise conventional peptide/MHC complex (Holoshitz 
et al., 1992). 
There are at least three molecular forms of the 1/8 TcR, a 
disulphide-linked heterodimer with TcR 1 polypeptide of 40-
kDa (Form 1) and two non-disulphide-linked heterodimers 
with TcR 1 polypeptides of 40- or 44-kDa (Form 2ab) and 55-
kDa (Form 2abc) (Brenner et al., 1987; Borst et al., 1987; 
Hochstenbach et al., 1988). The 1 polypeptides in these 
non-disulphide-linked 1/8 TcRs are encoded by the c12 gene 
and possess two or three second exon segments, 
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respectively, that lack cysteine residues (Lefranc et al., 
1986a; Pelicci et al., 1987). In contrast, the 1 
polypeptide in Form 1 is encoded by the c11 gene and has a 
single exon II that codes for cysteine (Lefranc et al., 
1986b; Pelicci et al., 1987). 
1.3.2 Structure of the TcR complex: CD3 components 
The CD3 (formerly T3) complex consists of at least five 
non-polymorphic polypeptides, 1, 8, E, ( and n and is non-
covalently associated with the TcR subunits (Ashwell and 
Klausner, 1990; Altman et al., 1990). Each chain is 
relatively small with core polypeptide molecular weights 
ranging from 16- to 28-kDa (Altman et al., 1990). The CD3 
1- and 8-chains are glycoproteins whereas the other chains 
are not glycosylated (van den Elsen et al., 1984; Gold et 
al., 1986; Ashwell and Klausner, 1990; Altman et al., 
1990). Most (-chains (90%) are found as homodimers whereas 
a small proportion (10%) form heterodimers with then 
subunit (Altman et al., 1990). Furthermore, (-Fc1 and n-Fc1 
heterodimers have also been observed (Klausner et al., 
1990; Orloff et al., 1990). 
Like the TcR chains, the CD3 complex components are members 
of the Ig gene superfamily because of their predicted 
structural homology to Ig domains (Gold et al., 1987; 
Williams, 1987; Hunkapillar and Hood, 1989). In contrast, 
the primary structure of each CD3 component has a 
considerably larger cytoplasmic domain, which may play a 
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role in interactions with intracellular components involved 
in signal transduction (Allison and Lanier, 1987; Ashwell 
and Klausner, 1990). The transmembrane region of each chain 
has a negatively charged residue (aspartic acid in o, E and 
(; glutamic acid in "() (Altman et al., 1990), which, by 
forming salt bridges with lysine residues in the 
transmembrane regions of the TcR chains, may stabilise the 
non-covalent association of the TcR/CD3 complex (van den 
Elsen et al., 1984; Gold et al., 1986; Allison and Lanier, 
1987). 
1.4 MOLECULAR GENETICS OF THE HUMAN T-CELL RECEPTOR GENES 
1.4.1 Chromosome localisation 
The TcR "(-chain locus maps to the short arm of chromosome 
7, at position 7pl5 (Murre et al., 1985) and the ~-chain 
locus to the long arm, at position 7q32 (Morton et al., 
1985). The a-chain locus is embedded within the a-chain 
locus (Griesser et al., 1988), which resides on chromosome 
14, at position 14qll-12 (Caccia et al., 1985). In mouse, a 
similar arrangement of o loci embedded within a loci, 
occurs on chromosome 14, whereas the~ and 'Y loci reside on 
chromosomes 6 and 13, respectively (Penninger et al., 
19 91) . 
The germline configuration of genes encoding different 
human TcR chains is similar to the Ig genes, and murine TcR 
genes. These comprise separate, non-contiguous V-, D-, J-
and C-region gene segments (Siu et al., 1984). Each locus 
will be discussed separately describing the structure, 
repertoire and genomic organisation of the TcR gene 
segments (refer to Figures 1.4 to 1.6 and Table 1.4). 
1.4.2 Genomic organisation of the human TcR a-chain locus 
Nucleotide sequence analysis of TcR a-chain cDNA clones 
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(Yanagi et al., 1985; Yoshikai et al., 1986; Klein et al., 
1987; Kimura et al., 1987) revealed that the expressed Va 
repertoire in humans consists of at least 41 Va gene 
segments grouped into 22 distinct subfamilies (Val to Va22) 
based on >75% nucleotide homology (Wilson et al., 1988). 
Val and Va2 are the largest subfamilies with nine and seven 
members, respectively, whereas 15 subfamilies are 
represented by a single gene (Wilson et al., 1988). More 
recently, anchored polymerase chain reaction (AN-PCR), 
designed to amplify sequences with unknown 5'-ends (Frohman 
et al., 1988; Loh et al., 1989), has been used to analyse 
Va gene expression by T-cells and has led to the 
identification of seven additional Va subfamilies (Vaw23 to 
Vaw29) (Roman-Roman et al., 1991). Furthermore, Yassai et 
al. (1992) identified a new Va family (VA30.1) and a new 
member of the Va6 family, bringing a total, to date, of 49 
human Va genes grouped into 30 distinct Va subfamilies. In 
comparison, 36 murine Va genes grouped into 13 subfamilies, 
have been reported (Wilson et al., 1988; Komori et al., 
1990). The human Va genes are located upstream of the Ja 
segments and each is composed of two exons separated by an 
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intron of 90 to 400 bp; the first exon (50 bp ) encodes the 
leader sequence and the second exon (2 50-350 bp ) encodes 
the remainder of the Va region (Wilson et al., 1988 ) . 
Combined studies have identified 46 Ja gene segments 
(Yoshikai et al., 1985; Yanagi et al., 1985; Yoshikai et 
al., 1986; Klein et al., 1987; Kimura et al., 1987; Wilson 
et al., 1988), although Klein et al. (1987) estimated that 
there may be more than 100 Ja segments in humans. Further 
analysis of the Ja repertoire by AN-PCR has identified 14 
novel Ja gene segments (Roman-Roman et al., 1991), bringing 
a total, to date, of 60 human Ja segments. The Ja gene 
segments are located at various distances upstream of the 
single Ca gene extending to at least 35 kbp of DNA 
(Yoshikai et al., 1985). Each segment encodes 16-25 amino 
acids of the V domain including a highly conserved central 
core sequence (Yoshikai et al., 1985; Klein et al., 1987; 
Kimura et al., 1987; Wilson et al., 1988). Despite 
conservation at the protein level, nucleotide homology 
ranges from 40-60% (Klein et al., 1987). 
The Ca gene has four exons (Yoshikai et al., 1985); exon I 
encodes most of the extracellular C domain (90 amino 
acids), exon II, the remaining 15 amino acids of the C-
region including part of the peptide connector, exon III, 
the transmernbrane and cytoplasmic tail domains (-35 amino 
acids) and exon IV contains 3'-untranslated sequences 
(Yoshikai et al., 1985). The transmernbrane region contains 
an arginine, as well as lysine residue, which may be 
involved in interactions with other polypeptide chains 
(Raulet, 1989a). 
1.4.3 Genomic organisation of the human TcR ~-chain locus 
Several studies (Tillinghast et al., 1986; Kimura et al., 
1986; Concannon et al., 1986) have indicated that the 
expressed V~ repertoire in humans consists of at least 54 
V~ gene segments grouped into 20 subfamilies (V~l-V~20) 
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(Wilson et al., 1988) and is estimated to contain 
approximately 60 (Concannon et al., 1986) and no more than 
100 V~ gene segments (Kimura et al., 1986). The largest 
subfamily appears to be V~6 with nine members, whereas 
seven families contain a single member and the remainder 
have two to five members (Wilson et al., 1988). More recent 
reports, though, have identified additional V~ gene 
families, namely V~w21 (TCRVB21: Wilson et al., 1990) with 
two members and V~w22, 23 and 24 each represented by a 
unique sequence (Ferradini et al., 1991; Robinson, 1991). 
Nine undescribed V~ segments belonging to known subfamilies 
have also been identified (Ferradini et al., 1991; Lunardi 
et al., 1992a), bringing a total, to date, of 68 human V~ 
genes grouped into 24 distinct V~ subfamilies. In 
comparison, there are 23 murine V~ genes grouped into 18 
subfamilies (Komori et al., 1990). Each human V~ gene 
segment is composed of two exons separated by an intron of 
about 100 bp; exon I (49 bp) encodes the hydrophobic leader 
sequence and exon II (295 bp) encodes the remaining five 
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amino acids of the leader sequence and most of the V domain 
(Siu et al., 1984). 
There are 13 Jfi gene segments organised into two clusters, 
Jfil and Jfi2 (see Figure 1.4), each located about five kbp 
upstream of a single Cfi gene and containing six and seven 
Jfi gene segments, respectively (Toyonaga et al., 1985). The 
Jfi gene segments (48 bp) have at least 55% nucleotide 
homology (Siu et al., 1984) and each encodes 15-17 amino 
acids of the V domain (Siu et al., 1984; Wilson et al., 
1988), including, as with the Ja segments, a highly 
conserved central core sequence (Klein et al., 1987). The 
two Dfi segments, Dfil and Dfi2, are about 600 bp upstream of 
Jfil and Jfi2, respectively (Toyonaga et al., 1985) and each 
encodes an additional three to four amino acids of the V 
domain (Wilson et al., 1988). 
Cfil and Cfi2 are approximately ten kbp apart and are highly 
homologous ·in coding sequence and genomic organisation, 
differing by only six amino acids in the 3'-coding region 
(Toyonaga et al., 1985). However, apart from a highly 
conserved region of about 95 bp, 3' of exon I, their intron 
sequences are different. Each Cfi gene is encoded by four 
exons, the first two exons encode the majority of the 
extracellular C domain (135 amino acids), the third exon 
encodes the transmembrane region and the fourth exon 
contains the cytoplasmic tail and 3'-untranslated sequences 
(Toyonaga et al., 1985; Wilson et al., 1988). 
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Figure 1.4 Genomic organisation of the human T-cell 
receptor fi-chain locus. The Vfi genes are located upstream 
of two Dfi/Jfi clusters, each associated with a single Cfi 
gene. Nomenclature according to Toyonaga et al. (1985). C: 
constant; D: diversity; J: joining; V: variable. 
V~l V~2 V~n D~l J ~l (l . 1-1 . 6 ) C~l D~2 J ~2 (2 . 1-2 . 7) C~2 
••• 11111110 11111111 D 
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1.4.4 Genomic organisation of the human TcR 1-chain locus 
On chromosome 7, the human TcR 1-chain genes span about 160 
kbp of germline DNA (reviewed by Raulet, 1989a; Lefranc et 
al., 1989; Lefranc and Rabbitts, 1990). Currently, there 
are fourteen known v1 genes, 12 of which belong to four 
subgroups, v1I-V1IV, based on nucleotide homology (Lefranc 
and Rabbitts, 1990). Subgroup I contains five functional 
genes (V2, V3, V4, VS and V8) and four pseudogenes (Vl, 
VSP, V6 and V7) (Lefranc et al., 1986a), whereas subgroups 
II, III and IV each contain a single V gene designated V9, 
VlO and Vll, respectively (Lefranc et al., 1986a; Lefranc 
et al., 1989). Two pseudogenes, VA and VB, are located 
upstream of V9 and Vll, respectively (Lefranc et al., 
1989). In the mouse system, there are seven v1, four J1 and 
four c1 genes (Raulet, 1989a; Penninger et al., 1991). 
There are two human J1 gene clusters (see Figure 1.5); J11 
contains JPl, JP and Jl; J12 contains JP2 and J2, located 
four kbp upstream of c11 and c12, respectively (Lefranc et 
al., 1989). JP is located four kbp upstream of Jl (Lefranc 
et al., 1986a). The nomenclature adopted by Quertermous et 
al. (1987) has J11.1, 1.2 and 1.3 in the first cluster of 
J1 segments and J12.1 and 2.2 in the second J1 cluster. 
c11 and c12 are separated by about 16 kbp (Lefranc and 
Rabbitts, 1985) and although they are highly homologous in 
their coding sequences, differ markedly in structure 
because of heterogeneity in the membrane proximal connector 
region, encoded by exon II (Lefranc et al., 1986b). The c11 
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Figure 1.5 Genomic organisation of the human T-cell 
receptor 1-chain locus. v1 pseudogenes are indicated by~ 
whereas the other v1 genes are functional. The v1 genes are 
located upstream of two J1 clusters, each associated with a 
single c1 gene. The c12 gene has either duplication or 
triplication of the second exon segment, represented by 
ex2R. Nomenclature according to Lefranc et al. (1989). C: 
constant; J: joining; V: variable. 
\}JV l V2 V3 V4 VS \}JVSP \}JV 6 \lfV7 VB \}JVA V9 VlO \}JVB Vll JPl JPJl Cyl JP2 J2 Cy2 
111111111111111 B a ~ I 111 I a ~ II I I 11 I 
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LJ LJ LJ 
vyr vyr r vyr r r vyrv 
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gene is composed of three exons which span about six kbp, 
representing the C domain (exon I: 330 bp), the membrane 
proximal connector region (exon II: 48 bp) and the 
transmernbrane and cytoplasmic domains (exon III: 141 bp ) 
plus a 3 1 -untranslated sequence (Lefranc et al., 1986b; 
Yoshikai et al., 1987). The c12 gene contains four or five 
exons depending on whether there are duplicated or 
triplicated second exon segments (Pelicci et al. 1987) and 
spans 9.5 or 12 kbp, respectively (Lefranc et al., 1986b; 
Buresi et al., 1989). The second exon segments of the c12 
gene lack codons for cysteine residues, thought to be 
involved in interchain disulphide bonding with 8-chains 
(Lefranc et al., 1986b; Pelicci et al., 1987). 
Consequently, there are several molecular forms of the TcR 
1/8 heterodimer, described in section 1.3.1.2, depending 
upon which C-region gene is utilised (Pelicci et al. 1987). 
1.4.5 Genomic organisation of the human TcR 8-chain locus 
The human 8-chain genes (reviewed by Raulet, 1989a; Lefranc 
and Rabbitts, 1990) span at least 30 kbp of DNA and consist 
of six Vo gene segments (Vol-Vo6) (Satyanarayana et al., 
1988; Hata et al., 1989; Takihara et al., 1989), three D8 
genes (Dol-Do3) (Loh et al., 1988; Takihara et al., 1988b), 
three J8 genes (J81-J83) (Takihara et al., 1988b) and a 
single Co gene (Takihara et al., 1988a). In the mouse, 
eight Vo subfamilies comprising at least ten Vo gene 
segments, two Do, two J8 and a single C8 gene, have been 
identified (Raulet, 1989a; Penninger et al., 1991). 
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The genomic organisation of the human a/o V-region has not 
been completely defined, although Vo and Va genes appear to 
be interspersed along the chromosome (Satyanarayana et al., 
1988). Unlike Vol and Vo2, which lie upstream of Co, Vo3 is 
approximately three kbp downstream of Co in an inverted 
orientation (Hata et al., 1989) (see Figure 1.6). The Vo4 
subfamily is highly homologous to a Va gene segment 
(Va6.1), differing by only 11 bp (Takihara et al., 1989), 
indicating the potential for overlapping usage of Va and Vo 
gene segments. Hybrid TcR Vo-Ja-ca transcripts have been 
reported (Miossec et al., 1990; Sottini et al., 1991a) as 
well as hybrid Va-Co transcripts (Guglielmi et al., 1988). 
The three functional Do segments, Dol, Do2 and Do3, have 
been located ten, 9.6 and one kbp upstream of Jol (Takihara 
et al., 1988b; Loh et al., 1988). Jol, Jo2 and Jo3 are -12, 
5.7 and 3.4 kbp upstream of the first exon of the Co gene 
(Takihara et al., 1988b). Each Jo segment encodes 16-19 
amino acids of the V domain including the consensus core 
sequence, Phe-Gly-X-Gly, characteristic of TcR J-region 
segments (Takihara et al., 1988b). 
The Co gene is encoded by four exons which cover 
approximately five kbp, at a position 85 kbp upstream of 
the Ca gene (Takihara et al., 1988a; Takihara et al., 
1988b). Exon I encodes the majority of the extracellular C 
domain, exon II encodes the connecting peptide and exon III 
encodes the transmernbrane region and cytoplasmic portion. 
The last exon contains 3'-untranslated sequences (Takihara 
et al., 1988a). As with the Ca gene, the transmernbrane 
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Figure 1.6 Genomic organisation of the human T-cell 
receptor a- and o-chain loci. Theo locus is embedded 
within the a locus between the Va and Ja gene segments. The 
Vo genes are interspersed along the chromosome with the Va 
genes and are positioned upstream of the Do and Jo 
segments. The Vo3 gene is located downstream of the Co 
gene, as opposed to Vol and Vo2. C: constant; D: diversity; 
J: joining; V: variable. 
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D ~ D f?J m u Im I 
va /v8 8 locus 
J 82 J 83 c8 v83 
I I 17:Il WW ~ 
' 
J a ca 
nnnnononono D 
a locus 
region of Co encodes a basic arginine, as well as lysine 
residue (Raulet, 1989a), which may be involved in 
interactions with other polypeptide chains. 
1.4.6 Polymorphism and disease association 
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Numerous restriction fragment length polymorphisms in the 
non-coding regions of the C and V gene segments of the TcR 
a- (Robinson and Kindt, 1985; So et al., 1987; Oksenberg et 
al., 1988; Grier et al., 1990; reviewed by Chan et al., 
1990), fi- (Berliner et al., 1985; Robinson and Kindt, 1985; 
Concannon et al., 1987; Oksenberg et al., 1988; Maksymowych 
et al., 1991) and 1-chain (Dunckley et al., 1988; Font et 
al., 1988; Ghanem et al., 1989; Ghanem et al., 1991), have 
been described. More recently, germline polymorphisms in 
the coding regions have been detected in some Vfi (Hansen et 
al., 1992; Charmley et al., 1993) and Va gene segments 
(Wright et al., 1991), which can lead to null alleles 
(Wright et al., 1991; Charmley et al., 1993). Deletion of 
germline Vfi gene segments is rare (Concannon et al., 1987), 
although repertoire polymorphism at the V1I locus has 
frequently been reported and is primarily due to deletion 
of the V14 and V15 gene segments (Font et al., 1988; Ghanem 
et al., 1989). Allelic variants of the c12 gene, which vary 
in the number of exon II segments (Lefranc et al., 1986a), 
can be detected by restriction fragment length polymorphism 
analysis (Buresi et al., 1989). 
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Several reports have revealed possible associations of 
germline polymorphisms of the TcR with various autoimmune 
diseases (reviewed by Kumar et al., 1989; Posnett, 1990; 
Hillert and Olerup, 1992; Steinman et al., 1992 ) , including 
multiple sclerosis (MS) (Seboun et al., 1989; Oksenberg et 
al., 1989), insulin dependent diabetes mellitus (Millward 
et al., 1987), RA (Gao et al., 1988; Whelan Funkerhouser et 
al., 1992), membranous nephropathy (Demaine et al., 1988), 
autoimmune hypothyroidism (Weetman et al., 1987) and 
juvenile rheumatoid arthritis (JRA) (Maksymowych et al., 
1992). However, since many groups have either found a 
different TcR restriction fragment length polymorphism 
association or have been unable to confirm these reported 
findings of TcR gene restriction fragment length 
polymorphisms and association with autoimmune disease, the 
evidence that certain TcR alleles actually influence 
disease susceptibility is inconclusive. 
1.4.7 Generation of TcR diversity 
Immature T-cells proliferate and differentiate in the 
thymus into mature and functional T-cells. An important 
process that occurs during T-cell ontogeny, is 
rearrangement of the individual germline TcR gene segments 
(Siu et al., 1984; Hayday et al., 1985; Kronenberg et al., 
1986). Rearrangement involves the recognition of 
recombination signals which flank the various V, D and J 
coding sequences, as with Ig genes (Early et al., 1980). 
Each signal is comprised of a highly conserved heptamer, a 
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variable spacer of 12 or 23 nucleotides and a conserved 
nanomer. Recombination signals with short spacers are found 
5' to D and J gene segments and those with long spacers 3' 
to V and D segments (Siu et al., 1984; Hayday et al., 
1985). Due to this arrangement and since a short spacer 
rearranges with a long spacer (Early et al., 1980), usage 
of D and J segments is optional. Furthermore, for the 8-
chain, multiple D segment usage is possible, thus 
increasing the potential for diversity of the 1/8 TcR (Loh 
et al., 1988; Raulet, 1989a). 
T-cell development in the thymus is thought to proceed via 
several complex stages, as proposed by studies in the mouse 
system (reviewed by Ferrick et al., 1989; Haynes et al., 
1989; Lafaille et al., 1990; Nikolic-Zugic, 1991). T-cell 
precursors or stem cells ("double-negative" CD4-CD8-
thymocytes) originate in the fetal liver or bone marrow and 
migrate to the thymus where they undergo extensive TcR gene 
rearrangement (Ferrick et al., 1989). Through a complex 
series of intermediates, these cells eventually diverge 
into a/~ and 1/8 committed lineages which subsequently 
undergo intrathymic positive and negative selection 
(Kappler et al., 1987; Schwartz, 1989; Von Boehmer and 
Kisielow, 1990). Commitment to the 1/8 lineage is 
accompanied by rearrangment of the 1 and 8 genes together 
with the activation of a silencers and a/~ rearrangement is 
usually associated with nonproductive 1/8 rearrangement 
(Ferrick et al., 1989). Since the 8 locus is situated 
between the Va and Ja genes, 8 genes are deleted during a-
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chain gene rearrangement (de Villartay and Cohen, 1990 ) . 
Mature T-cells emerge from the thymus as CD4-cDs- 1/0, CDs+ 
1/0, CD4+ a/fi and CDs+ a/fi T-cell subsets that possess a 
selected TcR repertoire (Ferrick et al., 1989). The 1/0 
receptor is the first to be expressed during thymic 
ontogeny, a few days prior to the a/~ TcR (Pardall et al., 
1987). 
Following TcR gene rearrangement, transcription and RNA 
splicing, the VDJ sequence of the primary TcR transcript is 
joined to a C-region sequence, producing a mature mRNA 
transcript which is then translated into a functional TcR 
polypeptide chain (Siu et al., 1984; Kronenberg et al., 
1986). Partially or unrearranged TcR genes can encode 
immature D-J-C or J-C transcripts with no V-region 
sequences (Yoshikai et al., 1984), which are probably non-
productive. In the case of TcR 1-chains, a high frequency 
of non-functional messages has been observed (Yoshikai et 
al• I 19 8 7) • 
In order to generate a TcR repertoire which can recognise 
the immense number of foreign antigens encountered by the 
immune system, enormous variability must be generated. This 
involves four major somatic mechanisms (Epplen et al., 
1987). (1) Combinatorial association of V, D and J gene 
segments produces a large number of different receptors, 
dependent on the size of the gene pools. (2) Imprecise 
joining (junctional diversity) deletes nucleotides from the 
ends of the rearranging gene segments and is augmented by 
N-region diversity, whereby random non-germline encoded 
nucleotides are inserted at the junctions of the gene 
segments (Epplen et al., 1987), by terminal transferase 
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(Baltimore, 1974). (4) Combinatorial association of a- and 
~-chains and r- and o-chains creates a vast repertoire of 
unique a/~ and r/o TcRs, respectively. Diversity of the TcR 
repertoire may be further increased by the formation of 
hybrid TcR genes or heterodimers (Tycko et al., 1989; 
Lipkowitz et al., 1990; Hochstenbach and Brenner, 1990), 
but it is expected that some of these chimaeric forms may 
be non-functional. Somatic hypermutation is not used to 
generate additional TcR diversity, as with the Ig genes 
(Kim et al., 1981), possibly avoiding the potential for 
generating autoreactive T-cell specificities, or T-cells 
with impaired antigen/MHC recognition. 
The human TcR gene repertoires have at least 3.0 x 103 (49 
Vax 60 Ja) possible different Va and 4.0 x 103 (68 v~ x 1 
(D~l) x 3 x 13 J~) + (68 x 1 (Dfi2) x 3 x 7) different v~ 
genes from combinatorial association of the individual TcR 
gene segments (see Table 1.4). In the case of v~, it is 
assumed that Dfil rearrangement can involve any of the 13 
functional J~ segments and that Dfi2 rearrangement can 
involve any of the seven functional gene segments in the 
Jfi2 cluster (see Figure 1.4) (Kronenberg et al., 1986). 
Furthermore, each diversity region can be transcribed in 
all three reading frames. Theoretically, these figures 
result in a maximum combinatorial association of -107 TcR 
a/fi V-regions in humans compared with -6.5 x 103 r/o v-
Table 1.4 Diversity of a/~ and 1/0 T-cell receptors. 
Gene segments T-cell receptor locus 
Variable 49 68 8 6 
Diversity* 2 3 
Joining 60 13 5 3 
Constant 1 2 2 1 
Variable gene 3.0 X 103 4.0 X 103 40 162 
combinations 
Potential 1.2 X 107 6.5 X 103 
heterodirners 
*Each diversity region segment can be productively 
transcribed in all three reading frames. 
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regions (40 V1- [8 V1 X 5 J1] chains X 162 Vo- [6 Vo X 3 Do 
x 3 x 3 Jo] chains). Diversity can be further increased by 
about 100-fold by N-region addition (Toyonaga and Mak, 
1987). Usage of multiple Do segments, which can be 
productively transcribed in all three reading frames 
(Takihara et al., 1988b), creates enormous potential for 
junctional and N-region diversity of the o-chains (Loh et 
al., 1988; Raulet, 1989a). Consequently, the V-D-J junction 
is likely to be important in determining the antigen 
specificity of certain 1/0 T-cells. However, the human 1/0 
repertoire is restricted in that most (50-70%) peripheral 
blood 1/0 T-cells express receptors encoded by a single V 
gene pair, namely Vo2 and V19 (Triebel et al., 1988; Borst 
et al., 1989). 
1.5 ANTIGEN RECOGNITION BY T-CELLS 
1.5.1 The Trimolecular complex 
T-cells function in the development and regulation of the 
immune response, eliminating invading organisms which 
harbour potentially harmful antigens whilst maintaining 
tolerance to self antigens. The acquisition of self-
tolerance is learned by T-cells, during thyrnic education, 
and involves positive and negative selection processes 
(Kappler et al., 1987; Schwartz, 1989; Von Boehmer and 
Kisielow, 1990). Positive selection effectively skews the 
TcR repertoire to recognise foreign antigen bound by MHC 
molecules (Schwartz, 1989; Von Boehmer and Kisielow, 1990), 
whereas negative selection eliminates T-cells with high 
affinity for self antigen/MHC (Kappler et al., 1987). 
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To discriminate between foreign and self antigens, T-cells 
recognise "processed" antigen presented by MHC gene 
products, expressed on the surface of an antigen-presenting 
cell, such as macrophage, dendritic, Langerhan's or B-cell 
(Haskins et al., 1983; Grey and Chesnut, 1985), a 
phenomenon called MHC-restriction. The recognition of a 
particular peptide/MHC complex is mediated by both V 
elements of the TcR heterodimer (Yague et al., 1985; Dembic 
et al., 1986; Saito et al., 1987), which interact to form a 
trimolecular complex (Figure 1.7). 
1.5.1.1 MHC molecule 
Products of the MHC class I and class II genes are highly 
polymorphic cell surface glycoproteins, which function in 
the development of the immune response. The three-
dimensional structure of a human class I MHC molecule, HLA-
A2, has been determined by X-ray crystallography (Bjorkman 
et al., 1987). The class I MHC molecule contains an a-chain 
with al, a2 and a3 domains and a fi2 microglobulin molecule. 
The peptide-binding site of this class I molecule, is 
predicted to be a groove formed from a platform of fi 
strands between the two a-helices of the membrane-distal al 
and a2 domains. Class II molecules are predicted to contain 
a similar peptide-binding pocket (Brown et al., 1988). 
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Figure 1.7 Diagrammatic representation of the trimolecular 
complex comprising T-cell receptor, antigenic peptide and 
MHC molecule. The variable (V) and constant (C) domains of 
the T-cell receptor a- and fi-chains recognise antigenic 
peptide bound by an MHC molecule, in this case class I 
molecule, expressed on the surface of the antigen-
presenting cell. 
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1.5.1.2 Antigenic peptide 
Processing of endogenous antigens (antigens sythesised 
within the cell) and exogenous antigens, involves 
fragmentation of the antigen into small peptides and is a 
prerequisite to binding by MHC molecules (reviewed by Long, 
1989; Gerlier and Rabourdin-Combe, 1989; Brodsky and 
Guagliardi, 1991). Endogenous antigens are degraded by non-
lysosomal proteolytic systems within the endoplasmic 
reticulum and presented by class I MHC molecules (Long, 
1989). In contrast, after internalisation into Golgi-
derived endosomes, exogenous proteins are degraded upon 
fusion with lysosomes containing acidic proteases, via the 
endocytic pathway, and usually presented by class II 
molecules (Long, 1989). Exogenous antigen processing 
intersects the biosynthetic pathway of MHC class II 
molecules, which, following release of the invariant chain 
from the peptide-binding site, renders these molecules 
accessible to binding of exogenous antigenic peptides 
(Long, 1989). 
Superantigens have recently been described as ligands that 
can stimulate T-cells expressing particular V~ chains 
regardless of other components of the receptor (reviewed by 
Fleischer and Schrezenmeier, 1988; Herman et al., 1991; 
Fleischer, 1991). T-cell recognition of superantigens 
requires interaction with class II molecules but not 
antigen processing (Herman et al., 1991). Receptor ligands 
of this type include self antigens encoded by the minor 
lymphocyte stimulating locus in mouse (MacDonald et al., 
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1988; Kappler et al., 1988) and some bacterial enterotoxins 
which stimulate human (Choi et al., 1989; Kappler et al., 
1989) as well as mouse T-cells (White et al., 1989), 
v~-specific fashion. A model for the interaction of a 
. in a 
superantigen with TcR and MHC has been proposed by Janeway 
et al. (1989), in which the superantigen binds as an intact 
protein to the sides of the class II molecule and the v~ 
subunit, effectively linking the T-cell and antigen-
presenting cell, without occupying the MHC peptide-binding 
site. 
1.5.1.3 TcR contact sites 
Regions equivalent to the three hypervariable or 
complementarity-determining regions (CDRs) of Ig V domains, 
which bind native antigen, have been identified in the TcR 
V-regions (Davis and Bjorkman, 1988; Chothia et al., 1988). 
In both Ig and TcR, CDRl and CDR2 are encoded within the V 
gene whereas CDR3 is represented by the V-J or V-D-J 
junction. Sequence polymorphism in the TcR is primarily 
concentrated within the CDR3 region, whereas the CDRl and 
CDR2 regions are less diverse. A model has been proposed 
for the interaction of TcR with peptide/MHC, in which CDRl 
and CDR2 of Va and v~ contact the side-chains of the MHC a -
helices and CDR3 interacts with the bound peptide (Davis 
and Bjorkman, 1988; Chothia et al., 1988). The exact nature 
of the TcR/peptide/MHC trimolecular complex awaits 
structural characterisation of the TcR, by crystallography. 
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1.5.2 T-cell activation 
Following ligand binding by the TcR, signal transduction 
induces expression of various T-cell "activation" genes, 
including IL-2 and IL-2R, which stimulate proliferation and 
differentiation of T-cells and effector functions (reviewed 
by Alexander and Cantrell, 1989; Altman et al., 1990; 
Weiss, 1990). Helper T-cells secrete cytokines and 
stimulate antibody production by B-cells whereas cytotoxic 
T-cells lyse target cells carrying foreign antigen (Altman 
et al., 1990). Signal transduction involves two independent 
pathways; the inositol phospholipid second messenger 
pathway and the tyrosine kinase pathway (Alexander and 
Cantrell, 1989). These pathways lead to elevated levels of 
intracellular calcium, activation of protein kinase C and 
tyrosine kinase. These kinases phosphorylate a wide range 
of proteins including CD3 1, CD3 o, CD4 and CD8, by protein 
kinase C, and CD3 (, by tyrosine kinase (Alexander and 
Cantrell, 1989; Weiss, 1990). Alternatively, signal 
transduction and T-cell activation may be mediated via 
interaction of lymphocyte function associated (LFA) -3 with 
CD2 (Meuer and Resch, 1989; Altman et al., 1990). 
1.5.3 1/0 T-cells and heat-shock proteins 
The nature of the ligands recognised by normal human 1/0 T-
cells remains elusive (reviewed by Kabelitz, 1992), 
although evidence has accumulated for preferential 
recognition of mycobacterial antigens, mainly by Vo2/V19-
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expressing T-cells (Kabelitz et al., 1990; De Libero et 
al., 1991; Kabelitz et al., 1991a; Panchamoorthy et al., 
1991; Ohmen et al., 1991; Pfeffer et al., 1992). 
Furthermore, hsp65 seems to be the major mycobacterial 
component that acts as the ligand for 1/8 T-cells (Raulet, 
1989b; Haregewoin et al., 1989; Pfeffer et al., 1990). 
Other ligands recognised by 1/8 T-cells include 
Staphylococcus enterotoxin A (Rust et al., 1990), 
Mycoplasma arthritides (Matthes et al., 1988), Plasmodium 
falciparum (Goerlich et al., 1991) and Molt-4 (De Libero et 
al., 1991) and Daudi cell lines (Sturm et al., 1990). 
It is postulated that 1/8 T-cells may play a role in immune 
surveillance and elimination of infected or "stressed" 
autologous cells expressing host-derived hsp (reviewed by 
Born et al., 1990b; Kaufmann and Kabelitz, 1991). There are 
a number of reviews on stress proteins and the immune 
response (see Kaufmann, 1990a; Young, 1990; Winfield and 
Jarlour, 1991). The main point emanating from these 
reviews, is the highly conserved nature of these proteins 
between prokaryotes and eukaryotes. 
By recognising bacterial hsp that are highly homologous to 
self hsp, the host immune response, mediated by 1/8 T-
cells, may result in immunopathology or autoimmunity, 
(reviewed by Kaufmann et al., 1990b; Res et al., 1991), 
implicating a potentially pathogenic role for 1/8 T-cells. 
1/8 T-cells accumulate in various human disease lesions, 
for example, skin lesions of leprosy (Modlin et al., 1989 ) , 
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intestine of patients with coeliac disease (Trejdosiewicz 
et al., 1991), sarcoidosis lung (Tamura et al., 1990), MS 
brain (Wucherpfennig et al., 1992), as well as in joint 
fluid (Keystone et al., 1991) and tissue (Smith et al., 
1990) of RA patients. Indeed, 1/0 T-cells from joints of RA 
patients exhibit a preponderance to proliferate in response 
to mycobacterial antigens and in some cases to hsp65 
(Holoshitz et al., 1989; Soderstrom et al., 1990; Pope et 
al., 1992), implicating a role for hsp-reactive 1/0 T-cells 
in the pathogenesis of RA. Furthermore, increased 
expression of the human counterpart of hsp65 in the 
cartilage-pannus junction of inflamed joints of RA patients 
(Karlsson-Parra et al., 1990) and cross-reactivity of 
Mycobacteria-specific SF T-cells with human hsp60 (Li et 
al., 1992), have been demonstrated. 
1.6 T-CELL RECEPTOR REPERTOIRE AND AUTOIMMUNITY 
The abililty of T-cells to distinguish self from non-self 
antigens is fundamental to the normal function of the 
irmnune system and is achieved by positive and negative 
selection of T-cells during thyrnic T-cell ontogeny (Von 
Boehmer and Kisielow, 1990). These processes are mediated 
by the interaction of TcR with peptide/MHC complex, the 
molecular basis of which has already been discussed in 
section 1.5.1 of this Chapter. As well as clonal deletion, 
other mechanisms such as clonal inactivation, or anergy of 
autoreactive T-cells in the periphery, are thought to be 
involved in maintaining irmnunological tolerance to self 
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components (Blackman et al., 1990; Ramsdell and Fowlkes, 
1990). However, if the mechanisms regulating self-tolerance 
breakdown, an immune response is directed against self 
antigen and this may result in the development of 
autoimmune disease (Sinha et al., 1990). 
1.6.1 Animal models of autoimmune disease 
Many animal models of autoimmune diseases (Table 1.5), 
which the target autoantigen is known, have shown 
. in 
restricted TcR V gene usage by pathogenic T-cells in the 
disease lesions (reviewed by Kumar et al., 1989; Komori et 
al., 1990). The best characterised of these is experimental 
allergic encephalomyelitis (EAE), a demyelinating disease 
mediated by myelin basic protein (MBP) -specific CD4+ T~ 
cells and which resembles human multiple sclerosis (MS) 
(reviewed by Zamvil and Steinman, 1990). Analysis of the 
TcRs expressed by encephalitogenic T-cell clones reactive 
with an immunodominant epitope from the amino terminal 
region of MBP, derived from EAE mice, revealed predominant 
usage of V~8.2 (Zamvil et al., 1988; Acha-Orbea et al., 
1988; Urban et al., 1988; Zaller et al., 1990), V~13 (Urban 
et al., 1988; Zaller et al., 1990), Va2.3 (Urban et al., 
1988), Va4.2 (Urban et al., 1988) and Va4.3 (Acha-Orbea et 
al., 1988) gene segments, although differences exist in V 
and J segment usage between different mouse strains 
(reviewed by Kumar et al., 1989; Brostoff and Howell, 1991; 
also see Table 1.5). In addition, homologous Va2 and V~8 
TcR structures were expressed by encephalitogenic T-cells 
Table 1.5 Animal models of autoimmune diseases. 
Experimental autoimmune 
disease model 
Experimental allergic 
encephalomyelitis 
Collagen-induced arthritis 
Non - obese diabetic mice 
MRL - lpr/lpr lupus mice, 
(NZB X NZW) Fl mice 
T-cell receptor 
repertoire 
Vfi8.2, Vfi13, Va2.3 and 
Va4.2 in B10.PL mice, 
Va4.3 and Vfi8.2 in PL/J mice, 
Va2 and Vfi8 in Lewis rat, 
Vfi17 and Vfi4 in SJL mice 
Vfi6, 
deletion of 50% of Vfi gene locus 
in collagen-induced arthritis 
-resistant SWR and AU/ssJ mice 
Vfi5 
Vfi8.2 and Vfi8.3, 
fi-chain gene deletion (Cfil, Dfi2 
and Jfi2) 
Possible relevant 
human disease 
Multiple sclerosis 
Rheumatoid arthritis 
Insulin-dependent 
diabetes mellitus 
Systemic lupus 
erythernatosus 
Reference 
a 
b 
C 
d 
e 
f 
g 
h 
. 
l 
References: aurban et al., 1988; Zaller et al., 1990, bAcha-Orbea et al., 1988; Zamvil et al., 1 988, 
cBurns et al., 1989, dsakai et al., 1988; Padula et al., 1991, eKurnar et al., 1989, fHaqqi e t al., 
1989; Haqqi and David, 1990, gKornori et al., 1990, hsinger et al., 1986, iYanagi et al., 1986. 
~ 
(X) 
from EAE rat (Burns et al., 1989), even though the 
epitope/MHC complex was distinct from that recognised ' in 
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the mouse model. These findings that a specific V-bearing 
TcR causes EAE, led Heber-Katz and Acha-Orbea (1989) to 
propose that EAE and possibly other autoimmune diseases are 
actually "V-region diseases". This hypothesis was supported 
by the effective prevention and reversal of EAE, by immune 
intervention using anti-Vfi8 and -Vfi13 specific monoclonal 
antibodies (MAbs) (Urban et al., 1988; Acha-Orbea et al., 
1988; Zamvil et al., 1988; Zaller et al., 1990). However, 
the findings of Vfi heterogeneity and fine specificity among 
encephalitogenic T-cell clones from SJL mice, argue against 
a dominant TcR Vfi gene in the pathogenesis of EAE (Su et 
al• I 19 9 2) • 
Another organ-specific autoimmune disease, collagen-induced 
arthritis (CIA), shares certain immunohistopathological 
features with human RA. CIA is induced in certain rat and 
mouse strains, after immunisation with collagen type II 
(CII), the major protein of articular cartilage (for review 
see Holmdahl et al., 1990). The development of CIA is 
associated with both cell-mediated and humoral immunity to 
CII and genetic studies have implicated Vfi6-bearing T-cells 
in the pathogenesis of the disease (Kumar et al., 1989). 
Interestingly, proliferative responses of SF T-cells from 
RA patients have been shown against CII (Londei et al., 
1989), a candidate endogenous antigen targeted in RA. 
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In the adjuvant arthritis (AA ) model of human RA, 
autoimmunity is induced in genetically susceptible rats by 
immunisation with Complete Freund's adjuvant containing 
heat-killed Mycobacterium tuberculosis in oil (Holoshitz et 
al., 1983). AA can be transferred to naive recipient rats 
by injection of T-cell lines or clones specific for 
mycobacterial antigens, providing direct evidence for the 
involvement of T - cells (Holoshitz et al., 1983; Van Eden et 
al., 1985). Mycobacteria-reactive T-cells have been shown 
to migrate to the synovium (DeJoy et al., 1990), however, 
the mechanisms by which these T-cells initiate and maintain 
chronic arthritis, is unknown, although cross-reactivity 
between M. tuberculosis and cartilage proteoglycans (Van 
Eden et al., 1985), or the mammalian counterpart to 
bacterial hsp65 (Kleinau et al., -1991), implicates 
antigenic molecular mimicry. The epitope recognised by the 
disease-inducing T-cells has been mapped to residues 180-
186 of hsp65 (Van Eden et al., 1988), implicating hsp-
reactive T-cells in the pathogenesis of AA. Furthermore, 
induction of AA can be blocked by pretreatment of rats with 
whole bacterial hsp65 (Van Eden et al., 1988), or peptides 
of hsp65 (Yang et al., 1990), possibly via inhibition of 
responses to this T-cell epitope (Hogervorst et al., 1991). 
1.6.2 Human autoimmune disease 
The observation that in experimentally-induced autoimmune 
diseases, pathogenic T-cells express a restricted V gene 
repertoire, has stimulated investigators to determine 
whether there is restricted TcR heterogeneity in human 
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autoimmune disease lesions (Cooke, 1991). However, since 
the target autoantigen in human autoimmune diseases is 
usually unknown, TcR repertoire expression by the disease-
promoting T-cells is more difficult to define. Most of the 
earlier investigations of T-cell clonality in human 
autoimmune disorders used Southern blot analysis to detect 
clonal TcR gene rearrangements, but this methodology lacks 
sensitivity and V gene usage may not be resolved. Another 
approach is the use of MAbs specific for various TcR V gene 
families, but the disadvantage of this is the limited 
availability, as yet, of MAbs. With the advent of the 
polymerase chain reaction (PCR), most studies now analyse V 
gene expression of TcR mRNA transcripts isolated directly 
from T-cells infiltrating the inflammatory lesion, or after 
in vitro expansion of T-cells with mitogens and/or IL-2, 
followed by T-cell cloning. Studies aimed at detecting 
oligoclonal T-cell populations in human autoimmune disease 
lesions have mainly focused on TcR a/fi usage in RA and MS. 
1.6.2.1 Rheumatoid arthritis 
Using MAbs, Brennan et al. (1988) have shown diversity of 
TcR idiotypes in RA synovium, although there were increased 
numbers of Vfi5- and Vfi8-expressing T-cells in some 
patients. In addition, considerable heterogeneity in TcR Vfi 
usage was found among RA SF T-cells (Gudmundsson et al., 
1992). Studies of TcR gene rearrangements in RA have 
yielded conflicting results. Whilst clonal heterogeneity of 
synovial T-cell populations from RA joints has been 
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reported (Savill et al., 1987; Keystone et al., 1988; Duby 
et al., 1989; Van Laar et al., 1991), others have found 
clonal dominance of TcR ~-chain rearrangements (Savill et 
al., 1987; Stamenkovic et al., 1988; Chatila et al., 1990; 
Miltenburg et al., 1990; Cooper et al., 1991; Van Laar et 
al., 1992; Korthauer et al., 1992; Cantagrel et al., 1993). 
It seems obvious that methodological differences may have 
accounted for some of these discrepancies, since some 
studies used freshly isolated synovial T-cells (Savill et 
al., 1987; Keystone et al., 1988) whilst others used 
T-cells initially cultured with IL-2 or T-cell growth 
factor (Stamenkovic et al., 1988; Miltenburg et al., 1990; 
Cooper et al., 1991; Korthauer et al., 1992; Cantagrel et 
al., 1993). Interestingly, instead of dominant ~-chain gene 
rearrangements, Ramos et al. (1989) found dominant 
rearrangements of the TcR 1 genes in SF T-cells of RA 
patients. V~ gene expression in RA lesions using various 
PCR protocols argue more compellingly for a restriction of 
the V~ repertoire by pathogenic T-cells, although, as with 
gene rearrangement studies, the data are conflicting. These 
studies are reviewed extensively in the discussion section 
of Chapter 3. 
To date, there are only a few reports on the analysis of 
TcR 1/0 usage in RA patients, most of which have used MAbs 
to the Vol, Vo2 and V19 gene products. Preliminary results 
indicate a predominance of Vol in the synovium and synovial 
fluid compared to the peripheral blood (Smith et al., 1990; 
Keystone et al., 1991). 
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1.6.2.2 Multiple sclerosis 
Restricted Va gene expression in brains of MS patients has 
been reported (Oksenberg et al., 1990), with only two to 
four rearranged Va transcripts detected in each of three 
brains examined. There is also evidence of oligoclonal T-
cell populations in the cerebrospinal fluid and peripheral 
blood of MS patients (Hafler et al., 1988), with common 
usage of the Vfi12 gene segment (Lee et al., 1991). In 
addition, Vfi usage of T-cell lines derived from blood of MS 
patients and reactive with the immunodominant region of 
MBP, showed shared Vfi17 and to a lesser extent Vfi12 gene 
segment usage amongst different individuals (Wucherpfennig 
et al., 1990). Interestingly, Vfi12 is homologous to the 
Vfi8.2 gene segment which is predominantly used by 
encephalitogenic, MBP-reactive T-cells in both mice and 
rats (Lee et al., 1991). 
1.6.2.3 Other autoimmune diseases 
Oligoclonality of activated T-cells has been detected in 
the peripheral blood of insulin dependent diabetes mellitus 
patients, although different Vfi families were used in 
individual patients, indicating heterogeneity of T-cell 
activation (Kontiainen et al., 1991). Also, oligoclonality 
of Vfi12 and Vfi13 transcripts has been detected in the lips 
of patients with Sjogren's syndrome (Yonaha et al., 1992). 
Restricted Va2.3 usage by CD4+ T-cells in lung 
bronchoalveolar lavage fluid of patients with sarcoidosis 
has recently been demonstrated and was found to correlate 
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with the HLA-DR3 haplotype (Grunewald et al., 1992 ) . The 
limited heterogeneity of Va/~ usage in SF T - cells from 
juvenile rheumatoid arthritis (JRA) patients showed 
evidence of oligoclonal expansion of V~20 transcripts 
derived from IL-2R-positive T-cells (Sioud et al., 1992 ) . 
Analysis of TcR usage in activated T-cell clones from 
patients with autoimmune thyroid diseases, Hashimoto's 
thyroiditis and Graves' disease, revealed numerous 
different~- and 1-chain gene rearrangements, indicating 
that the T-cell response in autoimmune thyroiditis is 
polyclonal (Lipoldova et al., 1989). In recent studies, 
though, using PCR to investigate Va/~ expression by T-
cells infiltrating thyroids of patients with autoimmune 
thyroid disease, a marked restriction in Va usage was 
revealed (Davies et al., 1991) despite widespread usage of 
V~ gene families (Davies et al., 1992), indicating that 
thyroid infiltrating T-cells are selectively accumulating 
because of their Va rather than V~ elements. In contrast, 
the study by McIntosh et al. (1993) revealed widespread 
usage of Va elements in the thyroids of patients with 
Graves' disease. 
1.6.3 Immunotherapy in autoimmune disease 
1.6.3.1 Non-specific therapeutic approaches 
Conventional therapy for the treatment of both organ-
specific and systemic autoimmune diseases is usually based 
upon immunosuppressive, or non-specific therapeutic 
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approaches. Non-specific modulation of T-cells includes 
physical (thoracic duct drainage, total lymphoid 
irradiation), chemical (immunosuppressive agents such as 
cyclosporine A) and biological (anti-T cell surface MAb 
treatment such as anti-CD4 and anti-IL-2R) based therapies 
(Miller et al., 1991). Reduction of joint inflammation has 
been shown in RA patients given cyclosporin (Tugwell et 
al., 1990) whilst anti-CD4 and anti-IL-2R MAbs have been 
effective in preventing and reversing experimental 
autoimmune diseases, such as EAE and lupus (Miller et al., 
1991). Preliminary results using a murine anti-CD4 MAb for 
the treatment of RA patients indicate clinical improvement, 
but whether long-term remission can be achieved with this 
approach, remains to be determined (Horneff et al., 1991; 
Reiter et al., 1991). Another approach is to target other 
T-cell accessory molecules involved in T-cell activation 
such as CDS, LFA-1 and CD2 (Adorini et al., 1990). 
1.6.3.2 Specific immune intervention 
Using the trimolecular complex as a target for specific 
immune intervention, animal models of experimentally-
induced autoimmune diseases have provided opportunities for 
new immunomodulatory strategies (reviewed by Adorini et 
al., 1990; Miller et al., 1991; Kingsley et al., 1991; 
Chiang et al., 1992). Several approaches, for example 
vaccination with synthetic TcR peptides or inactivated T-
cells, anti-TcR V~ or -class II MAb treatment and MHC 
blockade, have been used to prevent or downregulate the 
56 
inflammatory autoimmune response (Miller et al., 1991 ) . In 
addition, vaccination with mycobacterial hsp peptides has 
been used to prevent AA (Yang et al., 1990). Blocking the 
antigen-presenting activity of disease-associated class II 
MHC molecules with anti-MHC class II MAb could prevent 
activation of autoreactive T-cells and thus interfere with 
disease. Alternatively, blockade of the MHC binding site by 
peptide competitors has been shown to be effective in 
preventing the development of EAE (Adorini et al., 1990). 
Therapies directed against cytokines are also being 
developed in experimental models and include anti-cytokine 
MAbs, soluble cytokine receptor proteins and specific 
cytokine inhibitors (Kingsley et al., 1991). 
1.6.3.3 Oral tolerance 
Antigen-driven peripheral tolerance, in which specific 
antigens are delivered orally, has been shown to modify 
EAE, CIA and AA (reviewed by Thompson and Staines, 1990). 
MBP given orally to Lewis rats before immunisation with an 
otherwise encephalitogenic dose of the same antigen, 
lowered the incidence of EAE and suppressed clinical 
symptoms. Similarly, ingestion of soluble CII in animals 
prior to administration of an arthritogenic dose of CII, 
lowered the incidence of CIA (Thompson and Staines, 1990). 
Suppression of AA in rats was achieved with oral 
administration of CII (Zhang et al., 1990), whereas there 
was virtually no effect of orally administered 
M. tuberculosis, suggesting that autoinununity to CII may 
play a role in AA. 
1.6.3.4 TcR-based inununotherapy 
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Inactivated or attenuated MBP-specific T-cells have been 
used as vaccines to induce resistance to EAE by activating 
regulatory T-cells (Ben-Nun et al., 1981; Lider et al., 
1988). In addition, vaccination with synthetic TcR peptides 
corresponding to idiotypic determinants of the ~-chain CDR3 
region and Ja region, that are conserved among 
encephalitogenic T-cells, has been shown to induce 
resistance to EAE (Howell et al., 1989; Offner et al., 
1991). Anti-V~ MAbs have also been used to prevent EAE in 
mice (Acha-Orbea et al., 1988; Zamvil et al., 1988; Urban 
et al., 1988; Zaller et al., 1990). Suppression and 
prevention of AA in rats has been demonstrated with a MAb 
to the a/~ TcR (Yoshino et al., 1990) and in CIA, treatment 
with this antibody suppressed and reduced the severity of 
the disease (Goldschmidt and Holmdahl, 1991). Whether 
suppression can be achieved by treatment with a MAb to the 
1/0 TcR, remains to be investigated. 
1.7 CONCLUSIONS 
There is overwhelming evidence indicating restricted V gene 
usage by T-cells in various human autoinunune diseases, 
particularly in RA, although further studies are required 
to substantiate this. For RA, this requires complete 
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molecular characterisation of TcR repertoire expression, 
involving examination of V gene usage and extensive 
sequencing of individual TcR transcripts. Only this will 
allow unequivocal evidence as to whether, or not, there are 
oligoclonally-expanded T-cells in RA. 
If T-cells bearing homogeneous TcRs are involved in the 
initiation and/or perpetuation of joint destruction in RA, 
then the response mediated by those pathogenic T-cells 
could potentially be blocked using TcR-based immunotherapy, 
and thus prevent the disease. Such novel therapeutic 
strategies would be more specific and may be more effective 
than the conventional methods of immunosuppression used to 
treat RA patients. 
1.8 AIMS 
In view of the potential of the TcR as a target site for 
specific immune intervention in the treatment of RA, the 
aim of this project is to determine whether there is 
restricted heterogeneity of T-cells within the inflamed 
synovium and/or peripheral blood. Previous studies of TcR 
usage in RA have mostly been confined to the a/~ TcR and 
have yielded conflicting results (reviewed in section 3.5.1 
of Chapter 3). Conversely, limited data are available on 
the analysis of 1/0 TcR usage in RA. This area requires 
further investigation particularly because of the possible 
role of 1/0 T-cells in inflammation and autoimmunity (see 
section 1.5.3) and has provided the main focus of this 
thesis. 
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The experimental work described in this thesis aimed to 
test the following hypotheses: (1) That TcR a/~ and/or 1/0 
gene usage in the synovium of RA patients differs from TcR 
usage in the peripheral blood (Chapter 3). This hypothesis 
was tested using V gene family-specific PCR amplification 
of TcR transcripts and identification of amplified products 
by hybridisation with an internal TcR C-region 
oligonucleotide probe. (2) That a bias in particular TcR Vo 
gene usage in the synovium of RA patients is due to clonal 
dominance (Chapter 4). This hypothesis was tested by 
molecular characterisation of TcR o-chain transcripts 
expressed in the synovium and peripheral blood using a two-
step procedure involving firstly cloning of PCR-amplified 
TcR cDNA and subsequent DNA sequence analysis of individual 
TcR transcripts. To assess the degree of clonal dominance, 
this was followed by screening of TcR cDNA clones with 
oligonucleotides specific for particular V-J junctional 
regions. (3) That a bias in particular TcR v1 gene usage in 
the synovium of RA patients is due to clonal dominance 
(Chapter 5). This hypothesis was tested by molecular 
characterisation of TcR 1-chain transcripts expressed in RA 
synovium and peripheral blood. (4) That peripheral T-cell 
1/0 oligoclonality in RA patients of long-standing is 
persistent rather than transient (Chapter 6). This 
hypothesis was tested essentially by oligonucleotide 
screening of TcR cDNA clones, generated from transcripts 
isolated from blood collected from the same patients at 
least one year later. 
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CHAPTER 2 
MATERIALS AND METHODS 
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2.1 MATERIALS 
2.1.1 Chemicals, radioisotopes and enzymes 
The specific materials used in the laboratory procedures 
described throughout Chapters 2 to 6, are given below under 
the supplier's name. 
Ajax Chemicals, Auburn, NSW, Australia: NaOAc; MgCl2; KCl; 
NaCl; EDTA; NaP04 ; NaHC03; isoamyl alcohol; ethanol; HCl; 
acetic acid; isopropanol; xylene cyanol; bromophenol blue 
Aldrich Chemicals, Castle Hill, NSW, Australia: 
tetramethyl-ammonium chloride 
Amersham Int., Amersham, Buckinghamshire, UK: Hybond N+ 
nylon membrane discs; multiprime DNA labelling system 
Amicon, Danvers, MA, USA: centricon 100 microconcentrator 
Applied Biosystems, Foster City, CA, USA: dye-labelled 
primers; deoxy/dideoxynucleotide triphosphate (d/ddNTP ) 
mixes 
BDH Chemicals, Poole, Dorset, UK: sodium dodecyl sulphate 
ultra pure; 2-mercaptoethanol; sodium citrate; NH40Ac; 
polyethylene glycol6ooo; C0Cl2; sodium cacodylate 
Boehringer Mannheim, Castle Hill, NSW, Australia: Smar-, 
EcoRI- and Sall-restriction endonucleases; alkaline 
phosphatase; X-gal 
Bresatec Ltd, Adelaide, SA, Australia: [1- 32 PJATP (4000 
Ci/mmol); [a- 32 PJ d.ATP (3000 Ci/mmol) 
62 
DIFCO Laboratories, Detroit, MI, USA: bacto tryptone; yeast 
extract; agar 
Du Pont Ltd, Boston, MA, USA: Gene Screen Plus 
hybridisation transfer membrane 
Fisons, Sydney, Australia: heparin 
Flow Laboratories, North Ryde, NSW, Australia: RPMI 1640 
Fluka, Chemische Fabrik, Buchs, Switzerland: diethyl 
pyrocarbonate; guanidinium thiocyanate; formamide 
Fuji Photo Film Co., Tokyo, Japan: X-ray film 
Mallinckrodt, VIC, Australia: CaCl2; glycerol; dimethyl-
sulfoxide 
Merck, Darmstadt, Frankfurter Strasse, FRG: NaOH pellets 
Nycomed, AS, Norway: Lymphoprep™ 
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Pharmacia, Uppsala, Sweden: Ficoll 400; dextran sulphate; 
DNA polymerse I large fragment (Klenow); T4 polynucleotide 
kinase; Moloney murine leukemia virus reverse 
transcriptase; T4 DNA ligase; dNTPs; ATP; M13mpl8 vector 
DNA; A Hind III; terminal deoxynucleotide transferase 
Polaroid Co., Cambridge, MA, USA: polaroid film 
Promega, Madison, WI, USA: RNAsin; Thermus aquaticus (Taq) 
DNA polymerase; sequencing grade Taq DNA polymerase 
Sigma Chemical Co., St Louis, MO, USA: bovine serum 
albumin; Tris; sodium sarcosyl; guanidinium hydrochloride; 
concavalin A; agarose type II; proteinase K; mineral oil; 
dithiothreitol; gelatin; polyvinyl pyrrolidone; ethidium 
bromide; IPTG; salmon sperm DNA; deoxyribonuclease; 
collagenase type IV 
Wako Pure Chemical Ind., Novachem, Switzerland: phenol 
2.2 METHODS 
The methods described in this section are relatively 
standard, apart from AN-PCR and HLA-DR typing by PCR-
sequence-specific oligonucleotide (SSO) techniques. RA and 
systemic lupus erythematosus (SLE) patient clinical data 
and methods specifically related to a particular study, 
such as V gene family-specific PCR and surface 
64 
inununofluorescence staining, are described in the relevant 
results Chapter. 
2.2.1 Cell separation 
Peripheral blood (20-40 ml) was collected into 
preservative-free heparinized (10 U/ml) tubes and 
transported to the laboratory inunediately. RA samples were 
diluted with an equal volume of RPMI 1640, containing 10 rnM 
NaHC03, 20 rnM HEPES buffer, 10,000 U/1 penicillin, 10 mg/1 
streptomycin and 2 rnM L-glutamine (hereafter called 
medium). Peripheral blood mononuclear cells (PBMC) were 
separated by density gradient centrifugation over a Ficoll-
Hypaque gradient, as described in section 2.2.2. PBMC were 
stored in liquid nitrogen, in medium containing 20% (w/v) 
heat-inactivated fetal calf serum (FCS) and 10% (v/v) 
dimethylsulfoxide (DMSO). Control PBMC were isolated from 
normal heparinized blood by density gradient centrifugation 
and stored as described in section 2.2.2. 
Synovium was collected into Hanks' Balanced Salt Solution 
containing 10,000 U/1 penicillin, 10 mg/1 streptomycin and 
25 µg/1 amphotericin. The tissue was minced mechanically 
and digested with 5 mg/ml collagenase type IV and 0.15 
mg/ml deoxyribonuclease at 37°c for 2-3 h with shaking. The 
sample was filtered through a 200 µm pore mesh, diluted 
with medium and synovial membrane mononuclear cells (SMC) 
were separated by density gradient centrifugation over a 
Ficoll-Hypaque gradient, as described in section 2.2.2. SMC 
were stored in liquid nitrogen, in medium containing 20% 
(w/v) heat-inactivated FCS and 10% (v/v ) DMSO. 
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SMC and PBMC of RA patients were prepared in August 1989 to 
October 1990 at the Royal Prince Alfred Hospital, Sydney, 
preserved in cryoprecipitate, and then transported to 
Canberra in dry ice for later analysis. SMC and PBMC of RA 
patients and control PBMC were not cultured or stimulated 
in vitro. 
2.2.2 Density gradient centrifugation 
Peripheral blood was centrifuged at 2K for 10 min at room 
temperature in 10 ml sterile disposable plastic tubes. The 
interface between the plasma (top layer) and red cell 
pellet, which contains the buffy coat, was harvested. For 
most purposes, the buffy coat was diluted 1:1 (v/v) with 
phosphate-buffered saline (PBS) and 5-6 ml was layered over 
4 ml LymphoprepTM, in a 10 ml tube. After centrifugation at 
2K for 30 min at room temperature, the mononuclear cells, 
which form a white band in the top layer, were harvested. 
Cells were washed three times with ice-cold PBS, aliquoted 
into Eppendorf tubes and stored at -7o 0 c in a small amount 
of PBS. For SLE samples, the buffy coat was frozen directly 
in liquid nitrogen. 
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2.2.3 Preparation of genomic DNA 
High molecular weight DNA was isolated from PBMC according 
to the method of Jienpierre (19 87 ). Approximate l y 5 x 10 6 
PBMC were homogenised in 0.7 ml 6 M guanidinium 
hydrochloride solution containing 0.53 M NH40Ac, in an 
Eppendorf tube. Sodium sarcosyl (50 µl of 20% (w/v ) stock 
solution) and 7.5 µl proteinase K (10 mg/ml) were added and 
the mixture incubated at 60°c for 1 h. The DNA was 
precipitated by the addition of two volumes of ethanol and 
collected by centrifugation for 10 min in a bench top 
centrifuge. DNA was washed twice with ice-cold 70% (v/v) 
ethanol, air-dried and resuspended in 100 µl Tris-EDTA (TE) 
buffer (10 mM Tris/HCl, 1 mM EDTA [pH8.0]). The yield of 
DNA was estimated as described in section 2.2.4 and ranged 
from 300-600 µg/ml. For the preparation of genomic DNA from 
buffy coat, cells were initially washed twice with 10 mM 
NaCl/10 mM EDTA solution [pH8.0] and the DNA prepared 
according to the protocol described above. 
2.2.4 Estimation of DNA concentration 
The concentration of DNA solution was estimated by 
measuring the ultraviolet (UV) absorbance at 260 run in a 
Gilford 2600 spectrophotometer. A DNA solution with a 
concentration of 50 µg/ml was taken as having an absorbance 
of 1.0 in a 1 cm path length. 
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2.2.5 Restriction endonuclease digestion of DNA 
DNA was digested in a 40 µl reaction containing 1 x buffer 
(supplied ) and the appropriate restriction endonuclease, 
according to the manufacturer's specifications. In a 
typical reaction, approximately 5 units of enzyme were used 
per µg of DNA. 
2.2.6 HLA-DR typing: Amplification of HLA-DR genes 
HLA-DR genes were amplified from genomic DNA using the PCR 
and hybridised with radio-actively-labelled sequence-
specific oligonucleotides (SSOs) (Gao et al., 1991). For 
HLA-DR4 subtyping, a DR4-specific primer corresponding to 
the first HVR of HLA-DRfil and a 3' primer complementary to 
codons 87-94 were used in PCR amplification and the PCR 
product screened with SSOs specific for Dw4, DwlO, Dw13, 
Dw14 and Dw15 (Gao et al., 1990a). 
2.2.7 Isolation of total RNA 
2.2.7.1 DEP treatment of solutions 
To prevent degradation of RNA by ribonuclease, most 
solutions used for the isolation of RNA were treated with 
diethyl pyrocarbonate (DEP). DEP was added to a final 
concentration of 0.1% (v/v), the solution mixed thoroughly 
and then left overnight. Solutions were subsequently 
autoclaved. 
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2.2.7.2 Extraction procedure 
RNA was isolated from SMC and PBMC of patients and control 
PBMC by the acid guanidinium thiocyanate-phenol-chloroform 
extraction method (Chomczynski and Sacchi, 1987). To avoid 
contamination from ribonuclease, gloves were worn 
throughout the procedure and where possible each step was 
carried out at 4°c. Approximately 5 x 10 6 cells were 
homogenised in 500 µl of solution D which contained 4 M 
guanidinium thiocyanate, 25 rnM sodium citrate [pH 7.0], 
0.5% (w/v) sodium sarcosine and 0.1 M 2-mercaptoethanol, in 
an Eppendorf tube. Then 50 µl of 2 M NaOAc [pH 4.0], 500 µl 
phenol (saturated with 0.1 M Tris/HCl [pH 8.0]) and 100 µl 
chloroforrn:isoamyl alcohol (IAA) [49:1 v/v] were added with 
thorough mixing after the addition of each reagent. The 
mixture was shaken vigorously for 15 sec and then incubated 
on ice for 15 min. After centrifugation for 20 min in a 
bench top centrifuge, the supernatant was recovered and the 
RNA precipitated from the aqueous phase by the addition of 
an equal volume of ice-cold isopropanol at -20°c for 1 h. 
After centrifugation for 30 min, the pellet was redissolved 
in 150 µl solution D and the RNA precipitated with 
isopropanol, as before. Following centrifugation for 20 
min, the pellet was washed twice with ice-cold 75% (v/v) 
ethanol, vacuum-dried, resuspended in 20 µl DEP-treated 
sterile double-distilled water (ddH2 0) and stored at -7o 0 c. 
For RNA preparation from buffy coat, cells were initially 
washed twice with ice-cold 10 rnM NaCl/10 rnM EDTA solution 
[pH8.0], and RNA isolated according to the protocol 
described above. The yield of RNA was estimated as 
described in section 2.2.8 and ranged from 250 -500 µg/ml. 
2.2.8 Estimation of RNA concentration 
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The concentration of RNA solution was estimated by 
measuring the UV absorbance at 260 nm in a 
spectrophotometer. A RNA solution with a concentration of 
40 µg/ml was taken as having an absorbance of 1.0 in a 1 cm 
path length. 
2.2.9 First strand cDNA synthesis 
Approximately 10 µg of total RNA was converted to single-
stranded cDNA by incubation at 37°c for 1 h in a 50 µl 
reaction containing 1 x cDNA synthesis buffer (50 mM 
Tris/HCl [pH8.3], 75 mM KCl, 10 mM dithiothreitol (DTT), 
3 mM MgCl2), 1 mM of each deoxynucleotide triphosphate 
(dNTP), 50 pmole TcR C-region gene antisense primer (Cal, 
Cfil, c11 or Col, see Table 2.1), 25 units ribonuclease 
inhibitor (RNasin) and 50 units Moloney murine leukemia 
virus (M-MuLV) reverse transcriptase. At the completion of 
the reaction, the volume was increased to 200 µl with DEP-
treated sterile ddH20 and the cDNA extracted using an equal 
volume of phenol:chloroform:IAA [25:24:1 (v/v)J. Following 
centrifugation, the aqueous phase was recovered and 
concentrated to remove excess primer using a centricon 100 
microconcentrator, according to the manufacturer's 
instructions. The locations of the TcR C-region gene 
Table 2.1 Nucleotide sequence of T - cell receptor constant region gene primers. 
Primer Sequence (5' - 3') Primer Sequence (5' - 3') 
Cal GCTCCAGGCCACAGCACTGTTGCT C-yl GTCGTTAGTCTTCATGGTGTTCCC 
Ca2 CAGACTTGTCACTGGA C-y2 AGGTATGTTCCAGCCTTC 
Ca3 AATATCCAGAACCCTGACCCT C-y3 GGAAACATCTGCATCAAGTTGT 
C/31 GGCAGACAGGACCCCTTGCTGGTTAGGACAC C61 GACAGCATTGTACTTCCCACTGG 
C/32 TCCACTCGTCATTCTCCGAGAGCCCG C62 TTCACCAGACAAGCGACA 
C/33 AGAACTGGACTTGACAGCGGAAGTGGTTGC C63 GATGGTTTGGTATGAGGCTGA 
C/34 TGGCTCAAACACAGCGACCT 
Primers were designed from previously published sequences (Yoshikai et al., 1985; 
Toyonaga et al., 1985; Yoshikai et al., 1987; Takihara et al., 1988a). 
-...J 
0 
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Figure 2.1 Schematic representation of T-cell receptor 
constant region gene primers. The nucleotide positions of 
the primers correspond to the location in previously 
published genomic sequences (Yoshikai et al., 1985; 
Toyonaga et al., 1985; Yoshikai et al., 1987; Takihara et 
al . , 1988a). C: constant; D: diversity; J: joining; TcR: T-
cell receptor; V: variable. 
TcR genes 5 ' ___ V __ D __ J_________ C________ I 3' 
locus 
a Ca 3 Ca 2 Cal 
272 293 320 335 447 470 
C~4 I C~3 I I C~2 I I C~l I 
198 217 441 470 472 497 1168 1197 
y c y3 I I cy2 I I cy1 I 
6 27 75 92 178 201 
8 c 83 I I C82 I I C81 I 
124 144 171 189 273 295 
oligonucleotides Cal, C~l, c11 and Col, within the various 
TcR genes, are shown in Figure 2.1. 
2.2.10 Controls for PCR amplification 
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The positive control for V gene family-specific PCR 
amplification (described in section 3.3.6 of Chapter 3) was 
cDNA prepared from a pool of PBMC obtained from five 
healthy donors. PBMC (1-2 x 10 6 ) from each individual were 
intitially stimulated with concavalin A (Con-A) (10 µg/ml) 
for 72 hat 37°C/5% CO2 in RPMI medium containing 5% (v/v) 
human AB serum. Stimulated PBMC were then pooled prior to 
cDNA synthesis. Con-A was used to stimulate expression of 
TcR genes, particularly V~ genes, since some V~ genes may 
not be expressed in certain individuals (Choi et al., 1989; 
Rosenberg et al., 1992). Stimulated PBMC from five donors 
were pooled to ensure that all TcR V genes were represented 
in the control PBMC. Negative PCR controls (tubes with no 
cDNA) were included with each pair of primers to test for 
any possible contamination of reagents used for RNA 
isolation, cDNA synthesis or PCR amplification. 
2.2.11 AN-PCR amplification of TcR transcripts 
Following TcR cDNA synthesis, PCR was performed with 
single-sided specificity using anchor primers described by 
Frohman et al. (1988) and Loh et al. (1989). The procedure 
for amplification of TcR a-chain transcripts using the 
primers of Frohman et al. (1988), is outlined in Figure 
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2.2. Initially, TcR cDNA, prepared with the Cal primer, was 
tailed with poly A residues by incubation at 37°c for 10 
min and then at 65°c for 15 min in a 30 µl reaction 
containing 1 x Tailing buffer (100 mM sodium cacodylate 
[pH7.0], 2 mM C0Cl2, 0.2 mM DTT), 200 µM dATP and 15 units 
of terminal deoxynucleotide transferase (Frohman et al., 
1988). Alternatively, TcR cDNA, prepared with the Col 
primer, was tailed with poly G residues by incubation at 
37°c for 30 min and then at 70°c for 10 min in a 30 µl 
reaction containing the same components as for dA-tailing 
but with 1 mM dGTP instead of dATP. The volume of the 
reaction was then increased to 100 µl with DEP-treated 
ddH20 and the tailed cDNA extracted using an equal volume 
of phenol:chloroform:IAA [25:24:1]. Following 
centrifugation, the aqueous phase was recovered and 
concentrated to remove excess dNTP using a centricon 100 
microconcentrator, according to the manufacturer's 
instructions. The tailed cDNA was precipitated from the 
retentate (-50 µ1) with 0.1 volume 3M NaOAc and two 
volumes ice-cold ethanol overnight at -20°c. After 
centrifugation, the pellet was washed twice with ice-cold 
70% (v/v) ethanol, vacuum-dried and resuspended in 25 µl 
ddH20. For AN-PCR amplification of TcR transcripts, 5 µl of 
the tailed cDNA was used in a 100 µl PCR reaction 
containing the same components used for conventional PCR 
(see Chapter 3, section 3.3.6), except for the primers. The 
primers used for the 5'-end, in this case, were an anchor 
5'-GACTCGAGTCGACATCG-3' (ANl) (25 pmole) and ANl- (dT)17 
poly T primer (10 pmole) in conjunction with the 3'-nested 
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Figure 2.2 Procedure for anchored polymerase chain reaction 
amplification of T-cell receptor a-chain transcripts. 
Following first strand T-cell receptor cDNA synthesis with 
the Cal primer, the 3 1 -end of the cDNA was tailed with poly 
A residues. Tailed cDNA was then used as the template for 
PCR amplification using the ANl poly T and ANl primers 
(Frohman et al., 1988) in conjunction with Ca2. AN: anchor; 
C: constant; J: joining; PCR: polymerase chain reaction; V: 
variable. 
V J C 
mRNA 5' 3' .__ ___________________ ...J 
cDNA synthesis with Cal primer 
cDNA 3' 
Tail cDNA with dATP 
Tailed cDNA 3 'AAAAAAAAA I 
5 ' 
5' 
PCR with ANl poly T primer 
3 I AAAAAAAAA I 
ANl TTTTTTTTT I 
PCR with Ca 2 primer 
ANl TTTTTTTTT 
3' • 
PCR with ANl,ANl poly T 
and Ca2 (35 cycles) 
! 
PCR PRODUCT 
fZ1 5, 
fZ1 3' 
k%] 3 I 
I 5' 
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TcR C-region gene primer, Ca2. To facilitate cloning of the 
product, the anchor sequence in both 5' primers contained a 
Sall site (GTCGAC) whereas the Ca2 primer was modified (5 ' -
CAGGAAACAGCTATGACCGAATTC-Ca2-3') to include an EcoRl site 
(GAATTC) as well as the M13 reverse TAG. The AN2 (5 '-
GCATGCGCGGTCGACCGGAGGCC-3') and AN2- (dC)12 poly C primers 
described by Loh et al. (1989) were modified slightly to 
contain a Sall site and were used with Co2 for AN-PCR 
amplification of TcR o-chain transcripts. PCR conditions 
consisted of 35 cycles of amplification at 95°c for 1 min, 
58°c for 1 min and 72°c for 5.8 min, for the a-chain. For 
the o-chain, each cycle consisted of incubations of 95°c 
for 1 min, 56°c for 2 min and 72.5°c for 3 min. For the 
first and last cycles, in each case, the extension reaction 
was for 15 min. 
2.2.12 Agarose gel electrophoresis of DNA 
The percentage of an agarose gel varied depending on the 
size of the DNA fragments to be separated. For most 
purposes, a 1.25% (w/v) agarose gel was used to separate 
DNA fragments of about 200-700 bp. A 0.7% (w/v) agarose gel 
was used to separate larger fragments of approximately 6-8 
kbp (vector DNA). Agarose gels contained the appropriate 
amount of agarose dissolved in 1 x Tris-acetate EDTA (TAE) 
buffer (0.04 M Tris/acetic acid, 0.002M EDTA [pH 7.8]). 
Ethidium bromide was added to a final concentration of 
0.5 µg/ml. 
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For the separation of PCR-amplified TcR cDNA (generated 
from V gene family-specific or AN-PCR ) , 10 µl of each 
product was electrophoresed in a 1.25% (w/v ) agarose gel at 
120 volts for 1 h. Samples were prepared for 
electrophoresis by the addition of 0.2 volumes of 6 x 
sample buffer (30% (v/v) glycerol, 0.25% (w/v ) bromophenol 
blue, 0.25% (w/v) xylene cyanol). After electrophoresis, 
DNA fragments were visualised using a UV transilluminator 
at 254 nm wavelength. 
2.2.13 Southern blot analysis: Nucleic acid hybridisation 
2.2.13.1 Transfer of DNA onto nylon membranes 
After electrophoresis, the DNA was transferred from the 
agarose gel onto Gene Screen Plus hybridisation transfer 
membrane by capillary blotting, as described by Maniatis et 
al. (1982), using 0.4 M NaOH as the transfer buffer. 
Membranes were neutralised by rinsing briefly in 2 x SSC 
(0 .3 M NaCl, 0.03 M sodium citrate [pH7.0]), air-dried, 
fixed under UV light (254 nm) for 3 min and dried at 65°C 
for about 30 min. 
2.2.13.2 Hybridisation of DNA immobilised on nylon 
membranes: Protocol 1 
Membranes were prehybridised at 42°c for 5 h in heat-sealed 
plastic bags containing 5 x SSPE (5 mM EDTA, 50 mM NaP04, 
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900 mM NaCl, [pH7.4]), 5 x Denhardt's solution (0.1% (w/v ) 
bovine serum albumin (BSA), 0.1% (w/v) polyvinyl 
pyrrolidone (PVP), 0.1% (w/v) Ficoll 400), 0.1% (w/v) 
sodium dodecyl sulphate (SDS) and 100 µg/ml heat-denatured 
salmon sperm DNA. For the detection of TcR a- or ~-chain 
transcripts, filters were hybridised overnight at 42°c in 
the same solution containing 10 µl of 32 P-end-labelled 
internal oligonucleotide probe Ca3 or C~4 (see Table 2.1), 
prepared as described in section 2.2.14.1. For the 
detection of TcR 1- or o-chain transcripts, filters were 
hybridised overnight at 42°c in the same solution 
containing 10 µl of 32 P-end-labelled internal 
oligonucleotide probe C13 or Co3 (see Table 2.1), prepared 
as described in section 2.2.14.1. After hybridisation, 
filters were washed twice in 1 x SSPE /0.1% (w/v) SDS for 
20 min each at room temperature and once in 0.1 x SSPE/ 
0.1% (w/v) SDS for 10 min at 45°c. Washed filters were then 
exposed to X-ray film with intensifying screens at 
-7o 0 c. A schematic representation showing the locations of 
the TcR C-region gene probes Ca3, C~4, C13 and Co3, is 
given in Figure 2.1. 
2.2.13.3 Hybridisation of DNA immobilised on nylon 
membranes: Protocol 2 
Membranes were prehybridised at room temperature for at 
least 3 h in heat-sealed plastic bags containing Nasmyth's 
solution (10% (w/v) dextran sulphate, 1% (w/v) sodium 
sarcosine, 0.6 M NaCl, 0.18 M Na2HP04, 0.006 M Na2EDTA) and 
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100 µg/ml heat-denatured salmon sperm DNA (Nasmyth, 1982 ) . 
Filters were hybridised overnight at 65°C in fresh 
Nasmyth's solution containing 100 µg/ml heat-denatured 
salmon sperm DNA and random-primed DNA probe, prepared as 
described in section 2.2.14.2. The probe DNA was denatured 
by boiling for 5 min and chilled on ice immediately prior 
to use. After hybridisation, filters were washed 
sequentially at room temperature for 30 min in 2 x SSC/0.1% 
(w/v) SDS, at 65°c for 1 h in 1 x SSC/0.1% (w/v) SDS and at 
65°c for 30 min in 0.5 x SSC/0.1% (w/v) SDS. Washed filters 
were exposed to X-ray film with intensifying screens at 
-7o 0 c. 
2.2.14 Radio-labelling of DNA 
2.2.14.1 End-labelling of oligonucleotide 
Oligonucleotide (10 pmoles or 70-100 ng) was end-labelled 
by incubation at 37°c for 50 min in a 20 µl reaction 
containing 50 rnM Tris/HCl [pH 7.5], 20 rnM MgC1 2 , 20 rnM DTT, 
40 µCi [1- 32 P]ATP and 10 units T4 polynucleotide kinase. 
Probes could be stored at -20°c for no longer than two 
weeks, because, after this period, the specific activities 
would be greatly reduced. 
2.2.14.2 Random priming of DNA 
Approximately 60-100 ng of fragment DNA, prepared by 
electroelution as described in section 2.2.15.1, was 
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labelled by the random priming method using a commercially 
available kit (Pharmacia). The DNA was denatured by boiling 
for 2 min and chilled on ice. Then, 2.5 µl of reaction 
buffer, 2.5 µl primer solution, 2 µleach of dCTP, dGTP, 
dTTP solution, 1 µl enzyme solution and 2 µl [a- 32 PJdATP 
(Bresatec) were added and the reaction incubated at 37°C 
for 45 min. 
2.2.15 Cloning of specific DNA fragments 
2.2.15.1 Preparation of fragment DNA 
PCR-amplified TcR cDNA was precipitated by addition of 0.1 
volume of 3M NaOAc [pH6.0] and two volumes of ice-cold 
ethanol at -7o 0 c for 1 h. After centrifugation, the DNA 
pellet was washed once with ice-cold 80% (v/v) ethanol and 
resuspended in 13 µl sterile ddH20. For blunt-end cloning, 
the DNA was phosphorylated by incubation at 37°c for 45 min 
in a 20 µl reaction containing 50 mM Tris/HCl [pH7.5], 
20 mM MgCl2, 20 mM DTT, 2 mM ATP and 10 units T4 
polynucleotide kinase. For sticky-end cloning, the DNA was 
digested with EcoRI- and Sall-restriction endonucleases, 
according to the manufacturer's specifications. 
Phosphorylated or digested PCR product was separated on a 
1.25% (w/v) agarose gel, as described in section 2.2.12, 
and the DNA from a band approximately 400-700 bp was 
electroeluted as described below. 
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The DNA fragment of interest was localised using a long 
wavelength (300-360 nm) UV lamp to minimise damage to the 
DNA. The DNA band was excised from the agarose gel, placed 
inside a dialysis bag with 1 ml of 0.1 x TAE buffer and 
then placed into an electrophoresis tank containing 0.1 x 
TAE buffer. An electric current (200 volts) was applied for 
about 1 h, until the DNA had migrated out of the gel and 
could be visualised on the inner wall of the dialysis bag. 
To release the DNA from the wall of the dialysis bag, the 
polarity of the current was reversed for 30 sec. The buffer 
was recovered and centrifuged for 5 min to remove debris. 
The solution was extracted using phenol:chloroforrn [1:1 
-
v/v] and the DNA precipitated from the aqueous phase by 
addition of 0.1 volume of 3M NaOAc [pH6.0] and two volumes 
of ice-cold ethanol at -20°c overnight. After 
centrifugation, the DNA pellet was washed once with ice-
cold 80% (v/v) ethanol and once with ice-cold 95% (v/v) 
ethanol, vacuum-dried and resuspended in 20 µl sterile 
ddH20. To estimate the DNA concentration, 1 µl of the 
fragment DNA preparation was electrophoresed on a 1.25% 
(w/v) agarose gel, as described in section 2.2.12, and the 
intensity of the band compared with DNA fragments (A Hind 
III) of known molecular weight and concentration. 
2.2.15.2 Preparation of vector DNA 
For blunt-end cloning, Ml3mpl8 vector DNA (2 µg) was 
linearised by incubation at 2s 0 c for 2 h in 33 rnM Tris-
acetate, 10 rnM Mg-acetate, 66 rnM K-acetate, 0.5 rnM DTT 
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[pH7.9] containing 20 units Smar-restriction endonuclease, 
in a final volume of 40 µl. Alternatively, for sticky-end 
cloning, vector DNA was digested with a combination of 
EcoRI- and Sall-restriction endonucleases, according to the 
manufacturer's instructions. After digestion, 9 µl of 
sterile ddH20, 1 µl Tris/HCl [pH 8.4] and 1 unit calf 
intestinal alkaline phosphatase were added and the mixture 
incubated at 37°c for 30 min to dephosphorylate the DNA. 
The volume of the reaction was increased to 100 µl by 
addition of sterile ddH20, and the DNA extracted using 
phenol:chloroform [1:1 v/v]. DNA was precipitated from the 
aqueous phase with 0.1 volume of 3M NaOAc and two volumes 
of ice-cold ethanol at -20°c for 1 h. DNA was collected by 
centrifugation and the pellet washed once with ice-cold 80% 
(v/v) ethanol and once with ice-cold 95% (v/v) ethanol, 
vacuum-dried and resuspended in 50 µl sterile ddH20 to give 
a final concentration of 20 ng/µl. The vector (2 µ1) was 
analysed on a 0.7% (w/v) agarose gel, as described in 
section 2.2.12, to check that digestion of the DNA was 
complete. 
2.2.15.3 Ligation of fragment DNA to vector DNA 
Fragment DNA (100 ng), prepared by electroelution as 
described in section 2.2.15.1, was blunt-end ligated to 
20 ng Smar-cleaved Ml3mpl8 vector DNA by incubation 
overnight at room temperature in a 10 µl reaction 
containing 50 mM Tris/HCl [pH 7.6], 10 mM MgCl2, 5% (w/v) 
polyethylene glycol (PEG) 6000 , 1 mM ATP, 1 mM DTT and 
1 unit T4 DNA ligase. For sticky-end cloning with 
EcoRI/Sa1I-cleaved vector and fragment DNA, the same 
reaction components were used except for 0.5 units of 
ligase, instead of 1 unit, and the reaction mixture was 
incubated at 16°c. 
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2.2.15.4 Preparation of competent E. coli strain TG-1 cells 
A single colony of E. coli TG-1 cells was inoculated into 
10 ml 2 x YT medium (1.6% (w/v) bacto tryptone, 1% (w/v) 
yeast extract, 0.5% (w/v) NaCl) and incubated at 37°c 
overnight with shaking. Overnight culture was diluted 1/100 
into 20 ml fresh 2 x YT medium and incubated for a further 
2 hat 37°c with shaking. Cells were harvested by 
centrifugation at 2K for 5 min, resuspended gently in 10 ml 
of ice-cold 50 mM CaCl2, and incubated on ice for 30 min. 
Cells were again harvested by centrifugation, resuspended 
in 1 ml of ice-cold 50 mM CaCl2, and incubated on ice for 
at least 45 min before using. 
2.2.15.5 Transformation and plating of competent cells 
Competent E. coli strain TG-1 cells (200 µ1) were 
transformed with 10 µl of ligation mix by incubation on ice 
for 30 min, in an Eppendorf tube. Cells were then heat-
shocked at 42°c for 3 min and chilled on ice for at least 
15 min. For plating, 200 µl of fresh exponentially growing 
TG-1 cells were added to the transformed cells and this 
mixture was added to 3 ml warm (48°c) H-Top Agar (1% (w/v ) 
bacto tryptone, 0.5% (w/v) yeast extract, 0.8% (w/v ) NaCl, 
0.8% (w/v) agar) containing 20 µleach of X-gal (20 µg/ml ) 
and IPTG (100 mM), in a 10 ml tube. The contents of the 
tube were mixed thoroughly and then poured onto a H-plate 
(1% (w/v) bacto tryptone, 0.8% (w/v) NaCl, 1.2% (w/v) 
agar). Plates were inverted and incubated at 37°c 
overnight. 
2.2.15.6 Selection of recombinants: In situ hybridisation 
M13 single-stranded DNA was transferred directly onto 
Hybond N+ nylon membrane discs. Following incubation for 
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1 to 3 min at room temperature, membrane discs were peeled 
from the surface of the agar plate, UV-fixed for 3 min and 
dried at 65°C for 30 min. To determine the total number of 
TcR cDNA clones, including those with cDNA cloned in the 
forward or reverse orientation, discs were screened with a 
full-length TcR-specific probe, labelled as described in 
section 2.2.14.2. Hybridisation was performed as described 
in section 2.2.13.3. 
2.2.16 Automated DNA sequencing 
2.2.16.1 Preparation of single-stranded DNA template 
Ml3 single-stranded DNA was prepared from positively 
hybridising cDNA clones according to Maniatis et al. 
(1982). Each positively hybridising plaque was picked with 
a sterile glass Pasteur pipette and inoculated into 1.5 mls 
84 
of overnight E. coli strain TG-1 cells diluted 1 / 1 00 with 
fresh 2 x YT medium, in a 10 ml tube. Tubes were incubate d 
at 37°c for 7-24 h with shaking. Cells were removed by 
centrifugation for 5 min. To precipitate the single -
stranded DNA, 1 ml of the supernatant was incubated with 
200 µl PEG/NaCl solution (20% (w/v) PEG6ooo, 2.5 M NaCl ) at 
room temperature for 15 min. After centrifugation for 30 
min in a bench top centrifuge, the precipitate was 
recovered, taking care to remove all traces of PEG/NaCl 
solution. The pellet was dissolved in 100 µl TE buffer and 
the DNA extracted using phenol:chloroform [1:1 v/v]. DNA 
was precipitated from the aqueous phase by addition of 0.1 
volume of 3M NaOAc [pH6.0] and two volumes of ice-cold 
ethanol at -20°c overnight. The pellet was washed with ice-
cold 80% (v/v) ethanol, vacuum-dried and resuspended in 
25 µl sterile ddH20. The yield of single-stranded DNA was 
estimated, as described in section 2.2.17, and ranged from 
20-160 µg/ml. 
2.2.16.2 Sequencing protocol 
Approximately 1 µg of single-stranded DNA template was 
sequenced using an automated DNA sequencing system (ABI). 
Annealing reactions for each A and C bases involved 
incubation of the single-stranded template (0.15 pmol or 
150 ng) with 1.8 µl 5 x Taq sequencing buffer (50 mM 
Tris/HCl [pH8.4], 50 mM MgCl2, 250 mM NaCl) and 1 µl dye 
primer Joe (0.4 pmol/µ1) or Fam (0.4 pmol/µ1), 
respectively, at 65°c for 10 min, in a total volume of 
6 µl. Reactions were incubated at room temperature for 20 
min. For the extension reactions, 1 µl of the appropriate 
dNTP/ddNTP mix (ABI) and 0.5 units Taq DNA polymerase 
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(Sequencing Grade) in 1 x PCR buffer, were added and the 
mixtures incubated at 70°c for 10 min. A second reaction 
was then performed at 37°C for 10 min, after the addition 
of 0.7 units Klenow enzyme in 1 x Taq sequencing buffer. 
Annealing and extension reactions for each G and T bases 
required the M13 Tamra and Rox dye-labelled primers, 
respectively, and twice the volume of all reaction 
components. The four completed A, C, G, and T reactions 
were pooled by precipitation in ice-cold 95% (v/v) 
ethanol/0.1 M NaOAc, washed with ice-cold 70% (v/v) ethanol 
and then vacuum-dried. The pellet was resuspended in 5 µl 
deionised formamide, 1 µl 50 mM EDTA [pH8.0J, heated for 2 
min at 90°c and electrophoresed on a 6% denaturing 
polyacrylamide gel, using an ABI 370A automated DNA 
sequencer. The ABI version 1.30 software was used to 
perform the automatic fluorescence analysis and base 
calling. 
2.2.17 Estimation of single-stranded DNA concentration 
The concentration of single-stranded DNA template was 
estimated using a Hoefer Scientific Instruments TKO 100 
fluorimeter. A DNA solution with a concentration of 
100 µg/ml was taken as having a reading of 100. 
CHAPTER 3 
T-CELL RECEPTOR VARIABLE GENE USAGE IN 
RHEUMATOID ARTHRITIS PATIENTS 
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3.1 INTRODUCTION 
The synovial tissue and fluid of patients with RA contain 
activated T-cells that probably play a crucial role in the 
disease process which leads to joint erosion (reviewed by 
Panayi et al., 1992). T-cells expressing a/~ and 1/0 TcRs, 
present at the sites of joint inflammation in RA, could 
potentially initiate a local inflammatory response directed 
against a few joint-specific antigens. A TcR repertoire 
with restricted V gene usage may reflect a selective 
expansion of T-cells within the rheumatoid synovium. In 
studies of animal models of human autoimmune diseases, 
particularly murine EAE, restricted V~ gene expression by 
pathogenic T-cells specific for MBP, has been demonstrated 
(Zamvil et al., 1988; Acha-Orbea et al., 1988; Urban et 
al., 1988; Zaller et al., 1990). Furthermore, vaccination 
with MAbs directed against the specific V~ chains of those 
harmful T-cells has been used to treat and prevent EAE 
(Zamvil et al., 1988; Acha-Orbea et al., 1988; Urban et 
al., 1988; Zaller et al., 1990). This may have important 
implications for immune intervention in the treatment of 
human autoimmune diseases, like RA, provided that 
particular TcRs are indeed involved in initiating or 
perpetuating an aberrant immune response which may lead to 
the development of autoimmunity. 
There are several recent studies on the analysis of Va/~ 
gene expression in healthy individuals and in RA patients, 
although, for RA, the data are conflicting. These are 
87 
reviewed in the discussion section of this Chapter. In 
peripheral blood T-cells of healthy donors, TcR V~ (Doherty 
et al., 1991; Hu et al., 1992; Imberti et al., 1992) and Va 
gene expression (Imberti et al., 1992) using V gene-family 
specific PCR was found to be heterogeneous, and all V gene 
families tested for were detected. Conversely, limited data 
are available on the analysis of 1/5 TcR V gene expression 
in RA patients and in healthy donors. For healthy 
individuals, characterisation of TcR 1/5 usage in the 
peripheral blood has essentially been confined to the use 
of MAbs. In this study, V gene usage of TcR transcripts 
expressed by a/~ and 1/5 T-cell populations in the synovia 
and peripheral blood of RA patients, was investigated, as 
well as TcR 1/5 usage in the peripheral blood of healthy 
controls. 
3.2 AIMS 
The first aim of this study was to determine whether 
predominant Va and/or V~ gene usage of the . expressed a/~ 
TcR repertoire is a feature of synovial T-cells when 
compared with peripheral blood T-cells in a group of RA 
patients. The second aim was to characterise the repertoire 
of TcR v1 and Vo genes expressed in synovial and peripheral 
blood T-cells of RA patients, and in peripheral blood T-
cells of normal healthy individuals. 
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3.3 MATERIALS AND METHODS 
3.3.1 RA patients 
Peripheral blood and synovial tissue were obtained from 
seven RA patients undergoing elective joint surgery that 
involved either synovectomy or replacement. The study had 
approval from the appropriate institutional ethics 
committee. Patients were diagnosed according to the 
American Rheumatism Association 1987 revised criteria for 
the classification of RA (Arnett et al., 1988). The 
duration of disease ranged from eight to 30 years and the 
disease was still active in all patients as indicated by 
erythrocyte sedimentation rate and measurement of c-
reactive protein, just prior to surgery. All patients 
received small doses of prednisone and non-steroid anti-
inflammatory drugs. Patient 1 was also given cyclosporine-
A. Details of the RA patients, including HLA-DR type, age, 
sex, disease duration and the site at which a synovium 
biopsy was taken, are given in Table 3.1. 
3.3.2 Controls 
Peripheral blood was obtained from nine healthy donors 
(five female; four male) whose ages ranged from 23 to 45 
years. 
Table 3.1 Rheumatoid arthritis patient clinical data. 
Patient HLA-DR 
typea) 
1 DR7,DR10 
2 DR3,DR4(Dw14) 
3 DR2,DR4(Dw4) 
4 DR2,DR11 
5 DR4(Dw4) ,-
Sexb) Age Disease Site of 
(yr) duration (yr) biopsyc ) 
M 74 12 R elbow 
M 74 26 L wrist 
M 63 30 R elbow 
F 88 15 L wrist 
M 47 8 L wrist 
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6 DR1,DR7 M 63 20 R shoulder 
7 DRl -I F 48 11 R hand 
a) HLA-DR typing was performed as described in Chapter 2 
(section 2.2.6). 
b) M: male; F: female. c) R: right; L: left. 
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3.3.3 Cell separation 
Mononuclear cells were isolated from peripheral blood 
(PBMC) and synovium (SMC) of RA patients, as described in 
Chapter 2 (section 2.2.1). PBMC were isolated from 
heparinized blood obtained from four healthy donors, by 
density gradient centrifugation, according to the method in 
Chapter 2 (section 2.2.2). SMC and PBMC of RA patients and 
PBMC of controls were not cultured or stimulated in vitro 
prior to analysis. 
3.3.4 Isolation of total RNA and first strand cDNA 
synthesis 
RNA was isolated from SMC and PBMC of patients and control 
PBMC by the acid guanidinium thiocyanate-phenol-chloroform 
extraction method, essentially as described in Chapter 2 
(section 2.2.7). Approximately 10 µg of total RNA was 
converted to single-stranded cDNA by incubation at 37°c for 
1 h in a 50 µl reaction containing 1 x cDNA synthesis 
buffer (50 mM Tris/HCl [pH8.3], 75 mM KCl, 3 mM MgCl2, 
10 mM DTT), 1 mM of each dNTP, 50 pmole TcR C-region gene 
antisense primer (Cal, Cfil, c11 or Col, see Table 2.1), 25 
units RNasin and 50 units M-MuLV reverse transcriptase. 
Reaction products were purified by phenol-chloroform 
extraction followed by centrifugation in a centricon 100 
microconcentrator, as previously described in Chapter 2 
(section 2.2.9). 
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3.3.5 Design of primers for PCR 
Primers corresponding to the TcR v1 and Vo subgroups and 
all the C-region gene primers were designed from previously 
published V and C gene sequences. Selection of primers was 
based on several criteria including size of approximately 
20-25 bases and with about 50% GC content, to minimise 
differences in the theoretical melting temperatures 
[Tm=4(G+C) + 2(A+T)]. To assess the potential degree of 
primer/primer as well as primer self annealing, the 
sequences of primers were analysed using the PCR Primer 
Selection computer programme (Epicentre Software, Pasadena, 
USA). Sequences with minimal complementarity and without 
terminal palindromic sequences and secondary structure were 
selected for oligonucleotide synthesis. 
3.3.6 V gene family-specific PCR amplification of TcR 
transcripts 
Approximately 2% of single-stranded cDNA template was 
amplified in a 50 µl reaction containing 1 x PCR buffer 
(10 rnM Tris/HCl [pH8.4], 50 rnM KCl, 2.5 rnM MgCl2, 0.01% 
(w/v) gelatin), 0.2 rnM of each dNTP, 25 pmole 5' Va (Table 
3.2), Vfi (Table 3.3), v1 or Vo gene sense primer (Table 
3.4; Figures 3.1 and 3.2), 25 pmole of 3'-nested C-region 
gene antisense primer (Ca2, Cfi2, Cfi3, c12 or Co2, see Table 
2.1) and 1.25 units Taq DNA polymerase. DMSO at a final 
concentration of 10% (v/v) (Winship, 1989) was included in 
reactions with the Vfi2 and Vfi5 primers. Each reaction 
Table 3.2 Nucleotide sequence of 5' variable region gene primers used for polymerase 
chain reaction amplification of T-cell receptor a-chain rnRNA transcripts. 
Primer Sequence (5'-3') Primer Sequence (5'-3') 
Val CAGTCGGTGACCCAGCTT Vall AGAAAGCAAGGACCAAGTGTT 
Va2 GTGTTCCCAGAGGGAGCCATTGCC va12 CAGAAGGTAACTCAAGCGCAGACT 
Va3 GGTGAACAGTCAACAGGGAGA Va13 GCTTATGAGAACACTGCGT 
Va4 ACAAGCATTACTGTACTCCTA Va14 GCAGCTTCCCTTCCAGCAAT 
vas GGCCCTGAACATTCAGGA Va15 AGAACCTGACTGCCCAGGAA 
Va6 GTCACTTTCTAGCCTGCTGA Va16 CATCTCCATGGACTCATATGA 
Va7 AGGAGCCATTGTCCAGATAAA Va17 GACTATACTAACAGCATGT 
vas GGAGAGAATGTGGAGCAGCATC Va18 TGTCAGGCAATGACAAGG 
Va9 ATCTCAGTGCTTGTGATAATA Va19 CACAGCCTGGTGACTCAG 
ValO ACCCAGCTGGTGGAGCAGAGCCCT 
The sequences of Va2 to Va18 were obtained from a previously publishe d r eport 
(Oks e nberg et al., 1990). "° I\) 
Table 3.3 Nucleotide sequence of 5' variable region gene primers used for polymerase 
chain reaction amplification of T-cell receptor fi-chain mRNA transcripts. 
Primer Sequence (5'-3') Primer Sequence (5'-3') 
Vfil AAGAGAGAGCAAAAGGAAACATTCTTGAAC VfilO CTTATTCAGAAAGCAGAAATAATCAATGAG 
Vfi2 GCTGCAAGGCCACATACGAGCAAGGCGTCG Vfill TCCACAGAGAAGGGAGATCTTTCCTCTGAG 
Vfi3 AAAATGAAAGAAAAAGGAGATATTCCTGAG Vfi12 GATACTGACAAAGGAGAAGTCTCAGATGGC 
Vfi4 CTGAGGCCACATATGAGAGTGGATTTGTCA Vfi14 GTGACTGATAAGGGAGATGTTCCTGAAGGG 
Vfi5 CAGAGAAACAAAGGAAACTTCCCTGGTCGA Vfi15 GATATAAACAAAGGAGAGATCTCTGATGGA 
Vfi6 GGGTGCGGCAGATGACTCAGGGCTGCCCAA Vfi16 CATGATAATCTTTATCGACGTGTTATGGGA 
Vfi7 ATAAATGAAAGTGTGCCAAGTCGCTTCTCA Vfi17 TTTCAGAAAGGAGATATAGCTGAAGGGTAC 
Vfi8 AACGTTCCGATAGATGATTCAGGGATGCCC Vfi18 GATGAGTCAGGAATGCCAAAGGAACGATTT 
Vfi9 CATTATAAATGAAACAGTTCCAAATCGCTT Vfi19 CAAGAAACGGAGATGCACAAGAAGCGATTC 
The sequences of all Vfi primers were obtained from a previously published report 
(Wucherpfennig et al., 1990). 
'° w 
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Table 3.4 Nucleotide sequence of 5' variable region gene 
primers used for polymerase chain reaction amplification of 
T-cell receptor 1- and o-chain rnRNA transcripts. 
Primer 
v1r 
V1II 
V1III 
v1rv 
Sequence (5'-3') 
GGAGAACGAAGTCAGTCA 
CCAGTACTAAAACGCTGTC 
CAGCTATCCATTTCCACGG 
GCAAATAAGAGTGCCCAC 
Primer Sequence (5'-3' ) 
Vol TCTGGATCAAGTGTGGC 
Vo2 TCTGGGCAGGAGTCATGT 
Vo3 GGCACGCTGTGTGACAAA 
Vo4 GACACCAGTGATCCAAGTT 
Vo5 GATGACCAGCAAGTTAAGC 
Vo6 TATCATGGATTCCCA 
Primers were designed from previously published V gene 
sequences (Lefranc et al., 1986a; Lefranc et al., 1989; 
Takihara et al., 1989). 
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Figure 3.1 .T-cell receptor v1 gene sequences (first 120 
bases) of subgroups I-IV showing the locations of the 
oligonucleotide primers used for polymerase chain reaction 
amplification. Variable gene sequences from Lefranc et al. 
(1986a and 1989). Note that, unlike the other V1I subgroup 
genes, the V6 gene, which is a pseudogene, has several 
nucleotide substitutions in the region at the 5'-end of the 
v1I primer. 
V2 
Vl 
V3 
V.J 
vyr I vs 
V6 
V7 
va 
VyII [ V9 
VyIII [ VlO 
VyIV [ Vll 
1 60 120 
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TATGJTGCAGGTI:::ACCTAGAGCA."A.CCTCA.L...i\TTTcfdAGTA@rit~ddrdTd.n...n...n...n...1:..cAGCCCGCCTGGAATGTG'DJG 'I\::;TCTG::;A.A,.T_L.._L.._l,.Ai\TTTCTGC.L..."A.C.l\'I\=TGT."A.TATTGGT.A.T 
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CTTGGATTATI:::.L...i\A.l\G'DJGAGC."A.GTTC~@W.WAf¢Q.AmrfQ$.h.@.9"A..AGTC.L...A.G.L...L...MGTATTGAC.A.TACCTTGC.L...i\GAT.A.TCGAGC."A.C.L...AGGTT1'::;_n.._n.._1:..c.1:..GATGTCAT'I'=ACTGGTAC 
CTTGGGC.AGTTGGAAC.L...ACCTGAA.A.T.A.TI:::T.A.TTTCCAGACC.~~iMW.iVMMi ilW¢¢¢ !.@.A.TATI:::T'DJGA.A.GGC.i\TCCA'I\=c.n...A.GGCTTTAGC.A.GT.L...L...L...A.TI:::."A.T.A.C."A.CTGGTAC 
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Figure 3.2 T-cell receptor Vo gene sequences showing the 
locations of the .5' oligonucleotide primers used for 
polymerase chain reaction amplification. Variable gene 
sequences from Takihara et al. (1989). 
1 5 '-untranslated Leac'lPr 60 V::>r iable 
~:~~==~:~::::~::::~~=:~~~~~~~~~~~~:--------·-----------~----------------------:V~ctL~L~~·~·=·~---------------------·~~~ 1 ~~v 
Vol ACAACTCACATTTGTGCl1,.:r:,, .. :A.GAGCT .. A.CATGCC.l\CATGCTGTTCTCCl..i,.GCCTGC'I\3'I\3TGT .. A.TT'ISTGGCCTTCAG::::TAC'ro"MGAW'A.~m.'1GTG:GCCClo.•3 .. l,,_A.G3TTAC'I\::::AA.GCCC..A.GTC 
.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.•,•.•.•,·.·.·.·.·.·.·.·.·.·.·.·.·.·,·.·.·.·.·.·.·.·.· 
Vo2 GTGGTTGAG .. A.GGCAGAGCTGCCCCTGAGTGAGCCATGC .. A.GAGGATCTCCTCCCTCATCC..A.'1'::::TCTC'I\::::'I\::::TTJT:G.GG\:::~00.A.GTCA:TGTCAGCC .. A.TTG .. Z\•3TTG3TG::::c'I\3A_Z\C..i\CC..A.AAC 
Vo3 TTCTTACTGTGGGCTTTAGCTTTTTGTTTT'I\::::TACAGGGG,¢.t¢G.¢.'tG.[qtQAQ.,~GT .. Z\ACCC..'A,.G .. Z..·3TTCCCC3GACC..A.GAC 
Vo5 CTGCATCT'I\::::ACAGG..A.G3GATGGCCATGC'I\::::CTGG3GGCA'I\::::AGTGC'I\3ATI\::::TGTGGCTTC..A.GCC .. A.GACTGG3TA.l\..A.C .. A.·3'1':::: .. l\..'A,.CAGA .. A.G .. Z....'ATQ..~W,Q;¢.¢.M4¢AA~$f:r4,Q.QA.Z..AA.T'IC 
121 180 2..J O 
Vol ATCAGT .. Z\TCC .. Z\TGCCAGTG .. A.GG..l\..l\..A.GC .. A.GTCACCCTGAACTGCCTGTATG .. l\..A.AC..l\..A.GTTGG'I\3GTCATATTAT .. A.TTTTT'I\3GT .. Z\CAA.GC .. l\..A.CTTCCCAGC..l,,_l\..Z..GAGATG..A.TTT'I\::::CTT .. Z..T 
V02 AGTGCCTGTGTCAA.T .. A.GGGGTCCCTGCCACCC'I\::::AGGTGCTCCATG..l\..l\..A.GG .. A.GAAGCGATCGGT .. Z\ACT .. A.CTAT .. A.'I\:::: .. l\..A.C'Jl3GTACAGG..l\..A.GACCC..l\..A.GGT .. l,,_'A,.C..Z\C..A...A.TCACTT'I\::::ATAT .. l\. 
Vo3 GGTGGCG..A.GTGGCAGTG..A.GGTGGTACTGCTCTGCACTTACGACACTGTATATTCAAA.TCCAG..A.TTTAT'D::::TGGTACCGGATA.A.GGCCAGATTAT'D::::CTTTCAGTT'I\3TCTTTTATGGGG..A. 
Vo-1 CATATG.lG.A.G.GhG.'J.fa~A.it.GMG@:f:..Z\ TGGTCT .. A. TTCTGGTACA.A.GCAGCCCAGCAGTGG·3G .. Z....A.ATCGA TTTTTCTT A TTTA 
Vo5 ACCATCCCTGAGCG'Jl::::C .. A.GG..A....A.GG .. l\..A.GAA.TTTCTl1.TTCTGAA.CTGTGACTAT.A.CTA.A.CAGCATGTTTGATTATT'D::::CT .. i\'Jl3GT .. Z\C..l\..4 .. Z\..A....A...i\T.A.CCCTGCT·3..A...i\GG'Jl::::CT .. A.C..A.T'Jl::::CT,3AT 
241 300 300 
Vol TCGCCAGGGTTCTGATGAA.CAG..A...i\TGCM..A...A...A.GTGGTCGCTATTCTGTC .. l\..Z\CT'I\::::AA.G .. l\..i\AGCAGCG..l\..Z\..A.TCCG'I\::::GCCTT .. Z\..A.CCATTTCAGCCTTACAGCT .. i\GAAGATTC..li.GCAA.A.GTA 
Vo2 CCGAGAAAAGGACATCT .. A.TGGCCCTGGTTTCAA...A.G..A.CAA.TTTCC .. l\..i\GGTGACATTGATATTGCA.Z....i\G..A. .. i\CCTGGCTGTACTTA.A.GATACTTGCACC..A.TC .. 'AG .. Z\GAG .. A.G .. Z\TGAA.GGGTCTTA 
Vo3 TAA.C..A.GCAG..A.TCAGAA.GGTGCAGATTTTACTCAAGGACGGTTTTCTGTGA.i\ACACATTCTG .. A.CCCAG..A....i\AGCCTTTC..A.CTTGGTGATCTCTCC..A.GT .. l\..A.GG .. 4C'I\3.l\..A.G .. i\C.AGTGCC..i\CTT.A. 
Vo4 TCAGGGGTCTTATGACCAGC..l\..Z\..l,,_i\TGC .. Z\..A.CAGA.A.GGTCGCT .. A.CTCATTG .. l\..A.TTTCCAGAi\GGCAA.G'fa_i\_i\ATCCGCCAA.CCTTGTC..A.TCTCCGCTTCACAA.CTGGGGGACTC..A.GCA .. A.TGT .. A. 
Vo5 ATCT .. A.TA.A.GTTCCATTA.A.GG..A.TAAA...Z\..A.TG .. l\..A.GATGG .. l\..A.G..A.TTCACTG'D::::TTCTT .. A. .. l\..ACAZ\..AAGTGCC..l\..i\GC..i\CCTCTCTCTGCACATTG'Il3CCCTCCCAGCC'Jl3GAG.A.CTCTGCAGTGTA 
V06 :!tATM.1.t~AA'ft¢:¢.¢AGCCTGG ..A.GACTC..AGCC .. A.CCT .. A. 
361 Variable 
Vol CTTTTGTGCTCTTGGGGA 
V02 CTACTGTGCCTGTGACACCGTA 
V03 CTACTGTGCCT 
Vo4 TTTCTGTGC .. l\..A.TGAGAGAGG 
Vo5 CTTCTGTGC..A.GCA.i\G 
Vo6 CTTCTGTGCAGCAA.G 
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mixture was overlaid with mineral oil and subjected to 35 
cycles of amplification using a thermal cycler (Bartelt 
Instruments). PCR conditions for amplification of TcR a-
chain cDNA were 9s 0 c for 1 min, ss 0 c for 1 min and 72°c for 
1 min, for each cycle. For amplification of TcR fi-chain 
cDNA, PCR conditions were altered to 9s 0 c for 1 min, ss 0 c 
for 2 min and 72°c for 3 min, per cycle. For amplification 
of TcR 1- and 5-chain cDNA, each cycle consisted of 
incubations of 9s 0 c for 1 min, so 0 c for 1 min and 72°c for 
1 min. The positions of the TcR C-region gene primers Ca2, 
Cfi2, Cfi3, c12 and C82, within the various TcR genes, are 
shown in Chapter 2, Figure 2.1. 
3.3.7 AN-PCR amplification of TcR transcripts 
Following TcR cDNA synthesis, PCR was performed with 
single-sided specificity (see Chapter 2) using anchor 
primers described by Frohman et al. (1988) and Loh et al. 
(1989). The procedure for amplification of TcR a-chain 
transcripts using the primers of Frohman et al. (1988), is 
outlined in Figure 2.2. 
3.3.8 Southern blot analysis 
PCR-amplified TcR cDNA (10 µl) was electrophoresed in a 
1.25% (w/v) TAE agarose gel and blotted onto Gene Screen 
Plus hybridisation transfer membrane, according to the 
protocols described in Chapter 2 (sections 2.2.12 and 
2.2.13.1). Membranes were prehybridised and hybridised with 
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the appropriate 32 P-end-labelled oligonucleotide probe, as 
described in Chapter 2 (section 2.2.13.2), and the filters 
washed accordingly. 
3.3.9 Cloning of AN-PCR-amplified TcR transcripts 
Following digestion of AN-PCR-amplified TcR a-chain cDNA 
with EcoRI- and Sall- restriction endonucleases, the PCR 
product was separated on a 1.25% (w/v) TAE agarose gel, as 
described in Chapter 2 (section 2.2.12), and the DNA from a 
band approximately 400-700 bp was electroeluted according 
to the protocol described in Chapter 2 (section 2.2.15.1). 
Fragment DNA was then cloned into EcoRI/Sa1I-cleaved vector 
DNA according to the methods in section 2.2.15. 
Alternatively, AN-PCR-amplified TcR 8-chain cDNA was blunt-
end ligated into Smar-cleaved vector DNA essentially as 
described in Chapter 2 (section 2.2.15). After 
hybridisation of M13 plaque lifts with a random-primed 
full-length TcR a- (Yanagi et al., 1985) or 8-chain specific 
probe (section 2.2.15.6), positive cDNA clones were 
sequenced as described in Chapter 2 (section 2.2.16). 
3.4 RESULTS 
3.4.1 TcR Va and V~ gene usage in RA 
3.4.1.1 V gene usage of TcR a- and 8-chain transcripts 
expressed in Con-A stimulated pooled normal PBMC 
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Primers for 19 different human TcR Va gene families (Table 
3.2) and 18 V~ gene families (Table 3.3) were used for PCR 
amplification of rearranged TcR V-C mRNA transcripts in the 
PCR positive control cDNA (see Chapter 2, section 2.2.10 ) . 
The efficacy of the primers was considered satisfactory 
when a PCR product of the expected size could be visualised 
by ethidium bromide staining and its specificity was 
confirmed by hybridisation with an internal radio-labelled 
oligonucleotide probe. As shown in Figure 3.3 all the TcR 
Va (Figure 3.3.A) and V~ (Figure 3.3.B) gene families 
tested for were successfully amplified in the positive 
control. In no instance was it necessary to re-design the 
PCR primers, although the V~16 primer was re-synthesised 
because it was discoloured. 
3.4.1.2 V gene usage of TcR a-chain transcripts expressed 
in SMC and PBMC of RA patients 
TcR cDNA prepared from SMC and PBMC of five RA patients was 
amplified by the PCR using TcR Va gene family-specific 
primers, to analyse the presence or absence of expressed 
TcR a-chain transcripts. Figure 3.4.A shows that, for 
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Figure 3.3 PCR amplification and Southern blot analysis of 
rearranged TcR o- and fi-chain transcripts expressed in Con-
A stimulated pooled normal PBMC. (A) Lanes 1-19 corre·spond 
respectively to amplification of control cDNA with the Vol-
voi9 primers, each in conjunction with CO2. Blots were 
hybridised with an internal TcR Co region-specific 
oligonucleotide probe (Co3) and autoradiographs were 
exposed for 6 h. (B) PCR amplification was performed with 
the Vfil, 4, 7, 8, 9, 10, 11, 12, 16, 17, 18 and 19 primers, 
each with Cfi2 whereas amplification with the Vfi2, 3, 5, 6, 
14 and 15 primers, was with Cfi3 (as numbered lane 1 is 
Vfil). Blots were hybridised with an internal TcR Cfi region-
specific oligonucleotide probe (Cfi4) and exposed for 6 h. 
Approximate sizes are indicated in basepairs. C: constant; 
Con-A: concavalin A; PBMC: peripheral blood mononuclear 
cells; PCR: polymerase chain reaction; TcR: T-cell 
receptor; V: variable. 
A 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 
bp 
-500 
-250 
B 
1 2 3 4 5 6 7 8 9 10 11 12 14 15 16 17 18 19 
bp 
-550 
-400 
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patient 1, each Va gene family expressed in the PBMC is 
also represented in the SMC. After a longer period of 
exposure Va18 was detected in both PBMC and SMC. Thus, for 
this patient, there is clearly no biased usage of 
particular Va gene families in the expressed TcR a-chain 
repertoires, since SMC used the same set of non-restricted 
Va genes as PBMC. Similarly, there were no restrictions in 
the TcR a-chain repertoires of any of the other four RA 
patients studied. 
3.4.1.3 V gene usage of TcR 8-chain transcripts expressed 
in SMC and PBMC of RA patients 
Some differences, in terms of signal intensity, were 
observed between the expressed SMC and PBMC TcR ~-chain 
repertoires of patient 1. As shown in Figure 3.4.B, five V~ 
gene families (V~6, 9, 10, 12 and 18) appeared to be 
expressed at low levels in the SMC compared to the PBMC 
whereas V~ll and V~16 gene families were "weakly" expressed 
in both PBMC and SMC. V~ gene families were scored as 
"weakly" expressed when specific PCR products could not be 
visualised by ethidium bromide staining but were evident 
after prolonged exposure (24-48 h) of autoradiographs. 
Thus, although there were minor differences between the SMC 
and PBMC V~-chain repertoires of this patient, expression 
of all 18 TcR V~ gene families was detected in the SMC. 
A summary of the expression of TcR V~ gene families in SMC 
and PBMC of each of the five RA patients studied is given 
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Figure 3.4 PCR amplification and Southern blot analysis of 
rearranged TcR a- {A) and ~-chain transcripts {B) expressed 
in PBMC (a) and SMC (b) of RA patient 1. Lanes are marked 
as in Figure 3.3. Autoradiographs were exposed for 6 h 
except for the SMC in {B) which was exposed for 48 h. PBMC: 
peripheral blood mononuclear cells; PCR: polymerase chain 
reaction; RA: rheumatoid arthritis; SMC: synovial membrane 
mononuclear cells; TcR: T-cell receptor. 
A 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 
a 
b 
B 
1 2 3 4 5 6 7 8 9 10 11 12 14 15 16 17 18 19 
a 
b 
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in Table 3.5. Similar results were obtained for all 
patients, with most showing at least four Vfi gene families 
weakly expressed in the SMC compared to the PBMC. In 
contrast, Vfil, 3, 5, 14 and 15 gene families were 
positively expressed by SMC and PBMC of each patient. Most 
strikingly, for patient 5 (HLA-Dw4 homozygote), five Vfi 
gene families (VfilO, 11, 16, 17 and 19) were not expressed 
in the SMC, although Vfi16 was weakly expressed in the PBMC. 
It should be noted that three of these gene families (Vfi16, 
17, and 19) are each represented by a single gene (Wilson 
et al., 1988). A single-member V gene family would be more 
likely to be found absent than a multigene family, such as 
Vfi6 which contains at least nine family members (Wilson et 
al., 1988) or Vfi8 which contains five members (Siu et al., 
1986; Wilson et al., 1988). In summary, most Vfi gene 
families were detected in RA SMC and, although there were 
quantitative differences in TcR Vfi gene expression when 
compared to PBMC, there was no biased, or lack of usage, of 
particular Vfi gene families. 
3.4.1.4 AN-PCR amplification of TcR transcripts 
AN-PCR was initially performed using a Mycobacteria hsp65-
reactive T-cell line (provided by Ms E. Adams, Clinical 
Immunology Research Centre, University of Sydney) and the 
anchor primers described by Frohman et al. (1988), to 
amplify TcR a-chain transcripts. Two bands (-550 and -700 
bp) were observed on an ethidium bromide-stained agarose 
gel and both hybridised to the Ca3 internal oligonucleotide 
Table 3.5 T-cell receptor Vfi gene expression in peripheral blood and 
synovial membrane mononuclear cells of rheumatoid arthritis patients. 
Patient TcR Vfi gene families 
1 2 3 4 5 6 7 8 9 10 11 12 14 15 16 17 18 19 
1 PBMC + + + + + + w + + + w + + + w + + + SMC + + + + + w + + w w w w + + w + w + 
2 PBMC + w + + + + + + + + + w + + w + w w SMC + w + + + + w w w w + + + + + + + + 
3 PBMC + + + + + + w w w w w w + + w + + + SMC + + + + + + w w w - + + + + w w + + 
4 PBMC + + + + + + + w + w + + + + w + + + SMC + + + w + + + w + w w + + + w + + + 
5 PBMC + + + + + + + w + + + w + + w + + + SMC + w + + + + + w w - - + + + - - + 
Presence or absence of V gene families as denoted by+ or - ; 
w: weakly expressed, that is, visualised after prolonged exposure of 
autoradiographs but not evident with ethidium bromide staining. 
1---1 
0 
~ 
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probe. Although the cloning efficiency of the AN-PCR 
material was low, a few positive TcR a-chain cDNA clones 
were generated. Of ten cDNA clones sequenced, eight were 
full-length and most had a unique sequence, containing a 
different v- as well as J-region segment. The other two 
cDNA clones had truncated Ca-Ja sequences. By comparison 
with published Va gene sequences, the V genes used in these 
cDNA clones were Val.1, Va2, Va4.1, va11.1, Va14, Va15 and 
the recently described Vaw29 (Roman-Roman et al., 1991). 
Two of the cDNA clones were identical and used Va14. The 
cDNA clone containing the Vall.1 gene used a novel Ja 
segment, IGRJa02G (Roman-Roman et al., 1991). Thus, AN-PCR 
can be used to amplify TcR transcripts without knowledge of 
the 5' V gene sequences. Because of this, theoretically, 
there is no bias for any particular TcR sequence as is · 
potentially possible when V gene family-specific primers 
are used. In addition, AN-PCR provides a valuable tool with 
respect to identifying novel V gene subfamilies, as 
demonstrated in this experiment by identifying Vaw29 and a 
novel Ja segment, and assessing the size of the germline 
TcR repertoire. 
AN-PCR was then applied to the SMC and PBMC of RA patient 1 
and the SMC of RA patient 4, of which there was ample 
material, with the aim of amplifying TcR a-chain 
transcripts. Again the cloning efficiency was lower than 
that obtained with the cloning of conventional PCR 
material. In the SMC of patient 4, approximately 50 
positive cDNA clones were generated and 16 of these were 
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sequenced. Six of the clones contained full-length V-J-Ca 
cDNAs. The Va genes detected were Val, Va2 (in two clones), 
a Va gene similar to Va6.1, Vaw29 and an unidentified 
sequence, indicating a polyclonal population of T-cells. 
Seven of the cDNA clones had unusual ca gene 
rearrangements, one cDNA clone contained germline Ca 
sequences and two cDNA clones represented short a 
sequences. For patient 1, most of the cDNA clones sequenced 
from the PBMC were truncated a sequences (50-100 bp) or 
unusual ca gene rearrangements. Similarly, in the SMC of 
this patient, of the ten cDNA clones sequenced, seven had 
unusual Ca rearrangements. One full-length cDNA clone used 
Val and two cDNA clones were the same and contained a 
partial Va15 fragment. In a published report of TcR a-chain 
transcripts in normal PBMC, using AN-PCR, approximately 60% 
of the cDNA clones were V-J-Ca sequences whereas the 
remainder contained germline Ca or Ja-ca sequences (Roman-
Roman et al., 1991). It is obvious that for this approach 
to be successful, many TcR cDNA clones need to be generated 
and sequenced, due to the high proportion of probably non-
productive transcripts. 
3.4.2 TcR v1 and Vo gene usage in RA 
3.4.2.1 V gene usage of TcR 1- and o-chain transcripts 
expressed in Con-A stimulated pooled normal PBMC 
V gene usage in the PCR positive control cDNA (see Chapter 
2, section 2.2.10) was determined by PCR amplification of 
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rearranged TcR V-C mRNA transcripts using primers specific 
for the four human TcR v1 subgroups and the six Vo gene 
families (see Table 3.4). Expression of TcR V genes was 
considered positive when a PCR product of the expected size 
could be visualised by ethidium bromide staining and its 
specificity was confirmed by hybridisation with an internal 
radio-labelled oligonucleotide probe. In some cases PCR 
products could not be visualised on ethidium bromide gels 
but gave positive signals when hybridised. All the V gene 
family-specific primers successfully amplified rearranged 
TcR 1- (Figure 3.5, sample #C) and o-chain transcripts 
(Figure 3.6, sample #C) in the positive control, although 
compared to unstimulated normal PBMC, Vo4 transcripts were 
less readily detected. 
3.4.2.2 V gene usage of TcR 1-chain transcripts expressed 
in SMC and PBMC of RA patients 
TcR cDNA prepared from SMC and PBMC of seven RA patients 
was amplified by the PCR using TcR v1 gene family-specific 
primers, to analyse the level of diversity of the expressed 
TcR 1-chain repertoires. Figure 3.5 shows that in five of 
the seven patients studied there was no restriction in v1 
gene usage since SMC expressed the same set of v1 genes as 
PBMC. There were a few differences between the expressed 
SMC and PBMC TcR 1-chain repertoires of patients 3 and 4 . in 
that V1II (V19) was barely detected in the SMC compared to 
the PBMC and there was no detectable expression of V1IV 
(V111) in the SMC. In both of these patients, v1IV was 
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Figure 3.5 PCR amplification and Southern blot analysis of 
rearranged TcR 1-chain transcripts expressed in PBMC (a) 
and SMC (b) of seven RA patients and in Con-A stimulated 
pooled normal PBMC (#C). Lanes 1-4 correspond respectively 
to amplification of TcR cDNA with the v1r-v1rv primers, 
each in conjunction with c12. Blots were hybridised with an 
internal TcR c1 region-specific oligonucleotide probe (C13) 
and exposed for 6 h. Approximate sizes are indicated in 
basepairs. C: constant; Con-A; concavalin A; PBMC: 
peripheral blood mononuclear cells; PCR: polymerase chain 
reaction; RA: rheumatoid arthritis; SMC: synovial membrane 
mononuclear cells; TcR: T-cell receptor; V: variable. 
Patients 
(1) 
a 
b 
(5) 
a 
b 
1 2 3 4 1 2 3 4 
(2) 
1 2 3 4 1 2 3 4 
(6) 
1 2 3 4 1 2 3 4 
(3) (4) 
• 
(#C) 
1 2 3 4 bp 1 2 3 4 
(7) 
- 450 
- 400 
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weakly expressed in the PBMC. Thus, there were no marked 
differences between the SMC and PBMC TcR v1-chain 
repertoires, of any of the seven RA patients studied. 
Additional bands were observed in some of the PCR 
amplification products which may correspond to single- and 
double-stranded DNA, possibly due to unequal amounts of 
primers, as observed previously (Sottini et al., 1991b). 
3.4.2.3 V gene usage of TcR o-chain transcripts expressed 
in SMC and PBMC of RA patients 
V gene usage of the expressed TcR o-chain repertoires of 
seven RA patients was determined (Figure 3.6.A and Table 
3.6). Patients 1 to 4 each expressed a restricted Vo-chain 
repertoire in the SMC which predominantly used the Vol and 
Vo2 genes, as compared to the PBMC, whereas patient 5 
expressed a restricted Vo-chain repertoire both in the PBMC 
and SMC. Expression of Vo2, Vo3 (except patient 1) and in 
two of these patients (2 and 5), Vo6 genes were detected in 
the SMC. However, no expression of Vo4 or Vos was observed 
in the SMC of these patients. In contrast, patients 6 and 7 
showed no restriction in Vo gene usage since all six Vo 
genes were amplified in the SMC of each patient. The 
results showed variation in the PBMC Vo-chain repertoires 
of the seven RA patients tested (Figure 3.6.A and Table 
3.6). Vol, Vo2 and Vo3 genes were expressed in PBMC of all 
patients, whereas Vo4 was expressed in patient 2 and was 
barely detectable in patient 7. The Vos gene was absent 
from one individual (patient 5) although was only 
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Figure 3.6 (A) PCR amplification and Southern blot analysis 
of rearranged TcR o-chain transcripts expressed in PBMC (a) 
and SMC (b) of seven RA patients, in Con-A stimulated 
pooled normal PBMC (#C) and (B) in PBMC (unstimulated) of 
four controls. Lanes 1-6 correspond respectively to 
amplification of TcR cDNA with the Vol-Vo6 primers, each in 
conjunction with Co2. Blots were hybridised with an 
internal TcR Co region-specific oligonucleotide probe (Co3) 
and exposed for 6 h. Approximate sizes are indicated in 
basepairs. C: constant; Con-A: concavalin A; PBMC: 
peripheral blood mononuclear cells; PCR: polymerase chain 
reaction; RA: rheumatoid arthritis; SMC: synovial membrane 
mononuclear cells; TcR: T-cell receptor; V: variable. 
A 
Patients 1 2 3 4 5 6 1 2 3 4 5 6 1 2 3 4 5 6 1 2 3 4 5 6 (1) (2) (3) (4) 
a 
b 
(5) (6) (7) (#C) bp 
a 
- 500 
-200 
b 
-
B 
Controls 
(1) (2) (3) (4) 
-
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Table 3.6 T-cell receptor Vo gene expression in peripheral 
blood and synovial membrane mononuclear cells of rheumatoid 
arthritis patients. 
Patient TcR Vo gene families 
Vol Vo2 Vo3 Vo4 vos Vo6 
1 PBMC + + + + 
SMC + + 
2 PBMC + + + + + + 
SMC + w w w 
3 PBMC + + + w w 
SMC + w w 
4 PBMC + + + w w 
SMC + + w 
5 PBMC + + + 
SMC + + + w 
6 PBMC + + + + 
SMC + + + w + w 
7 PBMC + + + w + w 
SMC + + + w + w 
Presence or absence of V gene expression as denoted by 
+or-; W: weakly expressed. 
detected in patients 3 and 4 after prolonged exposure of 
autoradiographs (48 h). Vo genes that were only detected 
after prolonged exposure have been scored as "weakly" 
expressed. Lastly, Vo6 was absent or weakly expressed . in 
PBMC of all individuals except patient 2. Overall, in RA 
PBMC, Vo gene usage ranged from three Vo genes (patient 5) 
to all six Vo genes (patients 2 and 7). 
3.4.2.4 V gene usage of TcR o-chain transcripts expressed 
in unstimulated normal PBMC 
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Nine healthy control individuals were used to determine the 
"normal" TcR Vo-chain repertoire; results are given in 
Figure 3.6.B for four of the controls. Expression of all 
six Vo genes was found in each control tested, with the 
exception · of one individual (control 4) who did not express 
the Vo4 gene. Vo4 gene usage in PBMC of controls (8 of 9) 
was significantly different from that in RA patients (2 of 
7), with Fisher's exact test P=0.03. V85 and V86 gene 
expression was detected in PBMC of all controls, whereas in 
RA PBMC, V85 was absent in one patient (P=0.44) and V86 was 
absent in three patients (P=0.06). 
3.4.2.5 PCR analysis of germline Vo genes 
The marked differences observed between the PBMC of 
patients and controls, particular in V84 usage, raised the 
question of a possible deleted or defective V84 gene in 
some individuals. In the individuals who did not express 
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Vo4, the integrity of the Vo4 gene was confirmed by PCR 
amplification of genomic DNA with the 5' Vo4 primer (see 
Table 3.4) and a 3' Vo4 primer (5'-AGTTGTGAAGCGGAGATG-3' ), 
corresponding to nucleotides 325-342. Similarly, a 3' Vos 
primer (5'-TGCAGAGAGAGGTGCTTG-3'; nucleotides 307-324) was 
used for PCR, in conjunction with the 5' Vos primer (see 
Table 3.4), to confirm the integrity of the Vo5 gene. The 
specificity of each PCR product was confirmed by 
hybridisation with Co3. It was not possible to design a 
suitable Vo6 primer downstream of the existing 5' Vo6 
primer (see Figure 3.2), since the DNA fragment would be 
too small for genomic PCR analysis. 
3.4.2.6 AN-PCR amplification of TcR transcripts 
AN-PCR was initially performed using unstimulated PBMC from 
a normal individual and anchor primers similar to those 
described by Loh et al. (1989), to amplify TcR o-chain 
transcripts. As with AN-PCR amplification of TcR a-chain 
transcripts, two bands (-550 and -700 bp) were observed on 
an ethidium bromide-stained agarose gel. These bands 
hybridised to the Co3 internal oligonucleotide probe. 
Again, the cloning efficiency of the AN-PCR material was 
low, although a few positive TcR 8-chain cDNA clones were 
generated. Ten cDNA clones were sequenced, but the majority 
contained germline Jol-Co or Jo2-Co sequences with 
conserved recombination signal sequences which may 
represent immature o transcripts (van der Stoep et al., 
1990) derived from partially or unrearranged TcR genes 
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(Yoshikai et al., 1984). There was one full-length Vol-Jol-
Co cDNA clone and one clone with a truncated Do-Jo-Co 
message. In a previous report (Fagioli et al., 1991), TcR 
fi-specific cDNA clones consisting of J-C, D-J-C and 
sequences with a Cfi region preceded by genomic 5'-flanking 
regions, have been isolated from 1/5 T-cells. Whether the 
incomplete 5-chain transcripts sequenced in this study were 
derived from 1/8- and/or a/fi-expressing T-cells, is 
unknown. 
3.5 DISCUSSION 
3.5.1 TcR Va and Vfi gene usage in RA 
The results presented in this study indicate that the a/fi 
TcR repertoire in the rheumatoid synovium is diverse 
although there were quantitative differences in the levels 
of Vfi gene expression when compared to peripheral blood. 
This finding of TcR a/fi heterogeneity within RA lesions 
contrasts with previous reports of restricted TcR Va 
(Pluschke et al., 1991; Lunardi et al., 1992b) and Vfi gene 
usage (Sottini et al., 1991b; Paliard et al., 1991; Uematsu 
et al., 1991b; Lunardi et al., 1992b) in RA synovial fluid 
(SF) and biased Va usage recently demonstrated in RA 
synovial tissue (ST) (Bucht et al., 1992a; Williams et al., 
1992). Furthermore, Vfi usage among RA ST T-cells (Williams 
et al., 1992) and tissue derived IL-2R-positive T-cells 
(Howell et al., 1991), was highly restricted. In most of 
these studies though (Paliard et al., 1991; Pluschke et 
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al., 1991; Uematsu et al., 1991b; Lunardi et al., 1992b ) , 
the relevant V gene families (see Table 3.7 ) were over-
expressed in the inflamed joint but the majority of known V 
gene families were detected, indicating a largely 
polyclonal T-cell infiltrate. The report by Paliard et al. 
(1991) found that Vfi14 transcripts were virtually 
undetectable in IL-2-responsive peripheral T-cells of most 
RA patients, but were significantly elevated in synovial 
fluid. In the present study, and in others (Sottini et al., 
1991b; Yamamoto et al., 1992), Vfi14 transcripts were 
readily detected in PBMC of all patients tested. Whether 
these different findings reflect undetected differences 
between the patient series in disease progression, 
medication histories, or genetic backgrounds, is unknown. 
Also, differences in methodology, particularly cell-
culturing conditions, could dramatically affect and even 
inadvertantly skew the TcR repertoire. 
A summary outlining the various findings of TcR a/fi usage 
in RA lesions is given in Table 3.7. The source of T-cell 
mRNA and the method of PCR used in these studies varied. 
While Paliard and colleagues used anti-CD3 and IL-2 
stimulation to activate SF T-cells before RNA isolation and 
PCR analysis, IL-2R-positive ST (Howell et al., 1991) and 
freshly isolated T-cells, derived either from synovial 
fluid or synovial membrane, have mostly been used. Also, 
Williams et al. (1992) used ST T-cells that were initially 
cultured with phytohemagglutinin and IL-2. In vitro 
expansion of T-cell populations may skew the TcR repertoire 
Table 3.7 T-cell receptor V a/fi usage in rheumatoid arthritis lesions. 
Source of Method 
T-cell mRNA of PCR 
SF 
SF* 
VCJ. usage 
multiple VCJ. 
NT 
NT 
restricted VCJ. 
Result Reference 
Vfi usage 
Vfi7 bias Sottini et al. (1991b) 
Vfi14, oligoclonal Paliard et al. (1991) 
Vfi3, 14, 17 bias, oligoclonal Howell et al. (1991) 
multiple Vfi 
ST 
ST 
SF 
family 
family 
family 
family 
anchored VCJ.14, 15, FRl (w23), NT 
polyclonal 
Bucht et al. (1992a) 
Pluschke et al. (1991) 
ST 
SF 
ST* 
ST 
ST/SF 
SF 
family 
inverse 
multiple VCJ. 
multiple VCJ. 
family multiple VCJ. 
family restricted VCJ. 
family/SSCP NT 
family VCJ.10, 15, 18 
multiple Vfi 
Vfi2.1, Vfi3.1, polyclonal 
multiple Vfi 
restricted Vfi, polyclonal 
multiple Vfi 
Vfi4, 5, 13, oligoclonal 
01 i ve et al . ( 19 9 1 ) 
Uematsu et al. (1991b) 
Williams et al. ( 1992) 
Wi 11 i ams et al . ( 19 9 2 ) 
Yamamoto et al. (1992) 
Lunardi et al. (1992b) 
NT: not tested; PCR: polymerase chain rea~tion; SF: synovial fluid; ST: synovial tissue; SSCP: 
single-strand conformation polymorphism. T-cells were stimulated before PCR. ~ 
~ 
O'i 
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and thus alter the relative expression of the V gene 
families. Therefore, ideally, RNA isolated directly from 
unstimulated synovial T-cells should be used to analyse TcR 
usage, although a case can be made for examining 
preselected "activated" T-cells. Furthermore, since the 
processes of RA occur in the synovium, an analysis of T-
cells isolated from the tissue would be preferable to those 
isolated from synovial fluid. Taking these parameters into 
account, the present study, as with those of Yamamoto et 
al. (1992) and Bucht et al. (1992a), have shown multiple V~ 
gene family usage in uncultured ST T-cells. 
To analyse TcR repertoire expression, most studies used V 
gene family-specific PCR amplification of TcR cDNA, as in 
this study. This approach is at best semi-quantitative, 
although V gene family-specific PCR allowing quantitative 
assessment of individual V gene expression between the 
peripheral and synovial compartments, has been developed 
(Paliard et al., 1991; Lunardi et al., 1992b). Certain 
variations of conventional PCR have also been used, namely 
inverse PCR (Uematsu et al., 1991b) and AN-PCR (Pluschke et 
al., 1991), both of which involve nucleotide sequencing of 
TcR transcripts and allow estimation of the amount of an 
individual V gene family mRNA among the total T-cell mRNA 
pool. AN-PCR was considered as an alternative approach in 
this study and, although limited data were available for 
analysis, the results indicated heterogeneity of TcR a-
chain transcripts, at least in the SMC of one RA patient. 
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These methodological differences may account for some of 
the discrepancies in TcR a/~ usage observed in RA patients. 
In this study, AN-PCR generated a high proportion of 
incomplete and probably non-productive TcR transcripts. 
These transcripts consisted of D-J-C or J-C sequences 
juxtaposed by RNA splicing of the primary mRNA transcript, 
indicating that these transcripts were in vivo transcripts 
derived from partially or unrearranged TcR genes. A number 
of cDNA clones were also found to contain unusual Ca gene 
rearrangements. These may represent artifacts of PCR and 
cloning and of low level contamination of cDNA with genomic 
DNA. It is essential that the primer used for cDNA 
synthesis is removed before the tailing reaction, otherwise 
it too could become tailed and as a result interfere with 
the PCR reaction. 
In the PCR approach used here, V gene usage was assessed by 
the highly sensitive method of visualising PCR-amplifed 
products with a radio-labelled probe. The intensities of 
the bands do not necessarily correlate with the relative 
abundance of the corresponding cDNAs, since variation may 
be caused by technical differences, such as the efficiency 
of cDNA synthesis, PCR amplification, or the amount of mRNA 
template. It is possible that for V~, differences in PCR 
primer efficiencies contributed to the observed differences 
in signal intensities, even though no variation was 
observed with respect to TcR Va genes. The major 
disadvantage of using family-specific PCR to analyse TcR 
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repertoire expression, is that novel V gene families, which 
differ in sequence from the primers used, cannot be 
identified. 
This report clearly demonstrates extensive V-region 
diversity of a/fi T-cells in the rheumatoid joint. This 
finding is compatible with previous reports of clonal 
heterogeneity of TcR fi-chain gene rearrangements in 
synovial fluid (Savill et al., 1987; Duby et al., 1989; Van 
Laar et al., 1991) and membrane (Van Laar et al., 1991) and 
a polyclonal T-cell infiltrate, although in the earlier 
studies based on detection of TcR fi-chain gene 
rearrangements by Southern blotting, specific V gene family 
usage could not be identified. Using PCR methods, though, 
other studies have also revealed no marked restriction in 
Va (Sottini et al., 1991b; Uematsu et al., 1991b; Williams 
et al., 1992), or Vfi usage (Bucht et al., 1992a; Williams 
et al., 1992; Yamamoto et al., 1992), of RA joint 
infiltrating T-cells. In addition, Uematsu et al. (1991b) 
found that despite an enrichment of Vfi2 and Vfi3 
transcripts, the a/fi TcR repertoire in RA synovial fluid 
was highly heterogeneous. 
The quantitative differences in the expressed a/fi TcR 
repertoires observed between SMC and PBMC of patients with 
RA of long-standing, were with respect to Vfi-chains and not 
Va-chains. Many Vfi gene families were weakly expressed in 
RA synovium and may represent non-specific T-cells which 
have arisen, over time, by secondary recruitment as a 
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consequence of chronic tissue damage, or simply via local 
trapping of lymphocytes from the recirculating pool. 
However, a recent report has indicated that oligoclonal T-
cells constitute a small fraction of the total T-cell pool 
(Korthauer et al., 1992). Thus, clonal T-cells may not 
necessarily be over-expressed in the synovial compartment 
with respect to the peripheral blood. Nevertheless, these 
results suggest that some a/fi T-cells may have been 
maintained in RA synovium because of their expansion in 
response to an antigen(s) which is specific for the Vfi 
component of the a/fi TcR. Selective expansion of T-cells 
bearing particular Vfi has been taken as evidence of 
superantigenic stimulation of T-cells in the pathogenesis 
of RA (Paliard et al., 1991; Howell et al., 1991; Uematsu 
et al., 1991b; Sottini et al., 1991b), despite the presence 
of multiple Vfi gene families. However, in the reports by 
Paliard et al. (1991) and Howell et al. (1991), in which Va 
expression was not tested, the presence of T-cells 
expressing oligoclonal fi-chains would indicate the 
recognition of a conventional antigenic peptide rather than 
a superantigen, because of the importance of the V-D-J 
junction in antigen recognition. 
In the various studies described, the specific V gene 
families found over-represented in RA joints differed and 
in all patients examined there was no consistent increase 
in expression of any one particular V gene family. Factors 
such as HLA-DR type and clinical status are likely to 
affect a/fi TcR repertoire expression. Although Pluschke et 
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al. (1991) observed biased Va usage in synovial fluid of RA 
patients, the individuals examined had different HLA-DR 
types and only one expressed the RA-associated, DR4(Dw4) 
class II molecule, indicating that Va selection may have 
been independent of conventional MJiC-restriction. In the 
present study, there was also no apparent correlation 
between DR-type and TcR repertoire expression, since 
multiple V~ usage was found both in patients with and 
without (patient 4: DR2,DR11) the major RA-associated 
alleles. In one patient (patient 5: DR4(Dw4) homozygote), 
there was some evidence for a restricted TcR repertoire in 
the SMC when compared to the PBMC, indicating a possible 
synergistic effect of two disease-associated class II 
molecules and selection of V~-expressing synovial T-cells. 
Furthermore, in the study by Lunardi et al. (1992b), there 
was no correlation with HLA-DR type, disease duration or 
rheumatoid factor status and increased TcR repertoire 
expression, whereas Bucht et al. (1992a) demonstrated a 
restricted a/~ repertoire in the early stages of RA and 
increased diversity in RA of long duration. Given the 
massive tissue injury that has already occurred in patients 
with RA of long-standing, the findings of a polyclonal 
synovial T-cell infiltrate are not surprising, since in 
advanced disease, after extensive tissue destruction, 
multiple epitopes on self antigens may be recognised by 
T-cells. Ideally, in searching for the antigen(s) which 
potentially trigger and initiate the autoimmune T-cell 
response, TcR V gene usage should be analysed as early in 
the disease process as possible, to minimise the 
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contribution of bystander T-cells to the TcR repertoire. 
These cells would mask oligoclonal and potentially 
pathogenic T-cells, which in earlier stages of the disease 
might otherwise be enriched. 
3.5.2 TcR v1 and Vo gene usage in RA 
1/0 T-cells accumulate in various human disease lesions, 
including inflamed joints of RA patients (Smith et al., 
1990; Reme et al., 1990; Andreu et al., 1991), skin lesions 
of leprosy (Modlin et al., 1989), intestine of patients 
with coeliac disease (Trejdosiewicz et al., 1991), 
sarcoidosis lung (Tamura et al., 1990) and MS brain 
(Wucherpfennig et al., 1992a). Furthermore, 1/0 T-cells are 
significantly elevated in peripheral blood of patients with 
RA (Reme et al., 1990), autoimmune chronic liver disease 
(Wen et al., 1992), tularemia (Sumida et al., 1992) and 
sarcoidosis (Tamura et al., 1990). Together, these findings 
indicate a possible role for 1/0 T-cells in the development 
of inflammatory and autoimmune disorders. 
This study investigated the diversity of the 1/0 repertoire 
in peripheral blood T-cells and T-cells infiltrating the 
joints of RA patients, using V gene family-specific PCR to 
amplify TcR transcripts isolated directly from uncultured 
SMC and PBMC. In most patients studied expression of Vo 
genes in the synovium was highly restricted; SMC expressed 
a limited repertoire of Vo-chain transcripts which 
predominantly used the Vol and Vo2 genes, when compared 
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with PBMC. In contrast, there was no evidence for 
preferential usage of particular v1 genes since the 
repertoire of v1-chain transcripts expressed in SMC showed 
only minor differences compared to those expressed in PBMC. 
Previous reports using MAbs to detect 1/0 T-cells and their 
subsets have shown that synovial T-cells of RA (Smith et 
al., 1990; Keystone et al., 1991; Shen et al., 1992) and 
JRA (Kjeldsen-Kragh et al., 1990) patients express 1/0 
receptors which predominantly use the Vol gene, as do T-
cell clones derived from RA synovial fluid (Sioud et al., 
1990), as opposed to human PBMC where Vo2 appears to be 
predominant (Triebel et al., 1988; Borst et al., 1989). A 
preponderance of Vol-expressing T-cells has also been shown 
in the intestinal epithelium of coeliac patients (Rust et 
al., 1992) and in human immunodeficiency virus (HIV) -
seropositive patients (Kabelitz et al., 1991b). The 
consistent findings of a skewed TcR o-chain repertoire 
within the rheumatoid synovium may reflect selective 
infiltration and expansion of T-cells in response to a 
limited number of joint-specific antigenic determinants, 
and suggests that 1/0 T-cells may play an important role in 
the pathogenesis of RA. 
The PCR-based data from this study support a restricted TcR 
o-chain repertoire skewed towards Vol but were able to 
identify the other Vo-chain transcripts present in RA 
synovium. Some non-Vol transcripts found abundantly in the 
peripheral blood were scarcely detected in the synovium. 
However, since many factors contribute to the relative 
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efficiencies of PCR reactions, including template-primer 
binding and efficiency of cDNA synthesis, autoradiographic 
signal intensities do not necessarily correlate with the 
abundance of mRNA. Consequently, since Vo2 was also 
expressed in SMC of all patients, even though scarcely 
detected in some, Vo usage observed in this study was not 
exclusively restricted towards Vol. 
The extreme sensitivity of the PCR technique in detecting 
even small numbers of particular TcR transcripts confirms 
the earlier findings, based on MAb studies, that certain 
1/0 T-cells in affected joints have preferentially expanded 
and proliferated, in response to an antigen(s) which 
interacts primarily with the Vol element of the 1/0 TcR. 
Whether these particular T-cells are autoreactive and the 
nature of the antigen/ligand which these potentially 
arthritogenic T-cells recognise, remains elusive. Despite 
these unanswered questions, the predominance of Vol+ T-
cells within the inflammatory lesion suggests a potentially 
pathogenic role for these T-cells in RA. An alternative 
explanation could involve selective physiological tissue 
distribution, or selective retention of particular 1/0 T-
cells, which for some reason have migrated to the synovial 
compartment. Tissue-specific expression of Vo genes is well 
documented in mouse, in a variety of tissues such as skin, 
intestinal and female reproductive epithelia (Allison et 
al., 1991), and, although there is little evidence of this 
phenomenon in man (Groh et al., 1989), selective 
localisation of Vol+CD8+ T-cells within the epithelium of 
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the human large intestine has been reported (Deusch et al., 
19 91) . 
In the more common a/~ TcR, the V-elements of both TcR a-
and ~-chains usually contribute to the specificity of TcR 
for antigen/MHC (Dembic et al., 1986). In contrast, a group 
of ligands, so-called "superantigens", appear to stimulate 
T-cells expressing particular V~-chains regardless of other 
components of the receptor, although they do require 
interaction with class II molecules (Choi et al., 1989). 
Receptor ligands of this type include mouse mammary tumour 
virus antigens encoded by the minor lymphocyte stimulating 
locus in mouse (Kappler et al., 1988) and some bacterial 
enterotoxins which stimulate human (Choi et al., 1989) as 
well as mouse T-cells (White et al., 1989) in a V~-specific 
fashion. The nature of activation of 1/8 T-cells is not 
completely clear; some appear to require MHC-restriction 
(Haregewoin et al., 1989; Matis et al., 1989) and others do 
not (Holoshitz et al., 1989). A potential contribution of a 
superantigen to the pathogenesis of RA may explain the 
findings of restricted usage of V8 genes but not v1 genes 
in RA synovium. A striking feature of human 1/8 T-cells is 
their frequent reactivity towards mycobacterial antigens 
(Holoshitz et al., 1989; Raulet, 1989b; Haregewoin et al., 
1989; Pfeffer et al., 1990; Kabelitz et al., 1990) 
including, in some cases, the highly conserved 65-kDa hsp 
(Holoshitz et al., 1989; Haregewoin et al., 1989; Raulet, 
1989b). Such reactivity has analogy with T-cell activation 
triggered by superantigens (Kabelitz et al., 1991a; Ohmen 
126 
et al., 1991). However, these studies have shown that 
reactivity towards heat-killed M. tuberculosis is an 
exclusive property of V19(V1II)/Vo2-bearing T-cells and not 
Vol+ T-cells. In the present study, Vo2 and Vol were the 
predominant Vo genes expressed in RA synovium but there was 
no detectable bias in use of V19(V1II). Whether there is 
preferential pairing of Vo2 and V19 polypeptide chains 
within the rheumatoid synovium, is unknown. In two 
patients, there were barely detectable levels of v1II in 
SMC, compared to PBMC. This may reflect a reduction rather 
than predominance of v1II/Vo2+ T-cells in the synovium, 
possibly due to previous activation by a superantigen, 
since in the case of V~-specific superantigens, reactivity 
often leads to the eventual disappearance or inactivation 
of those peripheral T-cells bearing specific V~ elements; a 
phenomenon termed programmed cell death (Kawabe and Ochi, 
1991). 
A potential association with a superantigen may also 
contribute to the observation of variation in the TcR o-
chain repertoires of PBMC from patients when compared with 
controls. Most strikingly, Vo4 was expressed significantly 
less often in RA patients compared to controls. Similarly, 
deficiency in expression of V~14 of the TcR Q/~ in PBMC of 
some RA patients has been reported (Paliard et al., 1991 ) , 
although v~14+ T-cells were detected in the synovial fluid. 
Such a complete deletion of Vo4 as was observed here could 
reflect either superantigen-based negative selection during 
thymic maturation (Herman et al., 1991), or superantigen-
based programmed cell death (Kawabe and Ochi, 1991). 
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The particular bias in Vo usage observed in patients with 
RA of long duration may not necessarily correlate with any 
bias present early in the pathogenesis of the disease. 
Further, since only small numbers of autoreactive T-cells 
may be required for the chronic progression of RA, the 
apparent bias in Vol usage by SMC may be an observation 
less relevant to the development of RA, than the finding of 
small numbers of Vo2 rnRNA transcripts in SMC of most 
patients examined. These findings are compatible with 
reports that 1/0 T-cells in the rheumatoid synovium are 
often reactive to M. tuberculosis (Holoshitz et al., 1989; 
Raulet, 1989b) and that the response to M. tuberculosis is 
restricted to V19/Vo2-bearing T-cells (Kabelitz et al., 
1991a), if a superantigen is involved in the pathogenesis 
of RA. 
CHAPTER 4 
T-CELL RECEPTOR a-CHAIN OLIGOCLONALITY IN RHEUMATOID 
ARTHRITIS PATIENTS 
128 
4.1 INTRODUCTION 
Although the specificity and physiological function of 
normal human 1/0 T-cells remains largely unknown, evidence 
suggests that these cells may preferentially recognise 
mycobacterial antigens, including the highly conserved 65 -
kDa hsp (Haregewoin et al., 1989; Raulet, 1989b; Pfeffer et 
al., 1990), and may play a protective role during infection 
(Born et al., 1990b; Kaufmann and Kabelitz, 1991). However, 
because of the highly conserved nature of hsp between 
prokaryotes and eukaryotes, these antigens may also provide 
a link between infectious agents and autoimmunity, 
implicating a potential role for 1/0 T-cells in the 
development of some inflammatory and even autoimmune 
disorders. 
1/0 T-cells accumulate in the joint fluid (Keystone et al., 
1991) and tissue (Smith et al., 1990) of RA patients and 
various other human disease lesions. Furthermore, 1/0 T -
cells from the rheumatoid joint do indeed exhibit a 
preponderance to proliferate in response to mycobacterial 
antigens and in some cases to the 65-kDa hsp (Holoshitz et 
al., 1989; Soderstrom et al., 1990; Pope et al., 1992 ) , 
implicating hsp-reactive 1/0 T-cells in the pathogenesis of 
this disease. Mycobacteria-specific SF T-cells have been 
shown to cross-react with human hsp60, the mammalian 
counterpart to bacterial hsp65 (Li et al., 1992 ) , which is 
increased in expression in rheumatoid joints (Kar l sson-
Parra et al., 1990 ) , indicating the potential for mo l ecular 
mimicry in maintaining the chronic joint inflammation in 
RA. 
The inflamed synovium of RA patients contains 1/8 T-cells 
which, in contrast to v1 usage, express predominantly TcR 
V81- and V82-chains, as demonstrated by the findings 
presented in Chapter 3. Such T-cells may reflect local 
expansion as a result of previous stimulation of T-cells 
with a V8 region-specific antigen, or recruitment due to 
inflammatory signals, and may contribute to the 
pathogenesis of RA. If a specific antigen is responsible 
for the skewed 8-chain repertoire in RA synovium, the 
nature of this antigen, whether an infectious agent or a 
self antigen, remains an enigma. 
Compared with the a- and ~-chains of the TcR, which are 
defined by a large array of V-, D- and J-region elements, 
the 1/8 repertoire is less diverse with only eight 
functional v1 and five J1 segments and a few o V, D and J 
gene segments (reviewed by Lefranc and Rabbitts, 1990). 
Furthermore, the 1/0 TcR repertoire is restricted in that 
the majority of peripheral blood lymphocytes express 1/8 
TcRs encoded by the Vo2/V19 gene pair (Triebel et al., 
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1988; Borst et al., 1989). Diversity is generated primarily 
from junctional flexibility and the addition of N-region 
sequences, including P-nucleotides (Lafaille et al., 1989), 
at the junctions between the V-D, D-D, D-D-D, D-J and V-J 
segments (Loh et al., 1988). Consequently, the V-D-J 
junction is likely to be important in determining the 
specificity of certain 1/0 T-cells for antigenic peptide. 
4.2 AIMS 
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The purpose of this investigation was to assess the extent 
of clonality among Vol and Vo2 T-cell populations in the 
synovia and peripheral blood of RA patients, by sequencing 
the V-J junctional regions of rearranged TcR Vo-Co 
transcripts. A panel of controls was also examined for TcR 
o-chain oligoclonality in the peripheral blood. 
4.3 MATERIALS AND METHODS 
4.3.1 RA patients and controls 
Patients 1, 2, 3, 6 and 7 in this study correspond 
respectively with the patients examined in the previous 
analysis of V gene usage of 1/0 TcRs expressed in RA 
patients (Chapter 3). Patients 4 and 5 were excluded from 
this study since their Vo gene expression profiles, 
although restricted, resembled, to a certain extent, those 
of patients 1, 2 and 3. 
Four of the nine controls used in the study described in 
Chapter 3 were also included in this investigation. Each of 
the four controls expressed all six Vo genes in the PBMC. 
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4.3.2 Cell separation 
Mononuclear cells were isolated from peripheral blood and 
synovium of RA patients, as described in Chapter 2 (section 
2.2.1). PBMC were isolated from heparinized blood obtained 
from four healthy donors, by density gradient 
centrifugation, according to the method in Chapter 2 
(section 2.2.2). SMC and PBMC of patients and control PBMC 
were not cultured or stimulated in vitro. 
4.3.3 Surface immunofluorescence staining 
PBMC and SMC of RA patients were stained with antibodies to 
the a/~ TcR (TcR-1, Becton Dickinson Immunocytometry 
Systems, Mountain View, California, USA) and the 1/0 TcR 
(TcRol, T Cell Sciences, Cambridge, Massachusetts, USA) 
using an immunofluorescence technique. Cells were initially 
washed with PBS containing 0.1% (w/v) BSA and 0.1% (w/v) 
sodium azide and resuspended at 2 x 10 6 cells/ml in the 
same buffer. Cells were aliquoted into Eppendorf tubes at 
1 x 10 6 cells/tube and centrifuged. The supernatant was 
discarded and the cells resuspended in 25 µl of antibody, 
diluted 1:10 for TcR-1 and 1:5 for TcRol, and incubated on 
ice for 30 min. Cells were then washed three times with 0.5 
ml of buffer before the addition of sheep anti-mouse second 
antibody (Silenus, Hawthorn, VIC, Australia). Cells were 
incubated on ice for 30 min, washed twice with buffer, and 
then transferred to a FACS tube and counted on a FACScan 
(Becton Dickinson Immunocytometry Systems). A logarithmic 
scale was used to measure fluorescence intensity. Isotype 
matched negative controls were also run in an identical 
manner. Surface irnrnunofluorescence staining was performed 
at the Royal Prince Alfred Hospital, Sydney. 
4.3.4 PCR amplification of TcR transcripts 
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First strand 8-chain specific TcR cDNA was synthesised 
using the C81 primer, as described in Chapter 2 (section 
2.2.9), from total RNA isolated from SMC and PBMC of 
patients and control PBMC by the guanidinium thiocyanate-
phenol-chloroform extraction method (see Chapter 2, section 
2.2.7). Approximately 2% of single-stranded cDNA template 
was amplified in a typical 50 µl PCR reaction using the 
5' V81 or V82 sense primer (see Table 3.4) and the 3' C82 
antisense primer (see Table 2.1) with the PCR conditions as 
described in Chapter 3 (section 3.3.6). The specificity of 
each PCR product was confirmed by Southern blot analysis 
and hybridisation with C83 (see Table 2.1), according to 
the protocols described in Chapter 2 (section 2.2.13.1 and 
13. 2) . 
4.3.5 Cloning of PCR products 
PCR-amplified TcR 8-chain cDNA was concentrated by ethanol 
precipitation and phosphorylated, essentially as described 
in Chapter 2 (section 2.2.15.1). Phosphorylated PCR product 
was separated on a 1.25% (w/v) TAE agarose gel and the DNA 
from a band approximately 400-700 bp was isolated by 
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electroelution, as described in section 2.2.15.1. Fragment 
DNA was blunt-end ligated into SmaI-cleaved M13mp18 vector 
and used to transform bacterial host cells, according to 
standard procedures described in Chapter 2 (section 
2.2.15). To determine the total number of TcR o-chain cDNA 
clones, including those with cDNA cloned in the forward or 
reverse orientation, M13 plaques were transferred onto 
Hybond N+ nylon membrane discs (section 2.2.15.6) and 
screened with a full-length Vol- or Vo2-specific probe, 
obtained from a gel-purified Vol- or Vo2-specific PCR 
product, respectively, which was labelled by the random 
priming method (see Chapter 2, section 2.2.14.2). 
4.3.6 Automated DNA sequencing 
M13 single-stranded DNA was prepared from positive cDNA 
clones, according to the protocol described in Chapter 2 
(section 2.2.16.1) and sequenced using an automated DNA 
sequencing system as described in section 2.2.16.2. 
4.3.7 Screening of cDNA clones 
4.3.7.1 Synthesis of sequence-specific oligonucleotides 
Fourteen oligonucleotides, each pair (forward and reverse ) 
specific for a particular Vo-Jo junctional region sequence, 
were synthesised and used as probes to screen TcR o-chain 
cDNA clones. The probes (Table 4.1) were designed to detect 
Table 4.1 Nucleotide sequence of oligonucleotides used as probes to screen 
T-cell receptor V61- and V62-chain cDNA clones. 
Oligo-
nucleotide 
VDlOAl 
VDlOBl 
VDlOCl 
VDlODl 
VD20Al 
VD20Bl 
VD20Cl 
Sequence ( 5' - 3' ) 
(forward) 
GACTACGGAGGAGAAGGTG 
GGGTCGCCCTTTGATTTCC 
CCTACAGGTACTGGGCAGA 
GGATACGTTCGTGTACGATAA 
GCCTGTGCTGATCCCGATA 
GGGGATAGCGTTCGATAAAC 
GACGCGTTTACCAACTCTTC 
Oligo-
nucleotide 
VD10A2 
VD10B2 
VD10C2 
VD10D2 
VD20A2 
VD20B2 
VD20C2 
Sequence (5' - 3') 
(reverse) 
CACCTTCTCCTCCGTAGTC 
GGAAATCAAAGGGCGACCC 
TCTGCCCAGTACCTGTAGG 
TTATCGTACACGAACGTATCC 
TATCGGGATCAGCACAGGC 
GTTTATCGAACGCTATCCCC 
GAAGAGTTGGTAAACGCGTC 
1---1 
w 
~ 
the junctional regions of those cDNA clones that occurred 
more than twice in the sequence analysis. 
4.3.7.2 M13 plaque hybridisation 
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Membrane discs were prehybridised at 42°c for 2 h in heat-
sealed plastic bags containing 5 x SSPE (5 rnM EDTA, 50 rnM 
NaP04, 900 rnM NaCl [pH7.4]), 1% (w/v) SDS, 5% (w/v) dextran 
sulphate, 5 x Denhardt's solution (0.1% (w/v) BSA, 0.1% 
(w/v) Ficoll 400, 0.1% (w/v) PVP), 15% (v/v) forrnamide and 
100 µg/ml heat-denatured salmon sperm DNA. Discs were 
hybridised in the same solution for a further 2 hat 42°c 
with [32 PJ -end-labelled forward oligonucleotide probe, 
prepared as described in Chapter 2 (section 2.2.14.1). 
Membranes were washed twice in 3 x SSC (0.4 M NaCl, 0.045 M 
sodium citrate [pH7.0J) for 10 min each at room temperature 
and once in 3M tetramethylamrnonium chloride, 50 rnM 
Tris/HCl [pH8.0], 2 rnM EDTA and 0.1% (w/v) SDS at 55°c for 
30 min. Washed filters were then exposed to X-ray film with 
intensifying screens at -7o 0 c. The numbers of positive cDNA 
clones were recorded. Discs were stripped of probe by the 
repeated addition of boiling 0.1% SSC/0.1% (w/v) SDS 
followed by cooling and then re-hybridised with the 
reverse/complementary oligonucleotide probe, as described 
above. 
4.4 RESULTS 
4.4.1 Frequency of 1/8 T-cells in SMC and PBMC of RA 
patients 
To determine the frequency of 1/0 T-cells in RA patients, 
the ratios of 1/8:a/fi T-cells in paired SMC and PBMC 
samples, were calculated. The ratios ranged from 1:10 to 
1:7 in PBMC and 1:17 to 1:8 in SMC. 
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4.4.2 Molecular analysis of TcR Vol transcripts in PBMC of 
controls 
DNA sequences of the V-J junctions of 39 Vol-chain cDNA 
clones, derived from PBMC of four healthy donors, were 
determined. Vol transcripts expressed in normal PBMC showed 
no evidence of oligoclonality, since for each control the 
cDNA clones examined contained a different junctional 
region sequence (see Table 4.2). The majority of cDNA 
clones utilised the Jol gene which is the predominant J-
region segment used by human peripheral blood 1/8 T-cells 
(Takihara et al., 1988b), whereas the Jo3 and Jo2 segments 
were represented by two and one cDNA clone, respectively. 
The lack of TcR 5-chain oligoclonality observed in healthy 
individuals demonstrates the lack of bias in the PCR-based 
protocol for any particular TcR sequence, at either stage 
of PCR amplification or cloning of PCR-amplified TcR 
transcripts. 
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4.4.3 Molecular analysis of TcR Vol transcripts in SMC and 
PBMC of RA patients 
The V-J junctional region sequences of 94 cDNA clones 
containing rearranged TcR Vol-Cc chains, obtained from SMC 
and PBMC of five RA patients, were determined. The majority 
of Vol-chain cDNA clones from the PBMC of patients 1, 3 and 
7, had the same V-J combination and junctional region 
sequences, although the arrangement was different in each 
patient (see Table 4.2). All eight sequenced cDNA clones 
from PBMC of patient 1 were identical. Ten cDNA clones from 
patient 2 and all except two cDNA clones from patient 6, 
were unique. Overall, Vol transcripts expressed in the PBMC 
of RA patients were oligoclonal, as opposed to control 
PBMC, indicating that in vivo selective expansion of Vol+ 
1/8 T-cells expressing particular Vcl-Jol junctional 
regions had taken place in some patients. 
Evidence for Vol oligoclonality was found in the SMC of 
patient 1, since four of the nine cDNA clones sequenced 
were the same. In this patient, the synovial Vol+ 1/8 T-
cells appeared to represent two different dominant 
populations, because, in addition, two of the 8-chain 
sequences were identical to the dominant transcript 
detected in the PBMC of the same patient. The sharing of 
oligoclonal transcripts in SMC and PBMC of patient 1 
indicates that certain 1/8 T-cells have infiltrated, or 
leaked from, the synovial compartment. For the other 
patients, Vol transcripts expressed in the SMC showed 
138 
Table 4.2 Molecular analysis of T-cell receptor Vol -chain 
transcripts expressed in rheumatoid arthritis patients and 
controls. 
Donor 
Control 
1 PBMC 
2 PBMC 
3 PBMC 
4 PBMC 
Patient 
1 PBMC 
SMC 
2 PBMC 
SMC 
3 PBMC 
SMC 
6 PBMC 
SMC 
7 PBMC 
SMC 
Unique Vol sequences 
No. No. 
seq. observed 
10 
10 
9 
10 
8 
9 
10 
10 
9 
9 
9 
10 
10 
10 
10 
10 
9 
10 
0 
3 
10 
8 
5 
7 
7 
10 
4 
10 
Jo usage 
Jl J2 J3 
9 0 1 
9 1 0 
9 0 0 
9 0 1 
3 0 0 
10 0 0 
7 0 1 
5 0 0 
7 0 0 
7 0 0 
10 0 0 
4 0 0 
7 3 0 
Shared Vol sequences 
No. 
observed 
0 
0 
0 
0 
8 
2a) 
4 
0 
2 
4 
2 
2 
0 
6 
0 
Jo usage 
Jl J2 J3 
8 0 0 
2 0 0 
4 0 0 
2 0 0 
4 0 0 
0 0 2 
2 0 0 
6 0 0 
PCR-amplified TcR Vol-chain cDNA derived from PBMC and SMC 
was cloned into the Ml3 vector and a number of the cDNA 
clones sequenced. 
a) Two of the Vol sequences from SMC of this patient were 
identical to the dominant Vol transcript found in the PBMC 
of the same patient. 
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molecular heterogeneity, typical of a synovial T-cell 
infiltrate derived from polyclonal expansion. Although the 
majority of Vol-chain cDNA clones from SMC and PBMC of 
patients used the Jol gene, one unique cDNA clone used Jo3 
and three of the unique cDNA clones from patient 7 used the 
Jo2 segment. Jo2 was detected in one of the 39 Vol-chain 
cDNA clones (2.5%) from healthy controls. 
4.4.4 Molecular analysis of TcR Vo2 transcripts in PBMC of 
controls 
For controls, 36 Vo2-chain cDNA clones obtained from PBMC, 
were sequenced. The results given in Table 4.3 show that 
for controls all the junctional region sequences of the 
cDNA clones were different, demonstrating molecular 
heterogeneity of Vo2 transcripts and again an unbiased PCR 
amplification procedure. Most of the cDNA clones used the 
Jol gene, a few used Jo3 and a single cDNA clone contained 
the Jo2 segment. 
4.4.5 Molecular analysis of TcR Vo2 transcripts in SMC and 
PBMC of RA patients 
The V-J junctions of 82 cDNA clones containing rearranged 
Vo2-Co chains, obtained from SMC and PBMC of five RA 
patients, were sequenced. In contrast to control PBMC, 
oligoclonality of Vo2 transcripts was observed in PBMC of 
two of the patients studied; most strikingly, in patient 2, 
nine of the 12 o-chain sequences were identical and for 
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Table 4.3 Molecular analysis of T-cell receptor Vo2-chain 
transcripts expressed in rheumatoid arthritis patients and 
controls. 
Donor 
Control 
1 PBMC 
2 PBMC 
3 PBMC 
4 PBMC 
Patient 
1 PBMC 
SMC 
2 PBMC 
SMC 
3 PBMC 
SMC 
6 PBMC 
SMC 
7 PBMC 
SMC 
Unique Vo2 sequences 
No. No. 
seq. observed 
8 
9 
11 
8 
9 
7 
12 
6 
10 
1 
8 
10 
9 
10 
8 
9 
11 
8 
9 
2 
3 
4 
7 
1 
8 
5 
9 
8 
Jo usage 
Jl J2 J3 
6 0 2 
8 0 1 
8 1 2 
8 0 0 
9 0 0 
2 0 0 
3 0 0 
4 0 0 
7 0 0 
1 0 0 
7 0 1 
5 0 0 
9 0 0 
8 0 0 
Shared Vo2 sequences 
No. 
observed 
0 
0 
0 
0 
0 
2 
3a) 
9 
2a) 
3 
0 
0 
2 
3 
0 
2 
Jo usage 
Jl J2 J3 
2 0 0 
9 0 0 
3 0 0 
2 0 0 
0 3 0 
0 0 2 
PCR-amplified TcR Vo2-chain cDNA derived from PBMC and SMC 
was cloned into the M13 vector and a number of the cDNA 
clones sequenced. 
a) These Vo2 sequences represented deletions. 
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patient 3, three of the ten cDNA clones sequenced were the 
same (Table 4.3). These two dominant transcripts used Jal. 
The results indicate in vivo clonal expansion of peripheral 
Vo2+ 1/8 T-cells in these patients. However, the other 
patients showed no evidence for Vo2 oligoclonality in the 
PBMC. 
In SMC of some RA patients, Vo2 transcripts were poorly 
represented and barely detectable (see Figure 3.6). Thus, 
for patient 3, and to a lesser extent for patients 1 and 2, 
only a few full-length Vo2-chain cDNA clones could be 
generated from SMC. In the SMC of patient 6, there was 
evidence for oligoclonal T-cells bearing Vo2-Jo2-Co chains; 
in addition to this transcript, another a-chain sequence 
was represented twice. In patient 7, two of the ten a-chain 
sequences from SMC were the same. The nucleotide sequences 
of all the Vol and Vo2 gene segments derived from RA 
patients and controls did not vary from those previously 
published (Takihara et al., 1989). Two different kinds of 
deletions (type I and type II deletions), however, were 
detected among the cDNA clones obtained from SMC of 
patients 1 and 2 (see Figure 4.1). For deletion type I, the 
region of the Vo2 gene from nucleotide position 218 was 
deleted, resulting in a Vo2 transcript which consisted of a 
partial 5' Vo2 sequence directly adjacent to exon I of the 
Co gene. Similarly, for deletion type II, the region of the 
Vo2 gene upstream from nucleotide position 287 was deleted. 
From the deduced amino acid sequences it was apparent that 
these transcripts were in-frame. By using oligonucleotides 
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Figure 4.1 Schematic representation of the two types of 
deletions (type I and type II) detected in V52-chain 
transcripts by DNA sequencing. Oligonucleotide probes 
synthesised to flank the variable (V) and constant (C) 
regions of these transcripts are indicated by shading. 
These probes detected the deleted-type transcripts in 
peripheral blood mononuclear cells from controls as well as 
from RA patients. 
v 82 transcript 
Type I 
deletion 
Type II 
deletion 
V C 
218 
TCAAAGA@AA!ffircc.AfAoo:AAG.TCAcRtcTcA T 
::::::::::::::::::::;:;:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::;:;:;:;:;:;:;:;:;:;:;:::::;:;:;:;:;:;:::;:;:;:;:;: 
V C 
287 
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(5'-AGACCCAAGGAAGTCAGCC-3' and 5'-CAATTTCCAAGGAAGTCAGCC-3') 
which flank the two types of deletions as probes t o scre e n 
Southern blots of PCR - amplified Vo2-chain cDNA, express i on 
was detected in PBMC of both patients and controls. Thus, 
these transcripts were not specifically related to RA but 
demonstrate another possible mechanism for the generation 
of TcR a-chain diversity. 
4.4.6 Degree of TcR a-chain oligoclonality 
To estimate the frequency of the cDNA clones which were 
detected, by DNA sequencing, more than twice in the 
patients studied, oligonucleotides specific for the V-J 
junctional regions were used as probes to screen TcR o-
chain cDNA clones. An example is given in Figure 4.2, which 
shows the results of hybridisation of Vol-chain cDNA clones 
derived from SMC and PBMC of patient 1 and from control 
PBMC, with the forward (VDlOAl) and reverse (VD10A2) 
oligonucleotides, to detect the junctional region sequence 
of the dominant Vol-chain cDNA clone VDlOA. A total of four 
positive cDNA clones (of 70) can be seen in SMC compared to 
at least 200 (of -250) in PBMC, whereas 93 cDNA clones in 
the control failed to hybridise with either VDlOAl or 
VD10A2. As a percentage of the total number of full-length 
TcR a-chain cDNA clones, VDlOA represented about 6%, -80% 
and 0%, in these samples, respectively. The results are 
given in Table 4.4. The highest degree of oligoclonality 
was detected in PBMC of patient 1, where about 80% of Vol 
transcripts were oligoclonal, compared to about 6% in SMC . 
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Figure 4.2 Degree of T-cell receptor a-chain oligoclonality 
in RA patient 1. Vol-chain cDNA clones derived from SMC (a) 
and PBMC (b) of RA patient 1 and control PBMC (c), were 
hybridised with the forward oligonucleotide VDlOAl (A) and 
reverse oligonucleotide VD10A2 (B), to detect cDNA clones 
which contained the specific junctional region sequence of 
the dominant Vol-chain cDNA clone VDlOA. PBMC: peripheral 
blood mononuclear cells; RA: rheumatoid arthritis; SMC: 
synovial membrane mononuclear cells; V: variable. 
A a) 
• 
• 
• 
• 
B a) 
b) 
b) 
• • 
• 
• 
• 
•• 
c) 
c) 
Table 4.4 Degree of oligoclonality of T-cell receptor 8-chain transcripts expressed in rheumatoid 
arthritis patients and controls. 
Patient 
Patient Clone Total no. No. 
cDNA clones positive 
(forward/reverse) 
1 PBMC VDlOA -250 >200 (>100/>100) 
SMC 70 4 ( 3 /1) 
PBMC VDlOB -250 5 (1/4) 
SMC 70 15 (10/5) 
2 PBMC VD20A -250 >180 (>80/>100) 
SMC 6 0 
3 PBMC VDlOC 113 31 (15/16) 
SMC 150 0 
PBMC VD20B -250 83 (28/55) 
SMC 1 0 
6 PBMC VD20C 70 0 
SMC 43 19 (9/10) 
7 PBMC VDlOD 70 43 (17/26) 
SMC 53 1 
Frequency 
( % ) 
-80 
6 
-2 
22 
-75 
0 
28 
0 
-33 
0 
0 
44 
62 
0 
Control PBMC 
Total no. 
cDNA clones 
93 
93 
114 
62 
86 
114 
65 
No. 
positive 
0 
0 
0 
0 
1 
0 
0 
Frequency 
( % ) 
0 
0 
0 
0 
1 
0 
0 
To estimate the frequency of a particular cDNA clone, complementary oligonucleotides specific for 
the V-J junctional region were used as probes to screen TcR 8-chain cDNA clones derived from PBMC 
and SMC. 
1-1 
~ 
U1 
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However, the second dominant Vol transcript detected in 
this patient (VDlOB), predominated in the SMC at 22% 
compared with -2% in the PBMC, indicating in vivo clonal 
expansion of Vol+ 1/0 T-cells in the synovium of this 
patient. The highest degree of Vo2 oligoclonality was 
detected in the PBMC of patient 2, where about 75% of Vo2 
transcripts were oligoclonal (VD20A). For patient 3, the 
two dominant Vol- and Vo2-chain cDNA clones were detected 
in the PBMC at approximately equal frequencies, 28% for 
VDlOC and -33% for VD20B. A high degree of Vol 
oligoclonality (62%) was also seen in the PBMC of patient 7 
and the dominant Vo2-Jo2-Co transcript detected in SMC of 
patient 6 represented about 44% of the Vo2+ 1/0 T-cell 
population. VDlOD was detected in SMC of patient 7 and 
VD20C in PBMC of patient 6, after hybridising Southern 
blots of PCR-amplified o-chain cDNA with the appropriate 
oligonucleotides, indicating that these transcripts were 
expressed at low levels in these samples. 
4.4.7 Deduced amino acid sequence 
The nucleotide and deduced amino acid sequences of the 
junctional regions of the dominant Vol- (Figure 4.3) and 
Vo2-chain cDNA clones (Figure 4.4) detected in RA patients 
show that all of the cDNA clones, except VD20C, used the 
Jol gene. The sequences were in-frame, except for VDlOC, 
and therefore should represent functional transcripts. In 
the cDNA clone VDlOC, the rearrangement of the V, D and J 
gene segments resulted in a frameshift in that the deduced 
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Figure 4.3 T-cell receptor V-D-J junctional (A} and deduced 
amino acid sequences (B} of the dominant Vol-chain cDNA 
clones detected in RA patients. The junctional sequences 
have been aligned to obtain maximum sequence homology to 
published Dal, D82 and D83 sequences (Loh et al., 1988). 
. . 
Template - independent (N) nucleotides at the junctions of 
the germline V, D and J gene segments are indicated. The 
sequences of the oligonucleotides used as probes are 
indicated by underlining. The single-letter abbreviation 
for amino acid residues is used. D: diversity; J: joining; 
RA: rheumatoid arthritis; V: variable. 
(A) 
v81 Nl Dbl N2 D82 N3 D83 N4 J8{n) 
gerrnline TTGTGCTCTTGGGGA GAAATAGT CCTTCCTAC ACTGGGGGATACG ACACCGATAAACTCATCTTTGGAAAA (1) 
VDlOA TTGTGCTCTTGGGGA CTAC GGAGGAGAAGG TGGGGGA CCCGA CGATAAACTCATCTTTGGAAAA (1) 
VD10B TTGTGCTCTTGGG TCGC CCTT TGATTTCCTCCT ACTGGGGGATACG cc TAAACTCATTCTTGGAAAA (1) 
VDlOC TTGTGCTC CG ATAG G CCTTCCTAC AGGT ACTGGG CA GATAAACTCATCTTTGGAAAA (1) 
VDlOD TTGTGCTCTTGGGGA T CCTTCCT TTGAGGA GGATACG TTCGTGTA CGATAAACTCATCTTTGGAAAA (1) 
(B ) 
v81 N-D8-N J8(n) 
VDlOA CALG SPFDFLLLGDTP KLIFGK ( 1) 
VD10B CALG DYGGEGGGPD DKLIFGK (1) 
VDloca) LCS DRPSYRYWA DKLIFGK (1) 
VDlOD CALG DPSFEEDTFVY DKLIFGK (1) 
a) out of frame 
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Figure 4.4 (A): T-cell receptor V-D-J junctional (A) and 
deduced amino acid sequences (B) of the dominant Vo2-chain 
cDNA clones detected in RA patients. Template-independent 
(N) nucleotides at the junctions of the germline V, D and J 
gene segments are indicated. The sequences of the 
oligonucleotides used as probes are indicated by 
underlining. D: diversity; J: joining; RA: rheumatoid 
arthritis; V: variable. 
(A) 
Vo2 
gerrnline GCCTGTGACACCGTA 
Nl Do3 N2 
ACTGGGGGATACG 
VD20A GCCTGTG 
VD20B 
VD20C 
(B) 
GCCTGTGACA 
GCCTGTGAC 
VD20A 
VD20B 
VD20C 
Vo2 
CTG ATC 
CTGGGGGATA GCGTT G 
CCCAGT ACTGGGGGA CGCG 
N-Do-N Jo(n) 
GSYYCAC ADP DKLIFGK (1) 
GSYYCACD SWGIAF DKLIFGK (1) 
GSYYCACD PSTGGR VYQLFF (2) 
Jo(n) 
ACACCGATAAACTCATCTTTGGAAAA (1) 
CCGATAAACTCATCTTTGGAAAA (1) 
CGATAAACTCATCTTTGGAAAA (1) 
TTTACCAACTCTTCTTTGG (2) 
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amino acid sequence of the Vo region, but not the Jo 
region, was different to that of the published amino acid 
sequence. Compared to the Vo2-chain cDNA clones which 
contained only the Do3 segment, the Vol-chain cDNA clones 
had longer junctional region sequences due to the use of 
multiple Do segments. From analysis of the deduced amino 
acid sequences it was apparent that, as with the nucleotide 
sequences, there was extensive diversity at the protein 
level. 
4.5 DISCUSSION 
Current data on the numbers of 1/0 T-cells in synovial 
fluid, synovial tissue and peripheral blood of RA patients, 
are conflicting. Whilst Reme et al. (1990) found increased 
levels of 1/0 T-cells in the peripheral blood of RA 
patients compared to normal healthy donors, Smith et al. 
(1990) found significantly lower levels. Other studies have 
shown increased numbers of 1/0 T-cells in the inflamed 
joints of patients with RA (Smith et al., 1990; Reme et 
al., 1990; Andreu et al., 1991), although the role of 1/0 
T-cells in rheumatoid inflammation is not understood. In 
the report by Andreu et al. (1991), a selective expansion 
of 1/0 T-cells was found in the synovial membranes of seven 
RA patients, compared to peripheral blood, but the 
phenotype of these cells could not be defined serologically 
using MAbs specific for the V19, Vo2 and Vol-Jal gene 
products. These findings contrast sharply with those of 
Kjeldsen-Kragh et al. (1990), Chaouni et al. (1990) and 
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Keystone et al. (1991), in which there were no significant 
differences in T10 values between the RA synovial 
compartment and peripheral blood. In the present study, 1/0 
T-cell values, determined as the ratio of 1/0:a/~ T-cells, 
in both PBMC and SMC of RA patients were comparable to 
those previously reported in normal PBMC (Groh et al., 
1989), and in RA synovium (Chaouni et al., 1990) and 
synovial fluid (Keystone et al., 1991). 
In Chapter 3, V gene expression of 1/0 TcRs in PBMC of the 
same RA patients studied here showed a marked bias in TcR 
Vo usage when compared to normal PBMC. Whereas each of the 
nine controls expressed all six known Vo genes, with the 
exception of one individual who did not express Vo4, RA 
patients expressed as few as three Vo genes (Vol, Vo2 and 
Vo3) and only two of the seven patients expressed all 
Vo genes in the PBMC. Vo usage in SMC was even more 
' SlX 
restricted and skewed towards Vol, but Vo2 mRNA transcripts 
were detected, albeit at low levels in some patients. The 
conclusion was that, since only small numbers of 
autoreactive T-cells may be required for the chronic 
progression of RA, the apparent bias in Vol expression by 
SMC may have been less relevant than the finding of small 
numbers of Vo2 mRNA transcripts in SMC of most patients. 
This conclusion was compatible with reports that 1/0 T-
cells in the rheumatoid synovium are often reactive to M. 
tuberculosis (Holoshitz et al., 1989; Raulet 1989b); the 
response to M. tuberculosis is restricted to Vo2/V19-
bearing T-cells (Kabelitz et al., 1991a; Panchamoorthy et 
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al., 1991; Ohmen et al., 1991) and that activation of T-
cells by a superantigen, which in the case of V~ elements 
can lead to programmed cell death (Kawabe and Ochi, 1991), 
possibly accounted for the limited number of Vo2 rnRNA 
transcripts in RA synovium. However, in view of the 
oligoclonality of Vol transcripts in some RA patients, as 
described in this Chapter, the reluctance to attribute much 
significance to the bias in Vol usage by SMC of RA patients 
needs to be re-examined. 
The data presented in this report provide evidence for 
clonal dominance of Vol- and Vo2-expressing r/o T-cells in 
the peripheral blood and to a lesser extent in the synovia 
of RA patients. This suggests the potential involvement of 
antigen(s)/peptide(s) specific for the V-region and V-J 
junction of these T-cells in the pathogenesis of the 
disease. 
The chronic progression of RA would require the continual 
triggering of resting autoreactive T-cells to the activated 
state. It has been proposed, particularly in relationship 
to another autoimmune disease, multiple sclerosis (MS), 
that resting autoreactive T-cells could be activated 
systemically by molecular mimicry, involving epitopes of 
bacteria or viruses that are shared by host self antigens; 
or by superantigens (Wucherpfennig et al., 1991). 
Alternatively, or additionally, intercellular adhesion 
molecule (ICAM) interactions may be involved (Brod et al., 
1990). In the case of murine EAE, a report has identified 
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an integrin molecule as an adhesion receptor that mediates 
the attachment of circulating lymphocytes to inflamed brain 
endothelium (Yednock et al., 1992) and Brod et al. (1990) 
have demonstrated that activated T-cells expressing high 
densities of cell surface adhesion molecules can trigger 
neighbouring resting T-cells to proliferate, via adhesion 
pathways. This latter mechanism may permit a range of 
pathogens, not necessarily showing molecular mimicry with 
host self antigens, to stimulate the activation of 
autoreactive T-cells. Once activated, autoreactive T-cells 
may undergo clonal expansion and initiate an autoimmune 
response, after exposure to self antigen(s) in the target 
tissue. 
If such mechanisms contributed to the development of RA, 
one might expect that in patients with RA of long duration, 
some may show clonal expansion of particular T-cells in the 
periphery. This was the observation in the present study 
where four of five RA patients showed a strong bias towards 
usage of the same Vo-Jo combination and junctional region 
sequences in the PBMC, although the specific sequences were 
unique in each patient. This report of clonal dominance of 
TcR Vol and Vo2 transcripts, primarily in PBMC of RA 
patients, supports the concept of in vivo activation of T-
cells in the periphery; whether these particular 1/0 T-
cells are autoreactive, is unknown. 
It is possible that a superantigen, specific for the Vo 
region of the 1/0 TcR, may trigger T-cell activation and 
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that the powerful response may also invoke an antigen-
specific MIIC-restricted immune response, mediated by 1/ 0 T-
cells expressing specific Vo-Jo junctional region 
sequences. The recent reports of activation of human CD4-
CD8- TcR 1/0+ T-cells by the Mycoplasma arthritides 
superantigen (Matthes et al., 1988) and the recognition of 
a particular peptide/MIIC combination by certain 1/0 T-cells 
(Holoshitz et al., 1992), would lend support to this 
scenerio. After migration and entry into the synovium, 
activated autoreactive T-cells could then initiate an 
autoimmune response after exposure to self-antigen(s) . in 
the joint, which, depending on the type of antigen and mode 
of presentation, may result in clonal expansion of 1/0 T-
cells leading to oligoclonal T-cell populations in the 
synovia of some patients. 
In this study, the Vol and Vo2 repertoires in SMC of RA 
patients were largely polyclonal, although in some cases 
oligoclonality was detected. Furthermore, leakage of 
clonally-expanded T-cell populations from the joint into 
the periphery, as well as recruitment of non-specific T-
cells into the joint, may have accounted for the higher 
degree of oligoclonality of Vol and Vo2 transcripts 
observed in RA PBMC compared to SMC. In one of the patients 
tested, the sharing of oligoclonal transcripts between the 
SMC and PBMC indicates trafficking of T-cells between the 
synovial and peripheral blood compartments. The presence of 
mainly polyclonally-expanded Vol and Vo2 T-cell populations 
in SMC of most patients examined here, may reflect the 
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effects of a Vo region-specific antigen within the joint. 
This finding is compatible with previous studies which 
demonstrated that the Vol repertoires in cell lines derived 
from RA SF T-cells (IL-2 stimulated) (Bucht et al., 1992b) 
and in fresh SF T-cells (Sioud et al., 1991a), were 
polyclonal, although in the report by Sioud and colleagues, 
only six Vol transcripts obtained from a single RA patient 
were sequenced and no controls, either normal PBMC or RA 
PBMC, were analysed. Alternatively, a heterogeneous TcR 
repertoire may indicate the recognition of different 
epitopes of the same antigen, possibly as a consequence of 
diverse MHC genotypes, or stimulation by a number of 
diverse antigens. 
The specific clonal o-chain expression varied from patient 
to patient. Whether the host-specific clonal Vol and Vo2 
transcripts detected in this study are persistent or 
transient is an important question that is addressed in 
Chapter 6 of this thesis. If 1/0 T-cells expressing 
particular TcRs are continually represented in the 
peripheral blood of patients with RA and are critical to 
the immunopathogenesis of the disease, then immune 
intervention using synthetic TcR peptides may become 
possible as a form of treatment for patients with RA. 
CHAPTER 5 
T-CELL RECEPTOR V19-CHAIN OLIGOCLONALITY IN RHEUMATOID 
ARTHRITIS PATIENTS 
5.1 INTRODUCTION 
The response of normal human peripheral blood 1/8 T-cells 
to killed Mycobacteria is an exclusive property of the 
Vo2/V19-bearing T-cell subset (Kabelitz et al., 1991a), 
although in RA synovial fluid, Mycobacteria hsp65-
responsive T-cells commonly expressed Vol (Soderstrom et 
al., 1990). A further study by Bucht et al. (1992b) 
suggested that the Vol T-cell subset in RA synovial fluid 
consists of a preactivated population of T-cells in vivo. 
Mycobacteria-reactive Vo2/V19+ T-cells showed extensive 
junctional region diversity in both the 1- and o-chains 
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(Panchamoorthy et al., 1991; Ohmen et al., 1991), 
indicating that the 1/0 T-cell response against 
Mycobacteria is polyclonal and dependent on V-region 
expression rather than expression of specific junctional 
sequences. This is unlike the conventional mechanism of 
antigen recognition whereby a/fi T-cells reactive to a 
particular peptide/Mlle combination show restricted TcR a 
and/or fi V-J gene usage with relatively conserved 
junctional regions (Engel and Hedrick 1988; Hedrick et al., 
1988), but resembles the reactivity of human a/fi T-cells 
against bacterial superantigens (Choi et al., 1989). 
However, a recent report has shown that Vo2/V19 T-cell 
clones, generated from RA synovial fluid, can specifically 
recognise a nominal antigenic peptide presented by class II 
MIIC molecules (Holoshitz et al., 1992). Thus, 1/0 T-cells 
may recognise antigens by mechanisms similar to a/fi T-cells 
and therefore may contribute to the host immune response 
against foreign antigens in an antigen-specific, MHC-
restricted manner, as well as by a "superantigen-like" 
phenomenon. 
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Bacterial superantigens, such as Staphylococcus enterotoxin 
A (Rust et al., 1990) and a recently described lectin-
binding mycobacterial antigen (Pfeffer et al., 1992), 
activate human 1/8 T-cells and although a proportion of 
these cells express Vol or Vo2 TcRs the response is 
dependent on the expression of receptors encoded by the 
V19-chain, and is class II MHC-restricted. Thus, although 
several studies have demonstrated a predominance of the 
Vol+ subset of 1/8 T-cells in the synovial fluid (Sioud et 
al., 1990; Keystone et al., 1991; Bucht et al., 1992b) and 
membrane (Smith et al., 1990; Shen et al., 1992; also 
Chapter 3 of this thesis) of RA patients, the bias in Vo 
usage observed in RA synovium may merely reflect an 
association of these 8-chains with V19. 
5.2 AIMS 
The aim of the present study was to assess the clonality of 
V19-bearing T-cells in the synovia and peripheral blood of 
RA patients, for whom V-J o clonality had already been 
determined (see Chapter 4). The experimental approach was 
to sequence the V-J junctional regions of v19-chain cDNA, 
following amplification by the PCR. V-J junctional 
sequences were compared with those found in PBMC of healthy 
donors. 
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5.3 MATERIALS AND METHODS 
5.3.1 RA patients and controls 
Mononuclear cells were isolated from peripheral blood and 
synovium of five RA patients, examined previously for V 
gene usage of r/o TcRs (Chapter 3) and for Vol-Jo and Vo2-Jo 
clonality (Chapter 4). SMC and PBMC of RA patients were not 
cultured or stimulated in vitro. PBMC from five healthy 
donors were stimulated with Con-A and then pooled, as 
described in Chapter 2 (section 2.2.10). 
The methodology used for the molecular characterisation of 
vr9 transcripts expressed in RA patients was essentially 
the same as that used for the analysis of a-chain 
clonality. A brief resume of the methods used is given 
although Chapter 4 should be referred to for more detailed 
descriptions. 
5.3.2 PCR amplification of vr9 transcripts 
First strand r-chain specific cDNA was synthesised from 
approximately 10 µg of total RNA using the cr1 primer, as 
described in Chapter 2 (section 2.2.9). Approximately 2% of 
single-stranded cDNA template was amplified in a typical 
50 µl reaction using the 5' vr9 sense primer (s ee Table 
3.4) and the 3' cr2 antisense primer (see Table 2.1), with 
the PCR conditions as described in Chapter 3 (section 
3.3.6). The specificity of each PCR product was confirmed 
by Southern blot analysis and hybridisation with C13 (see 
Table 2.1), according to the protocols in Chapter 2 
(section 2.2.13.1 and 13.2). 
5.3.3 Cloning and sequencing of PCR products 
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PCR-amplified TcR 1-chain cDNA was phosphorylated according 
to the protocol in Chapter 2 (section 2.2.15.1) and 
separated on a 1.25% (w/v) TAE agarose gel (see section 
2.2.12). The DNA from a band approximately 400-700 bp was 
isolated by electroelution, as described in Chapter 2 
(section 2.2.15.1), and the fragment DNA blunt-end ligated 
into SmaI-cleaved M13mpl8 vector and used to transform 
bacterial host cells, according to standard procedures 
described in Chapter 2 (section 2.2.15). To determine the 
total number of TcR V19-chain cDNA clones, M13 plaques were 
transferred onto Hybond N+ nylon membrane discs and 
screened with a full-length V19-specific probe, obtained 
form a gel-purified V19-specific PCR product, which was 
labelled by the random priming method (Chapter 2, section 
2.2.14.2). M13 single-stranded DNA was prepared from 
positive cDNA clones and sequenced using an automated DNA 
sequencing system, essentially as described in Chapter 2 
(section 2.2.16). 
5.3.4 Screening of cDNA clones 
Seven oligonucleotides, plus seven in the reverse 
orientation, were synthesised and used as probes to screen 
Table 5.1 Nucleotide sequence of oligonucleotides used as probes to screen 
T-cell receptor Vr9-chain cDNA clones. 
Oligo-
nucleotide 
VG90Al 
VG90Bl 
VG90Cl 
VG90Dl 
VG90El 
JGPF 
JG2F 
Sequence (5'-3') 
(forward) 
TACTGTGCCTTAAAGAAACTCT 
TGTGGGAGTCGGACAAGAAA 
TGGGAGTTTTATAAGGAGAAA 
TGTGGGAGGAAGAGTTGGG 
TTGTGGGAGCGGTATAAGAAA 
AAATCAAGGTATTTGGTCCCG 
AGTGGAACAACACTT*GTTGTC 
Oligo- Sequence (5'-3') 
nucleotide (reverse) 
VG90A2 AGAGTTTCTTTAAGGCACAGTA 
VG90B2 TTTCTTGTCCGACTCCCACA 
VG90C2 TTTCTCCTTATAAAACTCCCA 
VG90D2 CCCAACTCTTCCTCCCACA 
VG90E2 TTTCTTATACCGCTCCCACAA 
JGPR CGGGACCAAATACCTTGATTT 
JG2R GACAACA*AGTGTTGTTCCACT 
*The coding region of the Jr2 gene segment differs from Jrl by a single G to T 
base substitution (Lefranc et al., 1986c). 
f-J 
lJl 
I..O 
16 0 
TcR V19-chain cDNA clones (Table 5.1). Five were specific 
for v1-J1 junctional regions that occurred more than twice 
in the sequence analysis and two were specific for J1P and 
J12 gene segments. Membrane discs were hybridised with a 
[32 PJ -kinased forward oligonucleotide, as described in 
Chapter 4 (section 4.3.7.2), and the numbers of positive 
clones recorded. Discs were stripped of probe and then re-
hybridised with the reverse/complementary oligonucleotide. 
5.4 RESULTS 
5.4.1 Molecular analysis of the V19 TcR repertoire in Con-A 
stimulated pooled normal PBMC 
DNA sequences of the V-J junctions of 17 V19-chain cDNA 
clones, derived from normal PBMC (Con-A stimulated), were 
evaluated. Of these, 15 used the J1P gene segment whereas 
the J11 and J12 gene segments were each represented by a 
single cDNA clone (Table 5.2). Preferential usage of J1P in 
V19 transcripts from unstimulated normal PBMC has 
previously been observed (Borst et al., 1989; Tamura et 
al., 1990), arguing against selective outgrowth of 1/8 T-
cells expressing these particular 1-chains upon stimulation 
with Con-A. Each V19 transcript examined had a unique 
junctional region sequence, demonstrating extensive 
diversity in the V19 TcR repertoire expressed in normal 
PBMC. The lack of 1-chain oligoclonality in normal PBMC 
demonstrates the lack of bias in the PCR-based protocol for 
any one particular TcR sequence. 
Table 5.2 Molecular characterisation of the V19 T- cell 
receptor repertoire in rheumatoid arthritis patients and 
controls. 
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Unique VJ9 sequences Shared VJ9 sequences 
Donor No. No. JJ usage No. JJ usage 
seq. observed Jl J2 JP JPl Nb) observed Jl J2 JPN 
Patient 
1 PBMC 9 3 0 1 2 0 0 4 0 4 0 0 
2 0 2 0 0 SMC 8 3 0 3 0 0 0 3 0 3 0 0 
2 0 2 0 0 
2 PBMC 8 3 0 1 1 0 1 5 0 5 0 0 SMC 7 3 0 3 0 0 0 4a) 0 4 0 0 
3 PBMC 10 3 0 0 3 0 0 5 0 0 5 0 
2 0 0 2 0 SMC 9 4 0 4 0 0 0 3 0 3 0 0 
2 0 2 0 0 
6 PBMC 9 5 0 1 4 0 0 2 0 0 2 0 
2 0 0 2 0 SMC 10 8 0 7 1 0 0 2 0 0 0 2 
7 PBMC 9 7 0 5 2 0 0 2 0 0 2 0 SMC 10 10 2 6 1 1 0 0 
Control 
PBMC 17 17 1 1 15 0 0 0 
PCR-amplified TcR V19-chain cDNA derived from PBMC and SMC 
was cloned into the M13 vector and a number of the cDNA 
clones sequenced. 
a) Four V19 sequences in SMC of this patient were identical 
to the dominant transcript found in the PBMC of the same 
patient. b) N represents V19 transcripts with no J-region 
segment. 
5.4.2 Molecular analysis of the V19 TcR repertoire in SMC 
and PBMC of RA patients 
5.4.2.1 J1 usage of V19 transcripts 
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The V-J junctional region sequences of 89 V19-chain cDNA 
clones, derived from PBMC and SMC of five RA patients, were 
determined. Most of the 17 V19 cDNA clones from PBMC of 
patients 1 and 2 used the J12 segment (13 of 17) whilst 
three used J1P and one had no J-region (Table 5.2). In 
marked contrast, the ten cDNA clones from PBMC of patient 3 
and all except one (of nine) from patient 6 used J1P. For 
patient 7, four of the nine cDNA clones used J1P and the 
remainder used J12. Overall, of the 45 V19 cDNA clones 
derived from PBMC of the five RA patients, 25 used J1P, 19 
used J12 and one had no J-region. In SMC of these patients, 
the vast majority of V19 transcripts used J12; of 44 V19 
cDNA clones 37 used J12, two clones used J1P, two clones 
used J11, a single clone used JPl and two had no J-region. 
5.4.2.2 Frequency of J1 usage 
To estimate the frequency of J1P and J12 usage in V19 
transcripts from RA patients, oligonucleotides specific for 
these J-region segments were used as probes to screen v19-
chain cDNA clones derived from SMC and PBMC. The results 
are given in Table 5.3. In PBMC of healthy donors, V19 
transcripts were found rearranged with J1P at a frequency 
of 80-90%, or with J12 at a frequency of 10-20%. These 
Table 5.3 Frequency of joining region usage of T-cell receptor Vr9 transcripts 
expressed in rheumatoid arthritis patients and controls. 
Donor 
Patient 
1 PBMC 
SMC 
2 PBMC 
SMC 
3 PBMC 
SMC 
4 PBMC 
SMC 
5 PBMC 
SMC 
Control 
PBMC 
PBMC 
Total no. 
cDNA clones 
84 
45 
-250 
-250 
110 
98 
110 
129 
132 
76 
82 
75 
J-yP usage 
No. Frequency 
positive (%) 
(forward/reverse) 
10 ( 4/ 6) 12 
3 (2/1) 7 
12 (6/6) 
-5 
7 ( 6/1) 
-3 
110 (51/59) 100 
11 ( 9 /2) 11 
89 (43/46) 81 
16 (8/8) 12 
65 (27/38) 50 
14 (5/9) 18 
64 (30/34) 78 
66 (38/28) 88 
J-y2 usage 
No. Frequency 
positive (%) 
(foward/reverse) 
68 (40/28) 81 
41 (21/20) 91 
>200 (>100/>100) 
-80 
>200 (>100/>100) 
-80 
1 (0/1) 1 
74 (33/41) 75 
24 (10/14) 22 
96 (43/53) 74 
72 (37/35) 55 
54 (25/29) 71 
10 ( 3 /7) 12 
14 (8/6) 19 
To estimate the frequency of JrP and Jr2 usage, .complementary oligonucleotides specific for these 
J-region segments were used as probes to screen Vr9-chain cDNA clones derived from PBMC and SMC. 
f-l 
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results confirm earlier reports of a bias in usage of the 
J1P gene segment in V19 transcripts from normal PBMC (Borst 
et al., 1989; Tamura et al., 1990). In PBMC of RA patients, 
there was individual variation in the relative expression 
of J1P and J12 in V19 transcripts. Three of the five 
patients showed an unusually high frequency of usage of the 
J12 segment, and this was particularly marked (-80%) ' in 
patients 1 and 2. In one exceptional patient (No.3), V19 
transcripts exclusively used J1P. In SMC of RA patients, J1 
usage of the V19 repertoire was more consistent between 
individuals, with J12 usage ranging from 70-90%. The 
overall bias towards J12, in all SMC samples and most RA 
PBMC samples, contrasts with the predominance of J1P in V19 
transcripts from normal PBMC. 
5.4.2.3 Junctional region diversity of VJ9 transcripts 
Evidence for oligloclonality in the V19 TcR repertoire was 
detected in PBMC of patients 1, 2 and 3. In each of these 
patients, there was a marked over-representation of V19 
transcripts that shared the same junctional region 
sequence, although these were unique in each patient (Table 
5.2). Most strikingly, for patient 2, five of eight cDNA 
clones were identical and used J12. For patients 6 and 7, 
although some sequences were repeated twice, most sequences 
were unique. In SMC of RA patients, evidence for V19 
oligoclonality was found in patient 2, since four of the 
seven cDNA clones were identical. The sequence of this 
dominant transcript was identical to that of the dominant 
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transcript detected in PBMC of the same patient. In SMC of 
patients 1 and 3, some sequences were repeated twice and 
three times, whereas eight of the ten cDNA clones from 
patient 6 and all of those from patient 7 had unique 
sequences. 
5.4.2.4 Degree of TcR VJ9-chain oligoclonality 
To estimate the frequency of the cDNA clones which were 
detected more•than twice in the RA patients, 
oligonucleotides specific for the V-J junctional regions 
were used as probes to screen V19-chain cDNA clones. The 
results are given in Table 5.4. The highest degree of 
oligoclonality was detected in the PBMC of patient 1 where 
about 60% of V19 transripts were identical (VG90A), 
compared to about 10% in the SMC. In addition, a second V19 
transcript was detected in the SMC of this patient (VG90B) 
which represented about 20% of the V19 T-cell population. 
VG90B was detected in PBMC of this patient, after 
hybridising Southern blots of PCR-amplified V19-chain cDNA 
with the appropriate oligonucleotides, indicating that this 
transcript was expressed at low levels in the PBMC. 
Therefore, in this patient, there appeared to be two 
different dominant populations in the synovium, indicating 
clonal expansion. A high degree of oligoclonality (56%) was 
also seen in PBMC of patient 3 whilst in the SMC a dominant 
transcript different to the one observed in the PBMC was 
detected at approximately 20%. Overall, V19 transcripts 
expressed in RA peripheral blood showed restricted V-J 
Table 5.4 Degree of T-cell receptor V19-chain oligoclonality in rheumatoid 
arthritis patients and controls. 
Patient Control PBMC 
Patient Clone Total no. No. Frequency 
cDNA clones positive (%) 
(forward/reverse) 
Total no. No. Frequency 
cDNA clones positive (%) 
1 PBMC VG90A 84 52 (27/25) 62 82 0 0 SMC 45 5 (2/3) 11 
PBMC VG90B 84 1 (1/0) 1 82 0 0 SMC 45 9 ( 4/5) 20 
2 PBMC VG90C 
-250 138 (76/62) 
-55 82 2 2 SMC 
-250 103 (57/46) 
-40 
3 PBMC VG90D 110 61 (33/28) 56 75 1 0 SMC 98 0 0 
PBMC VG90E 110 0 0 75 1 1 SMC 98 23 (13/10) 23 
To estimate the frequency of a particular cDNA clone, complementary oligonucleotides specific 
for the V- J junctional region were used as probes to screen V19-chain cDNA clones derived from 
PBMC and SMC. 
f-l 
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junctional diversity, indicating that in vivo clonal 
expansion of v19+ T-cells expressing particular v1-J1 
junctional regions had taken place. In contrast, V19 
transcripts expressed in SMC mostly showed extensive 
junctional diversity, indicative of a synovial T-cell 
infiltrate derived largely from polyclonal expansion. 
5.4.2.5 Deduced amino acid sequence 
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To determine whether a conserved amino acid sequence motif 
was encoded by the V-J junctional regions of the dominant 
V19-chain cDNA clones detected in RA patients, the primary 
structure of V-J junction was examined in terms of the 
deduced amino acid sequence. The nucleotide and deduced 
amino acid sequences (Figure 5.1) of the junctional regions 
of the dominant V19-chain cDNA clones show that all, except 
VG90D, used the J12 segment. VG90D used J1P. All sequences 
were in-frame and therefore should represent functional 
transcripts. From analysis of the amino acid sequences 
there appeared to be no conserved sequence encoded by the 
junctional regions of these cDNA clones. In each of the 
cDNA clones except VG90A, the junctional region contained a 
glutamic acid residue (E) which derived its nucleotides 
from the 3'-end of the V19 gene. 
5.5 DISCUSSION 
In the present study, the V-J junctional regions of 89 V19 
transcripts from SMC and PBMC of five RA patients and 17 
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Figure 5.1 T-cell receptor V-J junctional (A) and deduced 
amino acid sequences (B) of the dominant V19-chain cDNA 
clones detected in RA patients. Template-independent (N) 
nucleotides at the junctions of the germline V and J gene 
segments are indicated. The sequences of the 
oligonucleotides used as probes are indicated by 
underlining. The single-letter abbreviation for amino acid 
residues is used. J: joining; RA: rheumatoid arthritis; V: 
variable. 
(A) 
Gerrnline 
VG90A 
VG90B 
VG90C 
VG90D 
VG90E 
(B) 
V-y9 N 
CCTACTACTGTGCCTTGTGGGAGGTG 
CCTACTACTGTGCCTT 
CCTACTACTGTGCCTTGTGGGAG 
CCTACTACTGTGCCTTGTGGGAG 
CCTACTACTGTGCCTTGTGGGAGG 
CCTACTACTGTGCCTTGTGGGAG 
V-y9 
YYCAL 
N 
A 
TCGGAC 
TTTTATAAGG 
CGG 
J-y ( n) 
KKLFG (2) VG90A 
VG90B 
VG90C 
VG90D 
VG90E 
YYCALWE SD KKLFG (2) 
YYCALWE FYKE KLFG (2) 
YYCALWE E ELGKKI (P) 
YYCALWE R YKKLFG (2) 
Q:'Y(n) 
AATTATTATAAGAAACTCTTTGG ( 2) 
AAGAAACTCTTTGG ( 2) 
AAGAAACTCTTTGG (2) 
AGAAACTCTTTGG (2) 
AAGAGTTGGGCAAA (P) 
TATAAGAAACTCTTTGG ( 2) 
169 
V19 transcripts from normal PBMC, were sequenced. DNA 
sequence analysis revealed that in normal PBMC, despite 
preferential usage of the J1P gene segment, there was 
extensive junctional region diversity in the V19 
repertoire. This is compatible with the findings of Tamura 
et al. (1990), although in their study a few identical V19 
sequences (<20%), resulting from the direct joining of V19 
and J1P gene segments with no N-region additions, were 
found in unstimulated normal PBMC. Similarly, a recent 
report also found this particular sequence amongst a 
minority of V19-J1P chains in human 1/8 T-cells (Delfau et 
al., 1992). In marked contrast, in this study, a high 
degree of V19 oligoclonality was observed in PBMC of each 
of three patients, although the sequence of each dominant 
transcript was unique. In addition, the V19 repertoire in 
PBMC of two patients was skewed towards J12, as opposed to 
J1P in normal PBMC, indicating selective expansion of v19+ 
T-cells expressing particular V19-J12 junctional region 
sequences in the peripheral blood of these patients. 
However, V19 transcripts expressed in PBMC of another 
patient exclusively used J1P, suggesting recognition of an 
antigen/peptide specific for the V19-J1P region of the 1/8 
TcR. 
Mycobacteria-reactive V82/V19 T-cells have been shown to 
specifically express V19-J1P chains (Ohmen et al., 1991). 
Thus, in the peripheral blood of at least one RA patient it 
is possible that V19-bearing T-cells have previously been 
activated by mycobacterial antigens. Altogether, these data 
1 7 0 
indicate that V19-bearing T-cells in RA peripheral blood 
are largely derived from clonal expansion as a result of 
stimulation with a nominal antigen/peptide. In support of 
this, there is evidence which demonstrates that 1/0 T-cells 
can recognise conventional antigen presented by class II 
MHC molecules (Holoshitz et al., 1992). Furthermore, Vol 
and Vo2 oligoclonality detected in Mycobacterium leprae-
induced skin lesions, provides evidence for clonal 
selection of 1/0 T-cells in response to a human pathogen 
(Uyemura et al., 1991). 
In comparison with the findings from the previous report 
(Chapter 4), in which Vol and Vo2 transcripts from the same 
patients studied here were sequenced, V19 oligoclonality 
observed in this study, for patients 1, 2 and 3, appeared 
to correlate with Vol or Vo2 oligoclonality found in PBMC 
of these patients (summarised in Table 5.5). Whether the 
over-representation of identical V19 and Vol/Vo2 
transcripts were in fact derived from the same T-cells, is 
unknown. A recent report of analysis of the Vo2 and V19 
repertoires in the peripheral blood of patients with 
sarcoidosis, a granulomatous disorder possibly associated 
with Mycobacteria, has also shown that a large number of 
these transcripts shared identical sequences (Tamura et 
al., 1990). The dominant V19 transcripts that were 
identified in the blood of sarcoidosis patients used J1P. 
In addition, the V19-J1P combination was strikingly over-
represented in peripheral blood T-cells of a patient with 
tularemia, although the junctional regions were highly 
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heterogeneous (Sumida et al., 1992). Therefore, in certain 
immunological disorders, 1/0 T-cells may be preferentially 
activated in the periphery in response to a foreign antigen 
and as a result undergo selective expansion. 
The V19 repertoire in SMC of most RA patients showed 
molecular heterogeneity, although in some patients there 
was evidence of oligoclonal v19+ T-cells, especially in one 
patient (patient 2) where about 40% of V19 transcripts in 
SMC were the same and identical to the dominant transcript 
detected in PBMC. Similarly, for patient 1, oligoclonal V19 
and Vol transcripts were shared in the SMC and PBMC (Table 
5.5). The sharing of identical sequences indicates that 
certain 1/0 T-cells have infiltrated, or leaked from, the 
synovial compartment. It is unlikely that the synovia 
samples would have become contaminated with blood during 
the surgical procedure, since V19-J12 transcripts were 
over-represented in SMC of all patients examined even in 
cases where there was predominant, or exclusive use of J1P 
in V19 transcripts from PBMC (patients 3 and 4). In Chapter 
4, it was also shown that Vol and Vo2 T-cell populations in 
SMC were largely polyclonal, although in some cases 
oligoclonality was detected. Vol and Vo2 oligoclonality has 
recently been demonstrated in acute, demyelinating MS 
plaques (Wucherpfennig et al., 1992a) and in Leishmaniasis 
lesions (Uyemura et al., 1992), providing further evidence 
for a pathogenic role of 1/0 T-cells. In SMC of all 
patients examined here, there was a striking over-
representation of V19 transcripts that used J12, compared 
Table 5.5 Summary of T-cell receptor 1/0 usage in rheumatoid arthritis patients. 
Patient No. of detectable 
Vo genes 
Oligoclonality 
Vo2 
J'Y usage 
Vol V"(9 J"(P J"(2 
1 PBMC 4 +a) +a) - +a) 12 81 2 PBMC 6 - + +a) 
-5 
-80 3 PBMC 5 + + + 100 1 6 PBMC 4 - -
- 81 22 7 PBMC 6 + - - 50 55 
Patient 
1 SMC 2 + + - + + 7 91 
2 SMC 4 - - + 
-3 -80 
3 SMC 3 - - + 11 75 6 SMC 6 - + - 12 74 
7 SMC 6 - - - 18 71 
a) Represents the same dominant transcripts found in SMC. 
+ or - denotes the presence or absence of oligoclonality, as detected by DNA sequencing and 
hybridisation of cDNA clones with sequence-specific oligonucleotides. ++ 
presence of two different dominant clones. 
indicates the 
I-' 
....J 
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with normal PBMC. This finding is consistent with a 
previous study that found the V19-J1P T-cell subset under -
represented in RA synovium, as assessed by using MAbs 
(Chaouni et al., 1990). These findings contrast with v19+ 
T-cells in sarcoidosis lung which expressed predominantly 
v19-J1P chains (Tamura et al., 1990). 
173 
Overall, this report demonstrates a predominance of v19+ T-
cells expressing J12 in the rheumatoid synovium that are 
mainly polyclonal. A diverse V19 repertoire may indicate 
that multiple antigens or epitopes of the same antigen have 
been encountered. Alternatively, these cells may have been 
selectively maintained in RA synovium because of 
recognition of an antigen within the joint which is 
specific for the v19-J12 region of the 1/8 TcR, 
irrespective of junctional region sequence. This has 
analogy with T-cell activation involving a superantigen and 
may offer the best explanation for these findings. 
Following T-cell activation, some of these 1/8 T-cells may 
undergo clonal expansion leading to oligoclonal T-cell 
populations in SMC of some patients. Any leakage of 
clonally-expanded T-cells from the joint into the 
periphery, as well as recruitment of non-specific T - cells 
into the joint, may account for the lower degree of 
oligoclonality observed in the synovium compared to blood. 
These data are consistent with a model in which T-cells, 
including autoreactive cells, become activated in the 
peripheral blood in response to a foreign antigen. Once 
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activated, autoreactive T-cells migrate to the synovial 
compartment where they induce a response against self 
antigen(s). In some cases this may lead to clonal expansion 
of certain 1/8 T-cells. These findings suggest that an 
antigen in the rheumatoid joint is specifically recognised 
by V19-J12 T-cells, but whether these particular T-cells 
are autoreactive remains to be investigated. 
CHAPTER 6 
PERSISTENCE OF 1/8 T-CELL OLIGOCLONALITY IN RHEUMATOID 
ARTHRITIS PATIENTS AND T-CELL RECEPTOR USAGE IN SYSTEMIC 
. . 
LUPUS ERYTHEMATOSUS PATIENTS 
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6.1 INTRODUCTION AND AIMS 
The demonstration of oligoclonal expansion of certain TcR 
1/0 T-cells in the synovial tissue and peripheral blood of 
some RA patients, as described in Chapters 3 to 5 of this 
thesis, raises many further questions regarding the 
pathogenesis of autoimmmune disorders. Some of these 
questions, such as the nature of the ligand(s) interacting 
with the oligoclonal TcR 1/0 T-cells and the role of 
oligoclonal TcR 1/0 T-cells (regulatory or inflammatory) 
are beyond the scope of this thesis. Three other important 
questions have been addressed in this Chapter: (1) Whether 
the observed oligoclonality in a given RA patient is 
persistent with time, or transient . (2) Whether the 
restricted usage of TcR Vo genes in some RA patients could 
possibly be attributable to an immunosuppressive drug 
regime. (3) Whether the surprising finding of restricted 
usage of TcR Vo genes in the peripheral blood of some RA 
patients, as well as in the synovium, is a feature of other 
autoimmune diseases. 
6.1.1 Persistence of oligoclonal 1/0 T-cell populations in 
the peripheral blood of RA patients 
The studies described in this thesis have shown that TcR Vo 
usage in RA SMC is highly restricted (Chapter 3), which is 
consistent with the findings of others (Sioud et al., 1990; 
Smith et al., 1990; Keystone et al., 1991; Shen et al., 
1992). Furthermore, there are marked differences in Vo gene 
176 
expression in PBMC of patients compared with normal 
controls. Nucleotide sequencing of the V-J junctions of TcR 
Vol, Vo2 and V19 transcripts expressed in RA patients 
revealed a high degree of 1/0 T-cell oligoclonality, 
particularly in the PBMC (Chapters 4 and 5). These 
oligoclonal 1/0 T-cells may reflect antigen-driven clonal 
expansion and may play an important role in the 
pathogenesis of RA. However, whether 1/0 T-cells can 
accelerate disease progression, or whether these cells have 
a regulatory role, is unknown. 
The earlier findings presented in this thesis are 
consistent with a model in which autoreactive T-cells 
become activated in RA peripheral blood, in response to 
nominal antigen, and then migrate to the synovial 
compartment where they induce a response against self 
antigen(s). Since the chronic progression of RA would 
require continual antigenic stimulation and T-cell 
activation, it is feasible to suggest that oligoclonal 1/0 
T-cell populations may be persistently expressed in th~ 
peripheral blood of patients with RA. If immune 
intervention is a feasible proposition for inhibiting the 
progression of RA, then it is important to establish 
whether any TcR oligoclonality persists with time, and 
whether that oligoclonality is not continuously changing in 
response to a range of foreign, or host intracellular 
antigens that may be presented to T-cells as a consequence 
of tissue destruction. 
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The purpose of this investigation was to assess whether 
there is persistent 1/8 T-cell oligoclonality in the 
peripheral blood of RA patients. The strategy used was to 
screen PCR-amplified TcR cDNA, derived from PBMC of four RA 
patients, with ssos specific for TcR Vol, Vo2 and V19 
transcripts comprising V-J junctions found over-represented 
in PBMC of the same RA patients, in blood specimens 
collected up to three years previously. 
6.1.2 Influence of administered drugs in altering TcR Vo 
gene usage 
The skewed distribution of TcR Vo usage in the peripheral 
blood of RA patients when compared with healthy controls 
could not be attributed to any gerrnline defects in the Vo4 
or Vos genes in RA patients (see Chapter 3, section 
3.4.2.5). This raises the question of possible selective in 
vivo suppression of TcR Vo genes by the administration of 
small doses of prednisone and non-steroid anti-inflammatory 
drugs to all RA patients in this study. Since it would be 
unethical to either suspend treatment of the patients, or 
to take the converse approach of treating healthy donors 
with these drugs, an alternative strategy was adopted in 
order to test the possible effects of drugs on TcR 1/8 
usage. Patients with systemic lupus erythematosus (SLE ) 
receiving prednisone (with or without azathioquine ) , or 
hydroxy chloroquine, or no drugs at all, were recruited to 
the study. In this Chapter, eight SLE patients were 
examined for V gene usage of TcR 1/0 transcripts express e d 
in the peripheral blood. 
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In view of the findings of restricted Vo gene usage in RA, 
in peripheral blood as well as in the synovium, the purpose 
of this investigation was to determine whether the bias 
observed in the 1/0 TcR repertoire could possibly be due to 
a direct effect of drug treatment. 
6.1.3 TcR V 1/0 usage in the peripheral blood of patients 
with another autoimmune disorder, SLE 
Systemic lupus erythematosus (SLE) is an autoimmune 
connective tissue disorder involving multiple organs, and 
characterised by the production of numerous pathogenic 
autoantibodies, particularly antinuclear antibodies, and 
increased circulating immune complex levels (Drake and 
Kotzin, 1992). The etiology of SLE is unknown although 
multiple factors, including both genetic and environmental 
factors, are likely to contribute to the pathogenesis of 
this disease. There is evidence for a genetic association 
in SLE involving the MHC class II and complement genes. In 
Caucasians, HLA-DR2, -DR3 and C4A null alleles (C4A*QO ) are 
increased in SLE (Fielder et al., 1983; Hartung et al., 
1991). However, because of linkage disequilibrium within 
the MHC, the primary susceptibility locus predisposing to 
SLE has been difficult to identify, but cross-ethnic 
studies have shown a significant increase in the frequency 
of C4A null alleles in Caucasoids, Chinese and Japanese 
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(Dunckley et al., 1987). Complete or partial deficiency of 
the early complement component C4 could influence the 
development of SLE by interfering with the clearance of 
circulating immune complexes (Atkinson, 1986). These 
complexes could be deposited within the body causing the 
systemic tissue damage typical of SLE. 
A pathogenic model for SLE is thought to involve CD4+ 
T-cell-driven B-cell autoantibody production, which is 
triggered in the genetically susceptible host after 
exposure to an environmental agent (Drake and Kotzin, 
1992). However, as in RA, the antigen(s) which stimulate 
autoreactive T-cells remains obscure, although in murine 
lupus it has been suggested that pathogenic anti-DNA 
autoantibody-inducing helper T-cells may be selected for by 
cationic autoantigens (Adams et al., 1991). Using MAbs to 
various T-cell activation products such as HLA-DR and IL-2, 
evidence of in vivo activation of peripheral blood T-cells 
was found in SLE patients (Alcocer-Varela et al., 1991), 
which may reflect a response to autoantigens. It has been 
postulated that the T-cells involved in systemic 
autoimmunity may have been activated by a microbial 
superantigen, presented by B-cells which, as a result of T-
cell help, may be stimulated to produce autoantibodies 
(Friedman et al., 1991). However, although alterations in 
the V~ repertoire have been reported in murine lupus 
(Singer and Theofilopoulos, 1990), there is currently no 
substantial evidence for a skewing of the TcR repertoire in 
either murine lupus or SLE. 
The aim of this study was to determine whether there is 
restricted VS usage in PBMC of patients with another 
autoimmune disease, SLE. 
6.2 MATERIALS AND METHODS 
6.2.1 RA patients and cells 
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PBMC were isolated from peripheral blood obtained from four 
RA patients. Patients 2, 3, 6 and 7 in this study 
correspond to those patients examined previously for V51-
J5, V52-J5 and V19-J1 clonality (Chapters 4 and 5). PBMC 
were not cultured or stimulated in vitro. For clinical 
reasons, follow-up material was not obtained for patient 1. 
The new (1992) PBMC samples were taken three years after 
the original PBMC samples, except for patient 2 where the 
new PBMC sample was obtained 15 months later. The original 
samples were collected in August 1989 to October 1990. 
6.2.2 SLE patients and cells 
Peripheral blood was obtained from eight SLE patients. 
Patients were diagnosed according to certain revised 
criteria for the classification of SLE (Tan et al., 1982). 
Details of the patients, including age, sex, disease 
duration and drug treatment, are given in Table 6.1. Buffy 
coat was prepared from the peripheral blood of each 
patient, as described in Chapter 2 (section 2.2.2), and was 
Table 6.1 Systemic lupus erthythematosus patient clinical 
data. 
Patient Sexa) Age Disease Drug 
(yr) duration (yr) treatment 
1 F 46 15 prednisone 
2 F 28 7 hydroxy chloroquine 
3 F 46 23 prednisone 
4 M 34 5 hydroxy chloroquine 
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5 M 35 12 prednisone/azathioquine 
6 F 38 3 none 
7 F 21 3 prednisone 
8 M 66 17 none 
a) M: male; F: female. 
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a source of PBMC. SLE PBMC were not cultured in vitro prior 
to analysis. 
6.2.3 cDNA synthesis and amplification of TcR transcripts 
TcR o- and 1-chain cDNA were synthesised from total RNA, as 
already described (Chapter 2, section 2.2.9). For 
amplification of TcR a-chain cDNA, the Vol to Vo6 primers 
were used (Vol and Vo2 for RA samples), each in conjunction 
with Co2. For amplification of TcR 1 - chain cDNA, the v1r to 
v1rv primers were used (V1II/V19 for RA samples) with c12. 
PCR was performed essentially according to previously 
described protocols (Chapter 3, section 3.3.6) and the 
specificity of each PCR product was confirmed by agarose 
gel electrophoresis (2.2.12) and hybridisation with C13 or 
Co3, as described in Chapter 2 (section 2.2.13.1 and 13.2). 
6.2.4 Cloning of PCR products and screening of cDNA clones 
Specific PCR-amplified TcR cDNA was phosphorylated, agarose 
gel-purified and blunt-end ligated into SmaI-cleaved 
M13mpl8 vector, by standard procedures (Chapter 2, section 
2.2.15). To determine the total number of TcR-containing 
cDNA clones, M13 plaques were screened with a full-length 
random-primed Vol-, Vo2- or V19-specific probe. TcR cDNA 
clones were subsequently screened with SSOs already 
synthesised (see Tables 4.1 and 5.1) and designed to detect 
TcR transcripts comprising V-J junctions previously found 
over-represented in PBMC or SMC of the four RA patients. 
For J1 usage, the J1P and J12 specific oligonucleotides 
(see Table 5.1) were used as probes. 
6.3 RESULTS 
6.3.1 Persistence of oligoclonal 1/8 T-cell populations in 
the peripheral blood of RA patients 
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6.3.1.1 Frequency of Jy usage of Vy9 transcripts in RA PBMC 
The previous analysis of J-region segment usage of V19 
transcripts expressed in RA patients (Chapter 5) showed a 
striking bias towards usage of J12 in all SMC samples and 
in most PBMC samples whereas in control PBMC, the ratio of 
J1P:J12 usage is approximately 4:1. In contrast, for 
patient 3, V19 transcripts expressed in the PBMC 
exclusively used J1P. These marked differences in J1 usage 
between individual RA patients may reflect selection of 1/8 
T-cells by different antigens/peptides. In this study, J1 
usage of V19 transcripts expressed in PBMC of RA patients 2 
and 3, prepared up to three years after the initial 
specimen collection, was re-examined. 
To estimate the frequency of J1P and J12 usage, 
oligonucleotides specific for these J-region segments were 
used as probes to screen V19-chain cDNA clones. The results 
are given in Table 6.2. For comparison, the frequencies 
obtained from the earlier study (Chapter 5) on the original 
PBMC samples of the same RA patients, are shown. Due to 
Table 6.2 Frequency of joining region usage of T-cell receptor V19 transcripts 
expressed in rheumatoid arthritis patients. 
Patient Total no. No. 
J1P usage 
Frequ~ncy 
1989-199oaJ 1992 
Jy2 usage 
No. 
positive 
(forward/reverse) 
2 PBMC 
3 PBMC 
cDNA clones positive 
-160 
-110 
(forward/reverse) 
1 (0/1) 
114 (55/59) 
(%) (%) 
-5 
100 
0 
-100 
146 (70/76) 
7 (4/3) 
Frequ~ncy 
1989-199oaJ 1992 
(%) (%) 
-80 
1 
92 
6 
To estimate the frequency of J1P and J12 usage, complementary oligonucleotides specific for the s e 
J - region segments were used as probes to screen V19 - chain cDNA clones derived from PBMC. 
a) These frequency values were taken from the earlier study (Chapter 5) on the original PBMC 
samples of the same patients. 
f-' 
()'.) 
.p,. 
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lack of material, J1 usage was only tested in the 1992 PBMC 
samples of patients 2 and 3. For patient 2, the majority of 
V19-chain cDNA clones used J12, as before. Only a single 
cDNA clone that used J1P was detected. This is compatible 
with the present results obtained for 1/8 T-cell 
oligoclonality where every V19 transcript from patient 2 
appeared to be identical (Table 6.3). For patient 3, J1P 
usage was detected at approximately 100%, consistent with 
the original (1989) PBMC sample where J1 usage of V19 
transcripts was exclusively restricted to J1P, whereas the 
J12 segment was used in -6% of the V19-chain cDNA clones. 
This is in contrast to J1 usage of V19 transcripts 
expressed in normal PBMC, previously evaluated in Chapter 
5. The over-represented J1P usage cannot be solely 
accounted for by oligoclonality in the PBMC, since 
oligoclonality of V19 transcripts was only detected at -19% 
in the 1992 PBMC sample of patient 3 (Table 6.3). 
6.3.1.2 Persistence of y/8 T-cell oligoclonality in RA PBMC 
From the previous studies, using V gene family-specific PCR 
amplification and subsequent nucleotide sequencing of 
rearranged TcR v-c mRNA transcripts, to analyse TcR 1/8 
expression in RA patients, oligoclonality of certain TcR 1-
and 8-chain transcripts, primarily in PBMC and to a lesser 
extent in SMC, was demonstrated. The question is whether 
this oligoclonality is transient or persistent. 
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To estimate the frequency of TcR cDNA clones containing 
those particular V-J junctional region sequences, 
previously found over-represented in PBMC or SMC of the 
four RA patients, SSOs were used as probes to screen TcR 
Vol-, Vo2- and V19-chain cDNA clones. The results are given 
in Table 6.3. For comparison, the frequencies obtained from 
the earlier studies (Chapters 4 and 5), carried out on the 
original (1989-1990) PBMC samples of the same RA patients, 
are shown. Vol, Vo2 or V19 oligoclonality was not 
previously found in control PBMC derived from several 
normal individuals. For patient 3, Vol (18%) and Vo2 (27%) 
oligoclonality was similar to that previously detected 
whereas V19 oligoclonality was detected at about 19%, 
compared with 56% originally. Approximately 40% of Vol 
transcripts in PBMC of patient 7 were the same. The 
dominant Vol-chain cDNA clone (VDlOD) previously 
represented about 60% of the Vol population in this 
patient. Using immunofluorescence staining (Chapter 4, 
section 4.3.3), the 1/0 T-cell numbers, as a percentage of 
the total number of CD3+ T-cells, in patients 3 and 7 were 
9% and 3%, respectively, comparable to that found in normal 
peripheral blood T-cells (Groh et al., 1989). For patient 
6, -3% of Vo2 transcripts in the 1992 PBMC sample consisted 
of clone VD20C. This clone was orig.inally detected in the 
SMC of patient 6, at -44%, and was then only detected in 
the PBMC after hybridising Southern blots of PCR-amplified 
TcR cDNA with the appropriate oligonucleotides. 
Table 6.3 Persistence of 1/0 T-cell oligoclonality in 
rheumatoid arthritis patients. 
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Patient Clone Total no. 
cDNA clones 
No. 
positive 
Frequency 
1989 -1990a) 1992 
(forward/reverse) ( % ) 
2 PBMC VD20A 21 17 (7/10) -75 81 
VG90E -160 160 (100/60) -55 -100 
3 PBMC VDlOC -100 18 (5/13) 28 -18 
VD20B 52 14 ( 7 /7) -33 27 
VG90D -110 21 (11/10) 56 -19 
6 PBMC VD20Cb) 70 2 (0/2) 0 3 
7 PBMC VDlOD 37 15 ( 9 I 6) 62 40 
To estimate the frequency of a particular cDNA clone, 
complementary oligonucleotides specific for the V-J 
junctional region were used as probes to screen TcR cDNA 
clones derived from PBMC. 
a) PBMC collected at the time of joint replacement (see 
Chapters 4 and 5). b) The sequence-specific 
oligonucleotides used to detect clone VD20C were based on 
oligoclonal V-J junctional sequences detected in the 
original SMC sample of this patient (see Chapter 4). 
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A high degree of oligoclonality was detected in patient 2, 
with about 80% of V82 transcripts and nearly all of the V19 
transcripts identical. Figure 6.1 shows the results of 
hybridisation of V19-chain cDNA clones derived from the 
original (1990) SMC and PBMC samples of patient 2, from 
normal PBMC and from the 1992 PBMC sample of patient 2, 
with the forward (VG90Cl) and reverse (VG90C2) SSOs. These 
probes detect the V-J junctional region sequence of the 
dominant V19-chain cDNA clone VG90C. -In the original 
samples, a total of 103 positive cDNA clones (of -250) were 
detected in SMC, compared to 138 (of -250) in PBMC. As a 
percentage of the total number of V19-chain cDNA clones 
VG90C represented about 40% in SMC and about 55% in PBMC of 
this patient, reflecting a high degree of oligoclonality. 
In the 1992 PBMC sample, 160 positive cDNA clones (of -160) 
were detected. Thus, for patient 2, it appeared that clone 
VG90C now represents the entire peripheral V19 T-cell 
population, and is indicative of oligoclonal expansion. 
Overall, these findings show that those dominant TcR 1- and 
5-chain transcripts previously detected in the PBMC of the 
four RA patients were still present up to three years after 
the initial specimen collection. Thus, 1/8 T-cell 
oligoclonality appears to be persistent rather than 
transient. 
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Figure 6.1 Persistence of T-cell receptor V19-chain 
oligoclonality in RA patient 2. V19-chain cDNA clones 
derived from the original (1990) SMC (a) and PBMC (b) 
samples of RA patient 2, from normal PBMC (c) and from the 
1992 PBMC sample of patient 2 (d), were hybridised with the 
forward SSO, VG90Cl (A) and reverse SSO, VG90C2 (B), to 
detect cDNA clones which contained the specific junctional 
region sequence of the dominant V19-chain cDNA clone VG90C. 
PBMC: peripheral blood mononuclear cells; RA: rheumatoid 
arthritis; SMC: synovial membrane mononuclear cells; SSO: 
sequence-specific oligonucleotide; V: variable. 
A a) b) c) d) 
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6.3.2 Influence of administered drugs in altering TcR Vo 
gene usage and TcR V 1/0 usage in peripheral blood of 
patients with another autoimmune disorder, SLE 
6.3.2.1 V gene usage of TcR y-chain transcripts expressed 
in PBMC of SLE patients 
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To analyse the level of diversity of the expressed TcR 1-
chain repertoires, TcR cDNA prepared from buffy coat of 
eight SLE patients was PCR-amplified using TcR v1 gene 
family-specific primers (see Table 3.4). Figure 6.2 shows 
that, for most patients, there was no restriction in v1 
gene usage since SLE PBMC expressed each of the four v1 
subgroups, as in control PBMC (Con-A stimulated). There 
were some differences in V1IV expression because in PBMC of 
some patients v1rv was weakly expressed, or there was no 
detectable expression of v1rv. When additional PCR was 
performed using more TcR 1-chain cDNA template to amplify 
v1rv transcripts, weak expression of v1rv was detected in 
PBMC of SLE patients 1, 5 and 7 but there was still no 
detectable expression of v1rv in PBMC of patient 6. 
Overall, there were no marked differences between the SLE 
PBMC v1-chain repertoires when compared with control PBMC. 
6.3.2.2 V gene usage of TcR a-chain transcripts expressed 
in PBMC of SLE patients 
V gene usage of the expressed TcR a-chain repertoires of 
eight SLE patients was determined using TcR Vo-specific 
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Figure 6.2 PCR amplification and Southern blot analysis of 
rearranged TcR 1-chain transcripts expressed in PBMC of 
eight SLE patients and in control PBMC (sample #C, Con-A 
stimulated). Lanes 1 - 4 correspond respectively to 
amplification of TcR cDNA with the v1r-v1rv primers, each 
in conjunction with c12. Blots were hybridised with C13 and 
exposed for 6 h. C: constant; Con-A: concavalin A; PBMC: 
peripheral blood mononuclear cells; PCR: polymerase chain 
reaction; SLE: systemic lupus erythematosus; TcR: T-cell 
receptor; V: variable. 
Patients 
1 2 3 4 1234 1234 1 2 3 4 
(1) (2) (3) (4) 
1 2 3 4 
(#C) 
1 2 3 4 1234 1234 1 2 3 4 
(5) (6) (7) (8) 
--- --- ·-· 
... 
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primers (see Table 3.4 ) . Each patient expressed a 
restricted Va-chain repertoire in the PBMC, which 
predominantly used the Val and Va2 genes, as opposed to 
control PBMC (unstimulated), in which all six Va genes were 
detected (Figure 6.3 and Table 6.4). Expression of Val and 
Va2 (except patient 1) was detected in the PBMC of each 
patient examined. However, no expresion of Va4 (except 
patient 5) or Vas was observed in SLE PBMC. For Va3, 
expression was detected in PBMC of patients 4 and 5 but 
only after prolonged exposure of autoradiographs, whereas 
Va6 was readily detected in three of the patients. Va genes 
that were only detected after prolonged exposure have been 
scored as "weakly" expressed. The results (Table 6.4) 
showed variation in the PBMC Va-chain repertoires of SLE 
patients, although, in the majority of patients, the 
repertoire was biased to Val, Va2 and Vo6. Overall, in SLE 
PBMC, Vo gene usage ranged from one Vo gene (patient 1) to 
four Vo genes (patient 3). Furthermore, there were no major 
differences between patients who had received drugs and 
those who had not (patients 6 and 8). In the PBMC of 
patients 6 and 8, the expressed o-chain repertoires were 
highly restricted since only Vol and Vo2 transcripts were 
detected. In some cases, the PCR product hybridised as a 
doublet, rather than a single band, as was observed for TcR 
v1 usage in some RA patients (see section 3.4.2.2 and 
Figure 3.5), which, in view of the deletions detected 
amongst o-chain transcripts in the previous study in 
Chapter 4, may represent transcripts with and without 
various V gene deletions. 
193 
Figure 6.3 PCR amplification and Southern blot analysis of 
rearranged TcR a-chain transcripts expressed in PBMC of 
eight SLE patients and in control PBMC (sample C, 
unstimulated). Lanes 1-6 correspond respectively to 
amplification of TcR cDNA with the Vol-Vo6 primers, each in 
conjunction with Co2. Blots were hybridised with Co3 and 
exposed for 6 h. C: constant; PBMC: peripheral blood 
mononuclear cells; PCR: polymerase chain reaction; SLE: 
systemic lupus erythematosus; TcR: T-cell receptor; V: 
variable. 
Patients 
1 2 3 4 5 6 1 2 3 4 5 6 1 2 3 4 5 6 1 2 3 4 5 6 (1) (2) (3) (4) 
• •• 
1 2 3 4 5 6 
(C) 
1 2 3 4 5 6 1 2 3 4 5 6 1 2 3 4 5 6 1 2 3 4 5 6 
• 
(5) (6) (7) (8) 
·- • 
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Table 6.4 T-cell receptor Vo gene expression in peripheral 
blood mononuclear cells of systemic lupus erythematosus 
patients. 
Treatment Patient TcR Vo gene families 
Vol Vo2 Vo3 Vo4 Vo5 Vo6 
Prednisone 1 + 
3 + + w 
5 + w w 
7 + + 
Hydroxy chloroquine 2 + + 
4 + + w 
None 6 + + 
8 + w 
Presence or absence of V gene expression as denoted by+ 
or-; W: weakly expressed. 
+ 
+ 
w 
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6.4 DISCUSSION 
The data presented in this report indicate the persistent 
expression of clonally-expanded 1/0 T-cells in the 
peripheral blood of RA patients. In one patient, an 
extremely high degree of oligoclonality was found with 
virtually all V19 and the majority of Vo2 transcripts, 
expressed in PBMC, identical. It is tempting to speculate 
that these transcripts were derived from the same T-cells, 
especially since this particular V gene pair is usually 
found preferentially paired in normal PBMC (Triebel et al., 
1988; Borst et al., 1989). Furthermore, in another patient 
(patient 3), clonal expansion of 1/0 T-cells was still 
detected in the PBMC, although peripheral blood T-cells 
were largely polyclonal. 
These findings may prove particularly relevant in terms of 
the potential for immunotherapy in the treatment of human 
autoimmune disorders, like RA. In various animal models of 
autoimmune diseases such as EAE and AA, vaccination with 
attenuated disease-promoting T-cells, anti-V~ MAbs and 
synthetic TcR peptides, derived from oligoclonal V-J 
junctional sequences, have proved effective in preventing 
the progression of autoimmune disease in genetically 
susceptible animals (reviewed by Adorini et al., 1990; 
Kingsley et al., 1991). If T-cells bearing homogeneous TcRs 
are involved in the initiation and/or progression of joint 
destruction in RA, then the response mediated by those 
pathogenic T-cells could potentially be blocked using TcR-
based immunotherapy regimes. Such novel therapeutic 
strategies would be more specific than the conventional 
methods of immunosuppression used to treat RA patients. 
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In another autoimmune disease, insulin-dependent diabetes 
mellitus, peripheral autoimmunity to pancreatic glutamic 
acid decarboxylase persists in some patients, long after 
the destruction of pancreatic fi-islet cells (Kaufman et 
al., 1992), and is probably due to molecular mimicry of an 
endogenous, or exogenous antigen. However, in the case of 
RA, whether the TcRs expressed by those oligoclonal 1/0 T-
cells recognise autoreactive specificities, or mediate T-
cell responses involved in maintaining the chronic 
progression of RA, is unknown. 
V 1/0 gene usage was analysed in PBMC of eight SLE 
patients. Six of the patients were administered drugs, 
including non-steroid anti-inflammatory drugs, like those 
given to the RA patients, whereas the other two SLE 
patients were not receiving any form of drug treatment. As 
with the RA patients, there were no marked restrictions in 
the v1-chain repertoires in PBMC of SLE patients when 
compared with control PBMC. However, the Vo-chain 
repertoires in PBMC of SLE patients were highly restricted, 
as in RA patients, predominantly to the Vol, Vo2 and Vo6 
genes, both in individuals who had received drugs and those 
who had not. These results indicate that the bias in Vo 
usage observed in RA patients is most probably an 
autoimmune disease-specific phenomenon. Interestingly, 
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alteration in the 1/0 T-cell subset distribution has been 
demonstrated in the peripheral blood of SLE patients with a 
marked reduction in the Vo2/V19 T-cell subset, but not Vol+ 
T-cells, although there were significantly lower levels of 
total peripheral 1/0 T-cells in SLE patients compared with 
controls (Lunardi et al., 1991). In the peripheral blood of 
one of the patients examined here, Vo2 expression was not 
detected and in another two patients, Vo2 was weakly 
expressed. This analysis also provides some evidence for a 
skewed 1/0 TcR repertoire in the peripheral blood of SLE 
patients and suggests selective expansion of T-cells in 
response to a Vo region-specific antigen, supportive of the 
possible effects of a superantigen in SLE. Furthermore, 
these findings suggest the possibility of immune 
intervention in autoimmune disorders where the specific 
target tissue cannot be biopsied. 
CHAPTER 7 
FINAL DISCUSSION 
There are several lines of evidence supporting a 
fundamental role for T-cells in the pathogenesis of RA: 
(1) The synovial fluid and tissue of affected joints are 
effused by T-cells which display markers indicative of 
activated cells in vivo. (2) Therapies which result in T-
cell depletion or inhibit T-cell activation have an 
ameliorating effect on disease severity. (3) The 
association of RA with particular MHC class II molecules 
suggests that MHC-restricted antigen-driven T-cell 
responses mediate the inflammatory process. (4) In 
' immune 
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experimental animal models of RA and other autoimmune 
states, disease can be transferred to naive animals by the 
administration of T-cell lines or clones specific for the 
triggering self antigen. In addition, the pathogenic T-
cells, in the case of EAE, use a restricted set of V-region 
gene elements. (5) Specific immunointervention using TcR-
based strategies can prevent and reverse established 
experimental autoimmune disease in genetically susceptible 
animals. This raises the intriguing question of whether 
there is restricted TcR heterogeneity in RA and other human 
autoimmune diseases and whether TcR-based immunotherapy may 
be a practical alternative in the design of specific 
treatments for RA. 
To detect oligoclonal T-cell populations, most of the 
earlier investigations used Southern blot analysis to 
detect clonal TcR gene rearrangements. This methodology has 
been widely used for the detection of TcR ~ gene 
rearrangements in human T-cell malignancies, as markers of 
' 
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lineage and clonality (Bertness et al., 1985; Minden et 
al., 1985; Waldmann et al., 1985; Flug et al., 1985). The 
major limitation of using this procedure for the 
identification of clonal T-cells, is the lack of 
sensitivity, since it is estimated that at least 5% of a 
mixed cell population must be of oligoclonal origin before 
the clonal TcR gene rearrangement can be detected (Bertness 
et al., 1985). However, antigen-specific autoreactive T-
cells at the sites of autoimmune damage could account for a 
smaller proportion of total T-cells (Navarrete and 
Bottazzo, 1993) and may therefore be undetectable using 
restriction mapping of the TcR loci. In a report by 
Korthauer et al. (1992), clonal T-cells represented a 
minority of the synovial T-cell population in a RA patient, 
with an estimated frequency of 1 in 300 to 1 in 1000, and 
were only detected when IL-2-responsive T-cells were 
selected for. Thus, this methodology may not be feasible 
for the analysis of clonality of predominantly polyclonal 
T-cell populations. Another disadvantage of Southern 
blotting is that complete molecular characterisation of TcR 
gene rearrangements with an assignment to a given v-, D-
and J-region gene usage can only be resolved by 
hybridisation with a multitude of TcR-specific probes 
(Moisan et al., 1989) and even then junctional region 
diversity cannot be determined. 
Irnrnunophenotypic studies with TcR MAbs specific for 
particular V gene products, is often used to analyse 
expression of the TcR molecule at the T-cell surface. The 
• 
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obvious disadvantage is that, at present, the available 
MAbs are limited in the numbers of V gene families they 
recognise. There are currently three TcR V-region-specific 
MAbs recognising the Vol-Jol, Vo2 and V19 encoded 
determinants (Triebel, 1989; Kabelitz, 1992). However, 
despite their limited numbers, MAbs permit a direct 
quantitative analysis of V gene expression and therefore 
remain important tools in the search for restricted V gene 
usage in inflammatory disorders. 
Characterisation of the clonality of T-cell populations has 
previously been difficult due to the relatively 
unsophisticated molecular techniques that were available. 
However, the application of the PCR procedure (Saiki et 
al., 1988) has greatly facilitated the development of 
techniques that permit the rapid and efficient analysis of 
TcR repertoire expression in normal and pathological 
states. In addition, the extreme sensitivity of the PCR 
technique coupled with oligonucleotide hybridisation allows 
analysis of the TcR repertoire from a small number of 
T-cells (Bell, 1989). However, because of the requirement 
for sequence-specific primers at the 5'- and 3'-termini of 
the region to be amplified, conventional PCR is limited to 
the amplification of previously characterised genes or 
homologous multigene families. V gene family-specific PCR, 
described in Chapter 3 of this thesis, is a technique 
commonly used for the analysis of TcR expression, and 
involves amplification of TcR cDNA with primers specific 
for the V-region genes of interest (Roth et al., 1989; Hall 
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and Finn, 1992). The amplified material is then sequenced 
to examine the extent of junctional region diversity. The 
method is simple, rapid and efficient, although a large 
panel of V-region primers is required to analyse the TcR 
repertoire and even then novel V gene families which differ 
in sequence from the primers used, cannot be identified. 
Furthermore, because of the need for a large number of PCR 
reactions for any given sample, there is an increased risk 
of pipetting errors and contamination, although this can be 
minimised (Kwok and Higuchi, 1989). Also, as opposed to 
immunological analysis, the nature of pairing between a-
and ~-chains and 1- and a-chains cannot be resolved. 
Using this approach, a semi-quantitative assessment of V 
gene usage can be made from the amount of amplified 
product, although slight differences in the reaction 
conditions including buffer, nucleotide or primer 
concentrations, temperature, the efficiency of cDNA 
synthesis, PCR amplification of the primers, or the amount 
of mRNA template can dramatically affect the amplification 
efficiency and product yield (Hall and Finn, 1992). 
Nevertheless, numerous investigators have relied on the 
relative quantity of amplified products as an indicator of 
the level of TcR expression in a given sample. Various 
methods have been proposed to control for some of these 
variables and involve the co-amplification of a reference 
template or internal control, usually the C-region of the 
TcR, in the same reaction tube (Choi et al., 1989; Paliard 
et al., 1991; Lunardi et al., 1992b). Interestingly, in the 
2 02 
report by Paliard and colleagues, V~14 transcripts were 
virtually undetectable in the peripheral blood of RA 
patients when IL-2-responsive T-cells were selected for, 
but in the present study, and in others (Sottini et al., 
1991b; Yamamoto et al., 1992), this was not the case. The 
apparent lack of V~14 expression was confirmed by repeate d 
V~ determination, to rule out the possibility of "negative 
PCRs". In this study, PCR-amplified TcR transcripts were 
cloned and hybridised with oligonucleotides specific for 
junctional regions found over-represented during the 
sequence analysis. To assess the degree of oligoclonality 
of dominating T-cell clones, the numbers of positive cDNA 
clones were recorded and expressed as a percentage of the 
total number of TcR-specific cDNA clones. 
To overcome some of the problems encountered with 
conventional PCR, PCR-based strategies with single-sided 
specificity, namely AN-PCR (Frohman et al., 1988; Ohara et 
al., 1989; Loh et al., 1989; Pluschke et al., 1991; see 
Chapter 2) and inverse PCR (Ochman et al., 1988; Huang et 
al., 1990; Uematsu et al., 1991a), have been used for the 
amplification of rearranged TcR genes (reviewed by 
Marguerie et al., 1992; Panzara et al., 1992). In a single 
PCR reaction, it is possible to identify the entire TcR 
repertoire, including previously unidentified V gene 
families (Roman-Roman et al., 1991; Ferradini et al., 
1991), since all TcR transcripts present in a sample are 
made amenable to PCR and can potentially be amplified. 
Moreover, this approach is quantifiable allowing the 
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determination of individual TcR mRNA expression levels. The 
major disadvantages are that PCR amplification relies upon 
prior enzymatic manipulation of the template, such as 
tailing of single-stranded cDNA in AN-PCR and 
circularisation of double-stranded DNA in inverse PCR, 
which may bias the amplification. Secondly, owing to the 
high frequency of incomplete transcripts and possible PCR 
artifacts as identified in this thesis (see Chapter 3), 
very large numbers of clones need to be generated and 
sequenced in order to determine V gene usage and obtain a 
representative picture of the TcR repertoire. 
Several studies employing Southern blotting, MAbs or PCR 
approaches (V gene family-specific and single-sided PCR) 
have examined RA patients for the presence of oligoclonal 
T-cell populations in affected joints. These studies have 
been reviewed extensively in Chapters 1 and 3 of this 
thesis. There are a number of parameters that should be 
taken into account when analysing TcR repertoire expression 
in RA patients: (1) The origin and nature of the source 
material. Whether TcR transcripts have been isolated 
directly from fresh uncultured T-cells infiltrating the 
synovial fluid or synovial tissue, or from T-cell lines or 
clones generated after in vitro expansion of T-cells with 
mitogens. In vitro manipulation of T-cells may 
inadvertantly alter TcR repertoire expression, although a 
recent report indicated that culturing of T-cells, at least 
with IL-2, does not cause artifactual clonal selection but 
enhances IL-2 - sensitive and previously activated T-cell 
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clones (Cantagrel et al., 1993 ) . Furthermore, whether T-
cells have been selected for the expression of various T-
cell molecules such as CD4, CD8 (Gudmundsson et al., 1992) 
or IL-2R (Howell et al., 1991; Cantagrel et al., 1993). (2) 
The disease duration and other clinical variables such as 
rheumatoid factor status and medication histories. Long -
standing RA may be more useful for the analysis of TcR 
expression in studies relating to disease progression 
whereas earlier stages of the disease would be more 
relevant to disease initiation. (3) The genetic backgrounds 
of the patients under investigation. There is evidence 
that, at least in experimental animals, MHC molecules play 
an important role in shaping the TcR repertoire (Blackman 
et al., 1989; Berg et al., 1990). In the case of RA, the 
association primarily with certain HLA-DR4 haplotypes might 
reflect a genetic control of T-cell recognition, through 
the selection of TcR V-region elements (Weyand et al., 
1992b). (4) The methods used for TcR analysis, whether 
immunological or molecular. Differences in methodology, 
together with these other parameters, may have profound 
effects on the outcome of TcR usage in RA, and may account 
for the discrepancies that have previously been observed 
for TcR a/~ usage in RA lesions. 
This thesis examined the diversity of unstimulated a/~- and 
1/8-bearing T-cells in the synovia and peripheral blood of 
RA patients by molecular characterisation of the expressed 
TcR chains. In this study, V gene family-specific PCR 
amplification of TcR transcripts revealed that, unlike a/~ 
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T-cells which are highly heterogeneous in both 
compartments, Vol+, Vo2+ and v19+ T-cells in the periphery 
and to a lesser extent in the rheumatoid synovium are 
derived largely from in vivo oligoclonal expansion possibly 
as a result of stimulation with a nominal antigen/peptide. 
These findings implicate the importance of junctional 
region sequences in antigen recognition by human 1/0 T-
cells and the involvement of antigen-specific 1/0 T-cells 
in the progression of RA, although the response mediated by 
such T-cells could possibly be of a regulatory, rather than 
harmful nature. In the mouse, junctional region sequences 
can influence the antigen specificity of alloreactive 1/0 
T-cells (Rellahan et al., 1991) and the fine specificity of 
recognition of hsp65-derived peptides by 1/0 T-cell 
hybridomas (Born et al., 1990a). Furthermore, there is 
evidence for the recognition of a particular peptide/MHC 
combination by human vo2/v19+ T-cells (Holoshitz et al., 
1992). 
A model has been proposed for autoimmunity and RA based on 
the findings presented in this thesis. In such a scenario, 
it is envisaged that resting autoreactive 1/0 T-cells 
become activated and undergo clonal expansion in the 
peripheral blood of the genetically susceptible host, in 
response to a foreign antigen/peptide. It is possible that 
class II MHC molecules mediate susceptibilty to RA via the 
presentation of such "arthritogenic" peptides to 1/0 T-
cells. The mechanism of T-cell activation could involve 
molecular mimicry, a superantigen or cell-cell adhesion 
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interactions. There is evidence to support antigen-driven 
activation and clonal expansion of 1/0 T-cells in response 
to a human pathogen (Uyemura et al., 1991) and in patients 
with another autoimmune disease, sarcoidosis, 1/5 T-cell 
oligoclonality is common in the peripheral blood and 
disease lesions (Tamura et al., 1990). 
Following activation, autoreactive 1/5 T-cells then migrate 
to the synovial compartment possibly as a consequence of 
molecular mimicry of an exogenous and host self antigen in 
the joint, or inflammatory signals. Homing of specific T-
cells to the synovial microenvironment requires adherence 
and migration through the endothelium of blood vessel walls 
and is mediated by a wide array of cell surface adhesion 
molecules (homing receptors) and vascular addressins 
(reviewed by Stoolman, 1989; Osborn, 1990; Springer, 1990), 
that are induced in response to various cytokines (Pisetsky 
et al., 1991). In the synovial fluid of patients with JRA, 
there is an increase in CD4+ T-cells expressing CD2, CD29 
and CD45RO which may originate from T-cells that are 
initially activated in the blood and selectively migrate to 
the joints via homing receptors (Silverman et al., 1993). 
Similarly, SF T-cells of RA patients showed increased 
expression of CD29, CD2, LFA-3, and ICAM-1 (Takahashi et 
al., 1992), and for Vol+ 1/0 T-cells, a high expression of 
CD45RO and HLA-DR, indicative of in vivo activated "memory 
T-cells" (Bucht et al., 1992b). Furthermore, T-cells from 
rheumatoid joints showed enhanced binding to endothelial 
molecules, ELAM-1 and VCAM-1 (Postigo et al., 1992), which, 
together with VLA-4 binding to fibronectin (Laffon et al., 
1991; Postigo et al., 1992), present in high levels in RA 
synovium (Walle et al., 1990), may contribute to the 
lyrnphocytic infiltration of the synovium. 
It is expected that a large number of the T-cells present 
in rheumatoid joints are non-specific T-cells or T-cells 
reactive with antigens not necessarily involved in the 
initiation of the disease, which, after tissue damage, 
become available for presentation to T-cells. T-cell 
activation triggered by the interaction of CD2 and LFA-3, 
may be one pathway by which antigen non-specific T-cells 
are recruited as effector cells to the inflamed synovium 
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(Linardopoulos et al., 1992). Despite this, 1/0 T-cells are 
clearly non-randomly recruited to the synovium as indicated 
by the findings in this thesis of a selective infiltration 
of T-cells expressing Vol and Vo2 TcRs. However, although 
a/~ T-cells showed considerable heterogeneity, it cannot be 
ruled out that these T-cells play a significant role in 
disease initiation. To my knowledge, this is the first 
study using molecular techniques, of the analysis of the 
complete TcR 1- and a-chain repertoires expressed in RA 
patients. 
After exposure to a limited number of joint-specific self 
antigenic determinants, autoreactive 1/0 T-cells then 
initiate an autoimmune response which, depending on the 
type of antigen and mode of presentation, may result in 
clonal expansion leading to oligoclonal T-cell populations 
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in the synovia of some patients. The findings presented in 
this thesis demonstrate that 1/0 T-cells in the rheumatoid 
synovium are predominantly polyclonal, but in the case of 
v19+ T-cells show restricted usage of the J12 gene segment 
in all patients. These T-cells may be recruited to the 
joint in response to an antigen which is specific for the 
v19-J12 region of the 1/0 TcR. Whether such v19+ T-cells 
bear Vol or Vo2 TcR chains is unknown. In some patients, 
the same oligoclonal transcript detected in the peripheral 
blood was found in the synovium of the same patient, but 
usually with a lower degree of clonal dominance. It is 
possible that, although there is trafficking of oligoclonal 
T-cells between the peripheral and synovial compartments, 
non-specific T-cells present in affected joints contributed 
to this lower degree of oligoclonality. 
The elucidation of the TcR repertoire involved in a 
pathogenic process can have therapeutic implications, given 
the success of preventing disease progression in 
experimental autoimmune disorders, by directing specific 
forms of immunotherapy against V-region gene products or 
using synthetic TcR peptides designed from oligoclonal V-J 
junctional sequences (Adorini et al., 1990; Kingsley et 
al., 1991). In murine and rat EAE, pathogenic T-cells 
reactive with the immunodominant amino-terminal region of 
MBP used particular Va and V~ genes, although there were 
minor differences in V and J segment usage between 
different mouse strains (reviewed by Brostoff and Howell, 
1991; also see Table 5.1 in Chapter 1 of this thesis ) . In 
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the study by Urban et al. (1988) , 79% of MBP-reactive T-
cell clones derived from BlO.PL mice used V~8.2/J~2.6 and 
the remainder used V~13/J~2.2 whereas, for Va usage, 61% 
used Va2.3/Ja39 and the rest used Va4.2/Ja39. In addition, 
although V gene usage was not exclusively restricted to a 
single V gene pair, immune intervention with an anti-V~8 
MAb proved effective in preventing and reversing EAE (Urban 
et al . , 19 8 8 ) . 
For TcR therapy to be useful in human autoimmune diseases, 
the pathogenic process must involve specific oligoclonal T-
cell populations. Whether immunosuppression can then be 
made specific to the autoreactive T-cells, leaving the rest 
of the immune system intact, is an important issue facing 
immunologists today. The findings presented in this thesis 
may have implications for immune intervention in RA. TcR 
1/8 oligoclonality detected, in this study, amongst V81, 
V82 and V19 T-cell populations is persistent in the 
periphery of RA patients but the dominating T-cell clone is 
different in each patient, since the usage of junctional 
region sequences is highly heterogeneous. However, because 
each patient examined in this study had a different HLA-DR 
type even though all but one (patient 4) possessed an RA-
associated allele, and the antigen specificity of the 
oligoclonal 1/8 T-cells is unknown, a lack of association 
with 1/8 T-cell oligoclonality and the recognition of a 
particular antigen/MHC complex cannot be ruled out. 
Therefore, it would be of interest to analyse TcR 
repertoire expression in HLA-identical individuals. In the 
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report by Paliard et al. (1991 ) , the dominant TcR ~ 
clonotypes found in the synovial compartment were also 
different in each RA patient and in most cases multiple 
dominant clones were detected. Similarly, in MS, 
predominant V~ gene usage by MBP-specific T-cell clones 
varied between individuals (Wucherpfennig et al., 1992b). 
Moreover, there were differences in TcR a/~ repertoire 
expression in different plaques of MS brain (Ben-Nun et 
al., 1991) and in skin biopsies of Leishmaniasis lesions, 
1/0 T-cell oligoclonality varied in different 
microanatomical regions (Uyemura et al., 1992). In view of 
these findings, it would be of interest to examine TcR 
usage in different synovia specimens and in multiple joints 
o~ the same RA patients. A recent study (Van Laar et al., 
1992) demonstrated, by Southern blotting, variablilty in 
dominant TcR ~ clones from different synovial tissue 
fragments, although some of the dominant clones detected 
were shared by T-cell lines generated from different 
synovia specimens as well as from different joints of the 
same RA patients. 
In view of the findings in experimental animal models, the 
results presented in this thesis suggest that therapies 
directed against V-regions of potentially pathogenic Vol, 
Vo2 or V19 T-cells, may be of clinical benefit in the 
treatment of patients with established RA. Furthermore, a 
specific MAb antibody designed for V19-J12 gene products is 
a possibility for TcR-based antibody therapy. V19-J12 
transcripts are predominantly expressed in RA synovium of 
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all patients and may represent autoreactive T-cells that 
have previously been activated in the peripheral blood and 
then migrated to the synovial compartment. T-cells 
expressing the V19-J12 gene pair represent a minority of 
the T-cells in normal peripheral blood. Whether this is 
because they have autoreactive or regulatory properties, is 
unknown. However, treatment of patients as a group using 
synthetic TcR peptides may not be feasible because of the 
heterogeneity of TcR junctional region expression and would 
have to be tailor made for each patient. 
This thesis also demonstrated that TcR V6 gene expression 
in peripheral blood of patients with another autoimmune 
disease, SLE, is highly restricted, indicative of 
oligoclonal expansion of 1/6 T-cells, and stresses the 
importance of searching for oligoclonality in systemic as 
well as organ-specific autoimmune disorders. Moreover, this 
thesis indicates that restricted TcR 1/6 usage in RA 
patients is an autoimmune disease-specific phenomenon, 
favouring the feasibility of TcR-based immunotherapy in the 
treatment of this disease. 
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